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The

Dukat

laboratory

developed

2-amino-6-chloro-3,4-dihydroquinazoline

(A6CDQ) as a 5-HT3 receptor ligand. A6CDQ and one of its positional isomers, the 7-chloro
analog A7CDQ, produced antidepressant-like effects in the mouse tail suspension test
(TST). Activities at the 5-HT3 receptors or the serotonin transporter (SERT) were considered
as potential mechanisms for the antidepressant-like effect. However, we investigated and
systematically ruled out a solely 5-HT3 receptor or hSERT mediated mechanism of
antidepressant-like effect for both A6CDQ and A7CDQ.

The role of organic cation transporter 3 (OCT3) in the regulation of neurotransmitters
including serotonin (5-HT) provides an alternative mechanism of reuptake (uptake-2) and
the therapeutic potential of targeting hOCT3 to achieve antidepressant effects has been
established.

By

virtue

of

possessing

protonatable

nitrogen

atoms,

2-

aminodihyroquinazolines could potentially exhibit activity at OCT3. A major goal of our
present study was to explore the non-serotonergic mechanism of antidepressant-like effects
and to study the as yet unexplored structure-activity-relationships (SARs) at OCT3. We
examined the role of

i) the chloro group, ii) the methylene bridge and iii)

electronic/lipophilic effects at the 6-position. Only the presence and not the position of the
chloro group was deemed important. Removal of the methylene bridge did not affect hOCT
inhibitory activity. We determined the lipophilic properties of the substituent at the
quinazoline 5-, 6- and 7-position to be potentially more important than their electronic
properties.
We developed the first 3-D homology models of both the human and mouse
orthologs of OCT3, conducted docking studies and HINT analysis, and identified critical
amino acid residues interacting with 2-aminodihydroquinazoline analogs at hOCT3 and
mOCT3. Contrary to OCT inhibitory activity, the presence of both the chloro group and the
methylene bridge was deemed important for retention of antidepressant-like activity in the
mouse TST. Potential locomotor stimulant effects for TST-active doses were thoroughly
investigated and eliminated.
We have successfully investigated initial SAR of 2-aminodihydroquinazolines at
hOCT3 and generated the first 3-D homology models of hOCT3 and mOCT3. Highly potent
xxxvii

and selective compounds could potentially be developed as radioligands to probe the binding
site of OCT3 and as a mechanistically novel class of antidepressants.

xxxviii

I. Introduction
Depression is a serious central nervous system (CNS) disorder. Most clinically
employed antidepressants target one or both of two neurotransmitter systems (i.e., serotonin
and norepinephrine) by acting as, for example, reuptake inhibitors at the serotonin
transporter (SERT) or norepinephrine transporter (NET). Unfortunately, a large proportion
of depressed individuals are refractory to these agents.
SERT, NET and dopamine transporters (DAT) are capable of transporting all three
monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE) and dopamine (DA).113

This complicates matters, as we possess an overly simplistic view of reuptake of

neurotransmitters and depression. The transporters could be compensating for each other
and this might explain the lag that is observed during treatment with selective serotonin
reuptake inhibitors (SSRIs). In 1998, another mechanism of uptake of monoamine
neurotransmitters, called uptake-2 was identified to consist of organic cation transporter 3
(OCT3).14 Over the next two decades uptake-2 was characterized to be low-affinity, highcapacity uniporters and OCTs were shown to be capable of participating in the clearance of
5-HT and NE.15-18 OCT1-3 are expressed throughout the body, with OCT219,20 and OCT3
being primarily expressed in the brain whereas OCT1 was found primarily in the periphery.21
Moreover, OCT3 is expressed in areas of the brain which are believed to be involved in
depression.14,22,23 OCTs are expressed both on neurons and glial cells,16,24 and increasingly
OCT3 is thought to be involved in the reuptake of 5-HT and other monoamines.25-28 A
number of known antidepressants such as, desipramine, imipramine, amitriptyline, sertraline

and fluoxetine (FLX) were shown to inhibit OCT3 with desipramine and sertraline doing so
noncompetitively.29 Also, the antidepressant-like effect of fluvoxamine was shown to be
enhanced in the presence of decynium-22, a known inhibitor of OCTs17,21,30,31 in wild-type
mice in the mouse tail suspension test (TST), a rodent model used for the evaluation of novel
antidepressants.32 This effect was shown to be decreased in OCT3 knockout mice.33
Therefore, OCT3 presents an attractive target for a mechanistically novel class of
antidepressant agents and detailed structure-activity relationship (SAR) studies at OCT3
have not been reported.
The phenylguanidine, m-chlorophenylguanidine (mCPG; MD-354; Ki = 35 nM),34 a
5-HT3 receptor agonist, resulted from investigations of 1-phenylbiguanide, the first selective
5-HT3 agonist.34 Ring closure of phenylguanidines by way of introducing a methylene bridge
between the terminal nitrogen atom of the guanidine moiety and the phenyl ring gives rise
to 2-amino-3,4-dihydroquinazoline (ADQ). 2-Amino-6-chloro-3,4-dihydroquinazoline
(A6CDQ) was identified to be a 5-HT3 receptor competitive antagonist with high affinity
and high potency (Ki = 80 nM, IC50 = 0.26 µM).35 There exists literature precedence for 5HT3 receptor antagonists such as odansetron and bemesetron to produce an antidepressantlike effect in the mouse tail suspension test (TST).36,37 A6CDQ (ED50 = 0.23 mg/kg)35 was
20-times more potent than fluoxetine (20 mg/kg) in the mouse TST. Thus, we hypothesized
that the antidepressant-like activity of A6CDQ might be mediated via 5-HT3 receptor
antagonism. A positional isomer of A6CDQ, the 7-chloro substituted 2-amino-3,4dihydroquinazoline (A7CDQ), was also shown to be active in the mouse TST at comparable
doses to A6CDQ. However, A7CDQ (Ki = 1,975 ± 168 nM) was found to bind at 5-HT3
2

receptors with a 25-fold lower affinity than A6CDQ. One aim of the current study was to
determine the functional activity of A7CDQ at 5-HT3 receptors. The large difference in
binding affinities of A6CDQ and A7CDQ at 5-HT3 receptors, but comparable efficacy in
mouse TST suggested that the antidepressant-like effect observed might not be mediated via
5-HT3 receptors alone.
Fluoxetine (FLX), also known as prozac, is one of the most widely prescribed
antidepressants and belongs to the SSRI class of antidepressants.38 FLX inhibits SERT
potently (IC50 = 0.076 µM) and with high affinity (Ki = 1 nM).38 FLX lacks affinity for the
orthosteric site of the 5-HT3 receptor but behaves as a functional 5-HT3 receptor antagonist.39
The question arose: might quinazolines, A6CDQ and A7CDQ, be functionally active at
hSERT? To determine this, we examined A6CDQ and A7CDQ at hSERT using radioligand
binding, electrophysiological, molecular modeling and Hydropathic INTeractions (HINT)
studies.
Activities at 5-HT3 receptors and hSERT (releaser or reuptake inhibitor) provide an
insufficient explanation for the antidepressant-like effects observed. Since the quinazolines
have protonatable nitrogen atoms capable of existing as a positively charged moiety at
physiological pH, we explored phenylguanidines and quinazolines as potential OCT ligands.
Based on preliminary data, we studied the structure-activity relationships (SARs) of
quinazolines at OCTs by synthesizing analogs with varying substituents. To better
understand the molecular interactions between quinazolines and the transporter, we built the
first 3-dimensional homology models of the human and mouse orthologs of OCT3 (hOCT3
and mOCT3, respectively) based on the inorganic phosphate transporter (PiPT) as a
3

template. Docking of compounds followed by HINT analysis helped us score and rank the
favorable interactions observed in the ligand-transporter complexes.
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II. Background
1. Depression: Theories and molecular targets

According to the World Health Organization (WHO), depression is a central nervous
system (CNS) disorder that affects ~350 million people worldwide and is characterized by
debilitating melancholia and anhedonia. Furthermore, it is recognized as the leading cause
of illness-induced disability.40 In the United States alone, 9% of the population suffers from
depression.41 Traditionally, depression has been associated with low levels of the
neurotransmitters serotonin (5-HT) (1) and/or norepinephrine (NE) (2) in the synapses
(Figure 1). One of the most widely prescribed antidepressants, fluoxetine38 (prozac) (FLX;
3) (Figure 1) targets the serotonin transporter (SERT) and blocks it, thereby preventing the
reuptake of 5-HT (1) into the presynaptic neuron and increasing the concentration of 5-HT
(1) in the synapse. The class of drugs which target SERT are known as selective serotonin
reuptake inhibitors (SSRIs) and continue to be widely used even today. SERT and
norepinephrine transporters (NET) are recognized as uptake-1. Uptake-1 transporters are
high-affinity, low-capacity transporters.42 Other classes of antidepressants include, but are
not limited to, serotonin and norepinephrine reuptake inhibitior (SNRIs), selective
norepinephrine reuptake inhibtiors (NRIs), tricyclic antidepressants (TCAs) and monoamine
oxidase inhibitors (MAOIs). Unfortunately, a large portion of the population suffering from

depression show either partial response or no response to the current treatment options
available.43 So there is a pressing need for agents that act via a novel mechanism.
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Serotonin (1)

NH 2

HO
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CH 3

O
F 3C

Fluoxetine (3)

Figure 1. Structures of the neurotransmitters serotonin (5-HT; 1) and norepinephrine
(NE; 2) traditionally believed to be important in depression. Fluoxetine (FLX; 3)
(prozac), one of the most well known and widely prescribed antidepressants.
Depression is a mental disorder that is comprised of a number of debilitating
symptoms that are observed for greater than two weeks in an individual.44 The symptoms
include irritability, anhedonia (loss of interest in pleasurable activities), loss of appetite
and/or sleep, feeling of helplessness, worthlessness, guilt, low self esteem among others.44
Broadly, depression is categorized into two major classes – major depressive disorder
(MDD) and dysthymia.44 MDD, also known as clinical or unipolar depression, is further
classified into five subtypes – melancholic depression, atypical depression, catatonic
depression, post partum depression and seasonal affective disorder.44 Dysthymia, also
known as persistent depressive disorder (PDD), is a milder form of depression which tends
to last longer.44
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Following are some of the theories concerning the etiology of depression that have been
proposed:
a. Monoamine hypothesis:
One of the earliest theories regarding depression (1950’s) is the monoamine
hypothesis. The monoamine neurotransmitters consist of 5-HT (1) and the catecholamines –
dopamine (DA) (4) and norepinephrine (NE) (2). The biosynthesis and metabolism of the
catecholamine neurotransmitters are shown in Figures 2 and 3, respectively, while that of 5HT is shown in Figure 4. The amino acid precursor L-tyrosine (5), via a series of steps, is
converted to DA (4) and NE (2) (Figure 2).45 The amino acid precursor for 5-HT (1) is Ltryptophan (13) (Figure 4).46 The enzyme monoamine oxidase (MAO) is involved in the
metabolism of both the catecholamine, NE45 (2) and 5-HT46 (1) and converts the amine to
an aldehyde (Figures 3 and 4, respectively).
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Figure 2. Biosynthesis of catecholamines – dopamine (DA; 4) and norepinephrine (NE; 2) from
the amino acid precursor L-tyrosine (5). Adapted from Griffith et al.45
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Figure 3. Metabolism of norepinephrine (NE; 2) by the enzymes monoamine oxidase (MAO), catechol
O-methyl transferase (COMT), aldehyde reductase (AR) and aldehyde dehydrogenase (AD). Adapted
from Griffith et al.45
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The two major contributors to formulation of the monoamine hypothesis were studies
related to reserpine and iproniazid (21) (Figure 5). Reserpine is an alkaloid isolated from
dried root of Rauwolfia serpentina and was found to induce depression in hypertensive
patients.47-51 Isoniazid (22) and iproniazid (21) (Figure 5) were developed as antitubercular
agents and were found to cause elevation of mood in tuberculosis patients. They were later
determined to be monoamine oxidase inhibitors (MAOIs).52 In 1958, Everett and Toman53
proposed a rudimentary version of the monoamine hypothesis which stated that a deficiency
of monoamine in the central nervous system is responsible for depression. Jacobsen in 1964
stated that insufficient catecholamines results in depression.54
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OH
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Figure 5. Structures of iproniazid (21), isoniazid (22), imipramine (23) and tyramine
(24).

All of this eventually culminated in the catecholamine hypothesis for which Joseph
Jacob Schildkraut is credited. The hypothesis states that, “some depressions, if not all, are
associated with an absolute or relative deficit of catecholamines, particularly noradrenaline
(norepinephrine), in important adrenergic receptors in the brain. Contrariwise, elation may
10

be associated with an excess of such amines.”55 Around the same time, there was a growing
interest in determining the role played by 5-HT (1) in depression. Administration of
tryptophan (14), an amino acid precursor of 5-HT (1) (see Figure 4), along with an MAOI
resulted in greater improvement in depressed individuals than administration of a MAOI
alone.56,57 And so the 5-HT hypothesis was borne from the work of Coppen and states that a
deficiency in 5-HT leads to depression.58
Imipramine (23) (Figure 5), a tricyclic antidepressant (TCA), was found by Kuhn to
be effective in the treatment of depression.59 Eventually in 1964, imipramine (23) was shown
to block the reuptake of both NE (2) and 5-HT (1),60 lending further credibility to the
monoamine hypothesis of depression. Both, the MAOIs and TCAs are considered to be the
first generation antidepressants and are fraught with several side effects. The MAOIs reacted
dangerously with tyramine (24) (Figure 5) in foods such as cheese and certain wines
resulting in hypertensive crises61 while the TCAs have a number of unpleasant side effects
resulting from their action at muscarinic receptors such as blurred vision, dry mouth and
urinary retention.62,63 In 1961, iproniazid (21) (Figure 5) was withdrawn from the market due
to side effects related to the kidney.64
The second generation of antidepressants are comprised of selective serotonin
reuptake inhibitors (SSRIs) such as FLX (3;65 Figure 1), serotonin and norephinephrine
reuptake inhibitors (SNRIs) such as venlafaxine (25;66,67 Figure 6), and selective
norepinephrine reuptake inhibitors (NRIs) such as reboxetine (26;68 Figure 6) among others.
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All of these drugs work on the principle of increasing the concentration of the monamine
neurotransmitters, 5-HT (1) and/or NE (2), in the synapse keeping in line with the
monoamine hypothesis. In the past few years, there has been a shift towards drugs that act
at multiple targets as opposed to drugs that act selectively at one target (e.g. SSRIs, SNRIs).
These include agents that act at monoaminergic targets such as SERT, NET along with other
targets such as serotonin receptors (5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7)69-75 and GABA
receptors.76,77
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Venlafaxine (25)

Reboxetine (26)

Figure 6. Structures of venlafaxine (25), a serotonin and norepinephrine reuptake inhibitor
(SNRI), and reboxetine (26), a norepinephrine reuptake inhibitor (NRI).
Of the seven families of the 5-HT receptors, 5-HT1-7, only 5-HT3 receptors are ligand
gated-ion channel (LGIC) receptors.46 All of the other six families are G-protein coupled
receptors (GPCRs) and are either negatively or positively coupled to adenylyl cyclase (AC)
or phospholipase.46 5-HT3 receptors are most abundant in the chemoreceptor triggering zone
(CTZ)78 and it is for this reason that 5-HT3 receptor antagonists, such as ondansetron (27;
Figure 7), tropisteron (28; Figure 7) and others have been successfully used as antiemetics
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for chemotherapy-induced emesis.79,80 Besides the CTZ, 5-HT3 receptors have also been
identified in the hippocampus, amygdala, nucleus accumbens (NAc), and caudate
nucleus.78,81,82 5-HT3 receptors are located both pre as well as postsynaptically and are
involved in both control of 5-HT (1) release as well as neurotransmission.78 Because 5-HT3
receptors are LGIC receptors, they allow passage of Na+/K+ ions through the channel in
response to binding of an agonist.46 The potential role of 5-HT3 receptors in depression has
been studied and, in the past, 5-HT3 receptor antagonists such as ondansetron (27; Figure 7)
and bemesetron (29; Figure 7) have been shown to possess antidepressant-like activity in the
mouse TST.36,37 Moreover, the antidepressant-like effect of bemesetron (29; Figure 7) was
shown to be augmented by ketamine, a nonselective NMDA receptor antagonist.37
Tropisetron (28; Figure 7), another 5-HT3 receptor antagonist, was also shown to produce
antidepressant-like effects in the mouse and rat forced swim test (FST).83,84 mChlorophenylbiguanidine (mCPBG) (30; Figure 8), a known 5-HT3 receptor agonist,
successfully attenuated this effect of tropisetron (28; Figure 7) and other antidepressants
such as imipramine (23; Figure 5) and desipramine (31; Figure 8).83 This antidepressant-like
effect exerted by 5-HT3 receptor antagonists could be attributed to antagonism of the
postsynaptic receptors36 thereby allowing 5-HT (1) to interact with other postsynaptic 5-HT
receptors (such as 5-HT1A/B/C and 5-HT2A/2C receptors).78 Antidepressants belonging to the
distinct classes such as TCAs, SSRIs, NRIs have been shown to be functional antagonists of
5-HT3 receptors.39 This includes FLX (3), one of the most well known SSRIs.39 A number
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of groups have suggested that this 5-HT3 receptor antagonism might contribute partially to
the antidepressant effects of FLX (3).39,85-87 This is further bolstered by the fact that a
combination of 5-HT3 receptor antagonists with SSRIs leads to increased antidepressant-like
effects.36,87,88 For example, ondansetron (27; Figure 7) was shown to increase the
antidepressant-like effects of FLX (3) (SSRI) and venlafaxine (25; Figure 6) (SNRI) in
mice.36 Another point of interest is that treatment with ondansetron (27; Figure 7) was shown
to induce serotonin syndrome.89 This syndrome occurs when the levels of 5-HT (1) in the
synapse increases both in the central (CNS) and peripheral nervous (PNS) system. All of
this suggests that antagonism of 5-HT3 receptors could lead to an increase in 5-HT (1) and
holds therapeutic potential in depression.
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Figure 7. Structures of 5-HT3 receptor antagonists, ondansetron (27), tropisetron (28) and
bemesetron (29).
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Figure 8. Structures of the 5-HT3 receptor agonist m-chlorophenylbiguanide (mCPBG; 30)
and the antidepressant desipramine (31).

b. Glutamate/Neuronal plasticity hypothesis:
An idea that has been gaining momentum since the 1990's is the glutamate hypothesis
of depression. Glutamate (32; Figure 9) is considered to be an excitatory neurotransmitter,
with glutamate synapses accounting for the vast majority of the neocortex followed by
GABAergic synapses.90 Initially, it was thought that glutamate (32; Figure 9) binds to and
acts via the ionotropic glutamate receptors (iGluRs).91,92 Later on it was discovered that
glutamate (32) also exerts its action via another class of receptors called metabotropic
glutamate receptors (mGluRs).93,94 The iGluRs consist of three ligand-gated ion channel
(LGIC) receptors that modulate the flow of K+ and Na+ ions,91,92 while the mGluRs consist
of eight large G-protein coupled receptors (GPCRs) that exert their effect through second
messengers.93,94 The three iGluRs are α-amino-3-hydroxy-5-methylisoxazolepropionic acid
(AMPA), kainate and N-methyl-D-aspartate (NMDA) receptors.91,92 The eight mGluRs are
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further subdivided into three groups – group I consisting of mGlu1 and mGlu5, group II
consisting of mGluR2 and mGluR3 and group III consisting of mGluR4, mGluR6, mGluR7
and mGluR8.95 NMDA receptor antagonists were discovered to possess antidepressant-like
effect in a number of studies.96-100 This was confirmed via clinical studies in patients
suffering from MDD who were intravenously administered ketamine (33; Figure 9), a
nonselective NMDA receptor antagonist and showed rapid (within 2-4 hours of
administration) and sustained (up to 3-7 days after administration) antidepressive
effect.101,102 In subsequent years, this antidepressant effect of ketamine (33) has been linked
to its effect on neuronal plasticity, i.e., increasing the number and function of synapses in
the prefrontal cortex,103 increased signaling via mammalian target of rapamycin complex 1
(mTORC1)103 and increased levels of brain-derived neurotrophic factor (BDNF)104,105
(Figure 10). Other agents acting at NMDA receptors,106,107 as well as mGluR2/mGluR3
antagonists108-110 and agents that potentiate the activity of AMPA receptor111 have also
shown antidepressant-like effect in behavioral models (Figure 10).
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Figure 9. Structures of the neurotransmitter, glutamate (32) and selective NMDA receptor
antagonist, ketamine (33).
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Figure 10. Involvement of glutamate in depression. Stress causes a decrease in BDNF and potentiates long-term
depression (LTD). Ketamine (33) reverses this effect and potentiates long-term potentiation (LTP) giving rise to a
rapid antidepressant effect. This involves increasing concentration of glutamate (32) in the synapse by acting as an
antagonist at NMDA receptors, increasing concentration of BDNF and also by its actions at mTORC1. Other
agents, such as mGluR2/3 antagonists and those that potentiate AMPA also achieve similar effects in models of
depression. Adapted from Duman.112

c. GABA hypothesis:
ɣ-Aminobutyric acid (GABA) (34; Figure 11) is an inhibitory neurotransmitter that
functions in tandem with the glutamate system and signals via GABAA and GABAB
receptors.113 The concentration of GABA (34) was found to be reduced in the cerebrospinal
fluid (CSF) of patients suffering from MDD.114 The areas of the brain that have been
explored with respect to GABAergic neurotransmission are the occipital cortex (OCC),
anterior cingulate cortex and prefrontal cortex (PFC).
Two major types of studies have been undertaken so far to determine the role of
GABA (34) in depression. The first, magnetic resonance imaging (MRI), suggests a decrease
in concentrations of GABA (34) in OCC,115-118 anterior cingulate cortex,116 and PFC119 and
supports involvement of GABA (34) in depression. The second study involved the enzyme
glutamic acid dehydrogenase (GAD) and its level in various regions of the brain. GAD
converts glutamate (32) to GABA (34; Figure 12) and exists as two different isoforms –
GAD65 and GAD67.120 However, GAD67 expression studies have proven to be unreliable
since they show both a correlation121,122 and an utter lack of it123-125 in healthy and MDDsuffering individuals.
The synthesis and metabolism of GABA (34) and glutamate (32) are interconnected
(Figure 12). Reuptake of glutamate (32) by excitatory amino acid transporter (EAAT 1/2)
expressed on glial cells,120 its subsequent conversion to glutamine by glutamate
synthetase,126 followed by reconversion to glutamate (32) by glutaminase, and finally
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conversion of glutamate (32) to GABA (34) by glutamic acid dehydrogenase (Figure 12)
being the major steps. This serves as a major source for production of GABA (34).127
Reduction in number and function of glial cells and EAAT1/2 has been observed in MDD.128130

The idea that this reduction of glial efficiency could account for the reduction in levels

of GABA (34) observed in MDD has unfortunately not been substantiated.131 A number of
agents – agonists, antagonists and positive allosteric modulators (PAMs) – have been tested
at GABAA and GABAB to investigate their involvement in MDD. Some of these studies
have shown promising results, i.e., reduction of MDD scores by coadministration of
alprazolam (35;132 Figure 11), a PAM at GABAA, and effective combination of eszopiclone
(36; Figure 11), another PAM at GABAA with a SSRI.133,134 Other studies have shown no
significant advantage of targeting GABAA.135
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Figure 11. Structures of the inhibitory neurotransmitter ɣ-aminobutyric acid (GABA) (34),
and PAMs at GABAA, alprazolam (35) and eszopiclone (36).
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Figure 12. Biosynthesis of GABA (34) from glutamate (32). Glutamate (32) released in the synapse is taken up the
EAAT1/2 on glial cells and converted to glutamine which is reconverted to glutamate (32) and subsequently to GABA
(34). Adapted from Pehrson et al.120
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d. Cholinergic/Adrenergic imbalance hypothesis:
Janowsky et al.136 (1970’s) proposed the cholinergic-adrenergic imbalance
hypothesis and Dagyte et al.137 further defined it “depression was proposed to be a disease
of cholinergic dominance”. The evidence for this hypothesis resulted from studies involving
administration of acetylcholinesterase inhibitors (AChEIs), muscarinic acetylcholine
receptor (mAChR) antagonists, nicotinic acetylcholine receptor (nAChR) agonists and
antagonists. Diisopropylfluorophosphonate (DFP, 37), an irreversible AChEI (Figure 13),
was shown to produce depressive symptoms in normal individuals. Moreover, it was shown
to reduce mania in manic individuals.138 Other AChEIs, such as EA-1701139 (irreversible
AChEI) and physostigmine140-142 (38) (reversible AChEI, Figure 13) also produced similar
effects as DFP (37).
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Figure 13. Structures of diisopropylfluorophosphonate (DFP, 37), an irreversible AChEI,
and physostigmine (38), a reversible AChEI.
Acteylcholinesterase (AChE) is an enzyme that is responsible for terminating the
signaling of the neurotransmitter acetycholine (ACh) (39; Figure 14) by converting it to
choline (41) and acetate (42; Figure 15).143 AChEIs inhibit this enzyme and cause an increase
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in the amount of ACh in the synapse which binds to and activates mAChRs and/or
nAChRs.143 The tendency of AChEIs to produce depressive symptoms in normal individuals
coupled with the finding of increased choline concentrations in the brain of depressed
individuals144,145 further cemented the involvement of the cholinergic system in depression.
Administration of agents acting at mAChRs and nAChRs have shown potential to alleviate
some cognitive symptoms of depression. Scopolamine (43; Figure 14), a nonselective
muscarinic receptor antagonist was shown to produce antidepressant effects in patients
suffering from MDD.146 The mechanism by which scopolamine exerts this effect has not
been elucidated yet.146 With respect to nAChRs, the evidence is more divided. Both nAChR
agonists and antagonists have shown antidepressant-like effects.147-149 The regions of the
brain which have been repeatedly implicated in depression – hippocampus,150-153 PFC154 and
amygdala154,155-157 – all have cholinergic innervations. Thus, an imbalance of the cholinergic
system may be contributing to the dysfunction of these regions of the brain, ultimately
playing a role in depression. Despite being in existence since the time of the monoamine
hypothesis, the cholinergic/adrenergic imbalance hypothesis is still in development.
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Figure 14. Structures of acetylcholine (ACh, 39) and scopolamine (43), a non selective
muscarinic receptor antagonist.
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e. Anhedonia/Opioid hypothesis:
κ Opioid receptors (KOR) and the neuropeptide neurotransmitter dynorphins are
expressed in areas of brain that are implicated in depression – e.g. hippocampus, PFC,
amygdala, ventral tegmental area (VTA), and nucleus accumbens (NAc).158-162 κ Opioid
receptors are GPCRs that signal via Gαi.163 µ and δ Opioid receptors (MOR and DOR,
respectively) and nociceptin receptors (NOR) constitute the remaining members of the
opioid receptor family.163,164 It is believed that activation of a KOR causes dysregulation of
the dopaminergic system in the NAc and VTA, producing anhedonia (inability to feel
pleasure),165,166 a major symptom of depression. This has been further supported by
administration of a KOR agonist that produces prodepressive effects such as anhedonia and
aversive effects in rodents167-169 and dysphoria in humans,170,171 and KOR antagonists that
block these effects.172,173 The activation of KOR has also been linked to anxiety via its
actions in the amygdala,174,175 though this has been countered.176,177 Since KOR are GPCRs
that signal via Gαi, their activation causes inhibition of cAMP.163 Activation of KOR also
activates the MAPK pathway consisting of three kinases – extracellular regulated kinase
(ERK1/2), p38 stress kinase (p38), and c-Jun N-terminal kinase (JNK).178,179 MAPK cause
phosphorylation and activation of a number of cellular proteins like cAMP response
element-binding protein (CREB) and other transcription factors as well as AMPA receptors
and impact their trafficking.180
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f. Stress/Hypothalamus-pituitary-adrenal (HPA) axis hypothesis:
Increased levels of cortisol (44; Figure 16), a glucocorticoid, has been observed in
patients suffering from depression.181 Cortisol (44) is involved in a number of important
processes such as metabolism and regulation of the immune system, as well as behavior.182
Glucocorticoids such as cortisol (44) exert their effect via various steroid receptors, among
them mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs),183 which are a
part of a much broader family of nuclear receptors and are involved in regulation of gene
expression via transcription factors such as CREB among others.184
The production and release of cortisol (44) is affected by the
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Figure 16. Structure of the hypothalamus are increased185 (Figure 17). Glucocorticoids
glucocorticoid
cortisol
(44).
have a negative feedback loop wherein released
glucocorticoids bind and activate MRs and GRs expressed in the CNS (hippocampus)
leading to a decrease in the levels of CRH and ACTH and subsequently glucocorticoids186
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(Figure 17). Thus, hippocampal atrophy
observed in MDD187 might disrupt the
negative control on the HPA axis and
increases the levels of cortisol (44). In the
event of exposure to chronic stress this
negative feedback loop is affected and the
HPA

axis

is

hyperactivated,181,188

a

phenomenon observed in 50% of depressed
patients.183,189-191 Elevated levels of cortisol
Figure 17. The HPA axis and negative (44) contribute to the atrophy of neurons of
feedback loop mediated via glucocorticoid
receptors (GRs) and cortisol (44) that helps the hippocampus. This further diminishes the
to regulate it. Adapted from Pariante et al.192
negative control of the hippocampus on the
HPA axis. This self-sustained hyperactivity of the HPA axis is thought to retard neurogenesis
and contribute to symptoms observed in depression.193,194 The involvement of GR in reduced
neurogenesis has been shown by administration of a GR antagonist (reverses neurogenesis
brought about by HPA hyperactivity)195-197 and GR+/- knockout mice (decreased
neurogenesis and depressed phenotype).198 However, it is still not clear whether HPA
hyperactivity is a cause or effect of depression.182,185
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g. Stress/Neuroplasticity hypothesis:
The hypothesis states, “impaired mechanisms of neuroplasticity are a core
pathophysiological feature of MDD, that chronic stress is an important causal factor in the
development of this impairment, and that antidepressant treatments act, at least in part,
through mitigation of impaired mechanisms of plasticity”.199 Stress has been shown to affect
different regions of the brain in distinctly different manners.199 The hippocampus and PFC
are shown to atrophy as a result of chronic stress187,200-202 and this mirrors what has been
observed in depressed patients.128,203,204 The amygdala, on the other hand, shows signs of
increased activity by virtue of an increase in the number of synapses205 as observed in
MDD.206-208 The hippocampus is involved in a number of processes such as memory and
concentration209 that are impaired in patients suffering from MDD. Moreover, the
hippocampus positively modulates the dopaminergic neurons in the VTA and NAc and a
reduction in hippocampal activity leads to a decrease in dopaminergic activity in the VTA.
This is thought to contribute to the feeling of anhedonia observed in MDD.210 The increased
activity of the amygdala as a result of chronic stress leads to an increase in fear-induced
learning211 as well as anxiety in animal models.212 These changes in the morphology of the
brain are brought about by various mechanisms that regulate and participate in long-term
potentiation (LTP) and long-term depression (LTD). An increase in the concentration of
calcium ions and cyclic adenosine monophosphate (cAMP), a second messenger, causes
LTP via calcium-calmodulin kinase II and IV (CAMKII, CAMKIV).213 CAMKII increases
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the number of AMPA receptors and their function in synapses by phosphorylation.199
CAMKIV on the other hand activates CREB, a transcription factor,214 that along with other
neurotrophic factors such as BDNF, stabilize newly formed synapses.215,216 Chronic stress
impacts the levels of both CREB217,218 and BDNF219-224 and interferes with neurogenesis
leading to atrophy. Antidepressants, when administered chronically, have been shown to
reverse some of these effects of stress related to atrophy and neurogenesis.225,226

h. Neuroinflammation hypothesis:
“The cytokine hypothesis of depression posits that depression is caused by action of
cyotkines”.227 Cytokines are small molecular weight proteins that activate the immune
system in response to an infection. Interferons (IFNα, IFNβ, IFNɣ), a type of cytokines, have
been administered in the treatment of diseases such as cancer, multiple sclerosis and hepatits
C.228 Patients receiving IFNα developed depressive symptoms such as anhedonia, irritability
and fatigue.229-231 Around this time there was an increased interest in determining the
possible role of inflammation in depression. Smith (1991) put forth the theory that
“depression was associated with increased secretion of cytokines (especially IL-1) by
macrophages” and termed it the macrophage hypothesis of depression.232 Over the next few
years, efforts were made to correlate levels of cytokines233 and other inflammatory
markers234 to depression. Particular attention has been bestowed on cytokines such as
interleukins (IL-1β, IL-6) and IFNs. Unfortunately, contrary evidence exists for the
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involvement of IL-1β235-237 and IL-6.238,239 IFNs on the other hand have been shown to be
increased in individuals suffering from depression.240-242
Among the various molecular mechanisms by which cytokines are believed to
contribute to depression, activation of the HPA axis and action on the serotonergic system
have been studied extensively. Cytokines activate the hippocampus, which in turn causes
activation of the HPA axis. This leads to increased production of CRH, ACTH and
glucocorticoids. IL-1, IL-6 and tumor necrosis factor α (TNFα) are all believed to be capable
of this hippocampal activation.243 Increased levels of glucocorticoids eventually leads to
neuronal atrophy and dysregulation of the negative feedback on the hippocampus and results
in hyperactivation of the HPA axis similar to what is observed in response to stress. In terms
of actions on the serotonergic system, IFNα, IFNɣ, and IL-2 induce the enzyme indoleamine
2,3-dioxygenase.244 This enzyme is responsible for conversion of L-tryptophan (14) to
kynurenine (45) and quinolic acid (48) or kynurenic acid (47) as shown in Figure 18. This
indoleamine 2,3-dioxygenase-catalyzed metabolism leads to a depletion of L-tryptophan
(14), a precursor of 5-HT (1). The resultant depletion of L-tryptophan (14) could account for
the depressive symptoms observed.245,246 Moreover, the metabolites produced from Ltryptophan (14), 3-hydroxykynurenin (46) and quinolic acid (48), and kynurenic acid (47),
are NMDA receptor antagonist and agonists,247 respectively (Figure 18). Ketamine (33;
Figure 9), an NMDA receptor antagonist, has been shown to have a rapid antidepressant
effect102,106 and kynurenic acid (47) potentially possesses similar properties. On the other
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hand, NMDA receptor agonists can potentially cause depressive symptoms by virtue of
being neurotoxic.248-250
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Figure 18. Metabolism of L-tryptophan (14), a precursor of 5-HT (1), to form the metabolite
kynurenine (45) catalyzed by indoleamine 2,3-dioxygenase which is induced by IFNα, IFNɣ, IL2. Kynurenine (45) is further converted to 3-hydroxykynurenine (46) and quinolic acid (48), both
of which act as NMDA receptor antagonists and possess neurotoxic properties. Kynurenic acid
(47), on the other hand, is a NMDA receptor agonist and possesses neuroprotective properties.
Adapted from Loftis and Hauser228 and Zunszain et al.247
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2. Organic Cation Transporters (OCTs): Novel target for antidepressants
a. Classification:
Organic cation transporters (OCTs) belong to the SLC22 family of transporters.251
The solute carriers (SLCs) consist of 53 families of transporters (SLC1-53; Figure 19)
classified on the basis of their amino acid sequences.251,252 Besides the OCTs, the SLC22
family also consists of organic anion transporters (OATs), carnitine/cation transporters
(OCTNs) and urate transporters (URAT) (Figure 19).251,252 Transport by OCTs is
characterized as being polyspecific, independent of Na+, bidirectional253 and electrogenic.14
They are considered polyspecific and bidirectional since they are capable of transporting
substances varying widely in their sizes254 in either direction. They do not require Na+ to
drive the transport of substrates,253 unlike monoamine transporters such as SERT, NET and
DAT.255 Also, they are electrogenic, i.e., they generate an inward current as a result of
transport.14 OCTs are capable of interacting with a wide variety of substrates as well as
inhibitors254 – from endogenous substrates (e.g., DA,16,17 5-HT,16,17 NE,16,17,256 (4, 1, and 2
respectively in Figures 1 and 2); epinephrine (49), histamine (50) (Figure 20)16,17,256) to drugs
and xenobiotics (e.g., cimetidine (51), metformin (52) (Figure 20)257-262) and model cations
such as 1-methyl-4-phenylpyridinium (MPP+) (53;19,263-267 Figure 20), tetraethylammonium
(TEA+) (54;19,268-271 Figure 20). The substrates can either be positively charged species (e.g.
furamidine (55;272 Figure 20)) or uncharged species (e.g. cimetidine (51;257,258 Figure 20)
They are further subdivided into 3 types – OCT1, OCT2, and OCT3 (Figure 19).251
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Figure 19. A. The solute carrier (SLC) superfamily consists of different types of transporters including
mitochondrial, coupled, vesicular and passive transporters. B. The SLC22 family consists of the organic cation
transporters (OCTs), organic anion transporters (OATs), carnitine/cation transporters (OCTNs) and the urate
transporters (URATs). OCTs transport a wide variety of molecules independent of Na+ and pH and consist of three
subtypes (OCT1-3). Adapted from Hediger et al.251
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Figure 20. Structures of the neurotransmitters epinephrine (49) and histamine (50), antiulcer
drug cimetidine (51), hypoglycemic drug metformin (52), the model substrates 1-methyl-4phenylpyridinium (MPP+) (53) and tetraethylammonium (TEA+) (54), and antiprotozoal and
antifungal drug furamidine (55).

b. Expression:
The expression patterns of the three subtypes of OCTs are overlapping to some extent
and have been identified in various species including rodents such as rats and mice and other
mammals such as rabbits, pigs and humans. The first OCT that was discovered was cloned
from the kidney cells of rats and was named rOCT1.273 Subsequently, the corresponding
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orthologs were cloned from other species such as humans,19,263 rabbits274 and mice.275 OCT2
was also first isolated from rats,276 followed by humans,19 pigs,20 rabbits277 and mice.278
OCT3 was discovered by cloning and expression in the carcinoma cell line of human kidney
cells called Caki-1.256 Subsequently, OCT3 were also isolated and identified from rats14,281
and mice.280
In humans, the mRNA of hOCT1 is primarily detected in the liver19,262,281,282 while
that of hOCT2 is primarily expressed in the kidneys.19,281,282 Additionally, hOCT2 mRNA is
also detected in small intestine, lung, brain and inner ear.16,19,283-285 hOCT3 mRNA, on the
other hand, has a wider expression profile262,280 that includes the heart, liver, kidney, lung,
intestine, adrenal gland, placenta and brain.21 Specifically, hOCT1 is expressed in the
following regions of the human body – in hepatocytes on the sinusoidal (basolateral)
membrane,286 in the intestine on the lateral membrane of epithelial cells,287 in the lung on
the luminal (apical) membrane of the ciliated epithelial cells,283 and in the kidney on the
luminal (apical) membrane of tubule epithelial cells.288 The hOCT2 protein is detected in the
epithelial cells of the proximal tubule of the kidney on the basolateral membrane.286,289 It has
also been detected in the lung on ciliated epithelial cells, specifically the luminal
membrane283 and in the hippocampal region of the brain in pyramidal cells.16 In the brain,
hOCT3 is expressed on glial cells24 including the plasma membrane of astrocytes in
humans.290 Besides this, hOCT3 is also expressed in placenta on the basolateral membrane
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vesicles,266 in the lungs287 and intestine283 on the luminal membranes of epithelial cells and
in the liver on the sinusoidal membrane.262

c. Structure:
OCTs are comprised of ~543-547 amino acids arranged in the form of 12 α-helical
transmembrane domains (TMDs, Figure 21).21,291 The TMDs are connected to each other by
a series of intracellular loops (ICLs) and extracellular loops (ECLs). The N- and C-termini
of OCTs are located intracellularly.21,291 The ECL1 between TMD1 and TMD2 is large and
consists of a number of sites for glycosylation. This is believed to help in localization and
proper functioning of transporter. The ICL3 between TMD6 and TMD7 is also large and
consists of sites that are potentially phosphorylated by protein kinases A, C and G or tyrosine
kinase.21,291 This is a mechanism of regulation of the transporters.21,291 The OCTs share a
high degree of amino acid identity with each other – 70% between OCT1 and OCT2 and
~50% with OCT3.254
Unfortunately, the crystal structures of OCTs have not yet been solved. However,
homology modeling studies of rOCT1 based on the Escherichia coli lactose permease
transporter (PDB ID: 1PV6, 3.5 Å resolution)292 have revealed several amino acids that
might be important in the interactions with substrates and/or inhibitors.293-297 These amino
acids are located in TMDs 4, 10 and 11 and are all located at the same depth creating a
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binding region that is accessible from either the intracellular or the extracellular side.293-297
Mutagenesis studies have subsequently confirmed the importance of these amino acids.295

Figure 21. Schematic representation of OCTs. The 12 transmembrane domains are colored
blue to red from the amino (N) to the carboxyl (C) termini. A large ECL1 contains multiple
potential sites for glycosylation, while a large ICL3 contains multiple potential sites for
phosphorylation.

d. Identification of OCT3 as uptake-2:
Extraneuronal monoamine trasnporters (EMT) also known as uptake-2, were thought
to be low-affinity/high-capacity Na+-independent transporters unlike uptake-1 which are
characterized as high-affinity/low-capacity Na+/Cl--dependent transporters. In 1998, Wu et
al.14 established OCT3 as the EMT/uptake-2 using techniques such as Northern blot analysis,
RT-PCR and in situ hybridization. One of the defining features of the EMT is “sensitivity to
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steroids.”14 rOCT3 was shown to possess this trait by Wu et al.14 specifically with respect to
very similar inhibitory potencies of β-estradiol (56) (Figure 22) at EMT and rOCT3 (IC50 =
1.8 µM and 1.1 µM, respectively).
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β-etsradiol (56)
Figure 22. Structure of β-estradiol (56), having inhibitory potencies of 1.8 µM and 1.1 µM
at EMT and rOCT3,14 respectively.
e. Knockout (KO) mice models:
The three subtypes of OCTs have successfully been knocked out to generate viable
mouse models. These knockout (KO) mouse models have successfully implicated OCTs in
the excretion of drugs. A lack of OCTs in the KO mouse models affected the levels of drugs,
such as m-iodobenzylguanidine (57; Figure 23) and metformin (52; Figure 20), in several
organs including the liver of mice. The levels of model substrates such as TEA+ (54; Figure
20)298 and MPP+ (53; Figure 20),298 drugs such as m-iodobenzylguanidine (57; Figure 23)298
(anticancer) and metformin (52; Figure 20)299,300 (hypoglycemic) in the liver were found to
be lower in OCT1 KO mice as compared to wildtype (WT) mice. Unlike in OCT1 KO mice,
the levels of TEA+ (54) were unaffected in OCT2 KO mice when compared to OCT2 WT
mice.301 This was thought to occur because of compensation by OCT1 expressed in the
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kidney of mice.254 In order to better understand this phenomenon, OCT1/OCT2 double KO
mice were generated.301 These displayed a considerably higher level of TEA+ (54; Figure
20)301 and the drug cisplatin (58; Figure 23)302,285 (anticancer) as compared to WT mice
indicating that OCT1 and OCT2 might be involved in the excretion of MPP+ (53) and
cisplatin (58). The levels of MPP+ (53) were observed to be greatly reduced in the hearts of
OCT3 KO mice as well as in fetuses born of OCT3 KO mice.303 Moreover, OCT3 has also
been implicated in salt-intake regulation304 as well as regulation of behavioral responses to
fear and anxiety.
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Figure 23. Structures of anticancer drugs m-iodobenzylguanidine (57) and cisplatin (58).
f. Polymorphisms:
Single nucleotide polymorphisms (SNPs) have been identified in all three human
OCTs. Kerb et al.305 identified five SNPs resulting in changes in amino acid residues - R61C,
C88R, F160L, G401S, M420del. Out of these five, three of them – R61C, C88R, and G401S
– resulted in a decrease in uptake of MPP+ (53) indicating that these residues are potentially
important for both affinity and selectivity of substrates.305 The mutant M420del did not show
reduced uptake for the model substrate MPP+ (53) but did for metformin (52)
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(hypoglycemic) and might be involved in variability observed among patients.300 Unlike for
hOCT1, hOCT2 was studied in a larger and ethnically much more diverse population
showing 27 potential sites for variations in the gene.306 Some SNPs resulting in single amino
acid mutations were specific for certain groups of populations such as African-American,
and Mexican-American population group.306 It was postulated that because of its role in
excretion of xenobiotics from the kidney, “there is selection against changes in amino acid
sequence of hOCT2”.306 Six SNPs were detected for hOCT3 in a Caucasian population
group.307 However, none of these SNPs resulted in amino acid mutations indicating the
importance of this transporter in the human body.307

g. Updating the monoamine hypothesis:
An increasing number of studies have displayed the therapeutic potential of targeting
OCT3 for antidepressant effect. Administration of corticosterone (59; Figure 24) showed a
greater antidepressant-like effect in the FST when compared to a TCA.308 Corticosterone
(59) is a known blocker of OCTs.308 In 2008, Baganz et al.25 demonstrated an increase both
in mRNA levels as well as protein expression of OCT3 in the hippocampal region of the
mouse brain in SERT+/- (heterozygous) and SERT-/- (knockout) as compared to SERT+/+
(homozygous) mice. Despite this increase in levels of OCT3, no change was observed in
distribution patterns with OCT3 being expressed within the same areas of the hippocampus
as SERT.25 Decynium-22 (60;309 Figure 24), an OCT3 inhibitor (IC50 = 0.9 µM),29 was
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shown to inhibit uptake of histamine (50) by OCT3 to a significantly large extent in SERT/-

mice as compared to SERT+/- and SERT+/+ mice.25 Histamine (50) was utilized since it is a

substrate for OCT3 but not SERT and other monoamine transporters.18,310 A similar trend
was observed in the mouse TST, wherein decynium-22 (60) (1.0 µg/kg) was seen to possess
antidepressant-like activity in SERT-/- and SERT+/- mice but not in SERT+/+ mice.25 This
further cemented the idea that OCT3 might act as a compensatory mechanism of reuptake
of 5-HT (1) from the synapse which might “kick-in” in the absence of SERT (uptake-1) or
upon inhibition of uptake-1 by SSRIs and contribute to unresponsiveness to SSRIs.
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Figure 24. Structures of corticosterone (59), a known blocker of OCTs308 and decynium-22
(60), a known OCT3 inhibitor (IC50 = 0.9 µM).29
In another study, decynium-22 (60; Figure 24) was shown to increase concentrations
of 5-HT (1) in the medial hypothalamus in rats by 200% and ~400% above the baseline in
the absence and presence of mild restraint.303 This indicated a role for OCT3 in the clearance
of 5-HT (1) in the medial hypothalamus.303 Further, Feng et al.311 showed a similar increase
in basal 5-HT (1) levels by 200-650% upon administration of decynium-22 (60) (10, 30 and
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100 µM) by microdialysis in the medial hypothalamus of rats. Activation of the HPA axis
leading to an increase in corticosterone (59), a glucocorticoid, was shown to cause down
regulation of OCT3 as a result of chronic inhibition and decreased 5-HT (1) clearance in
mouse hippocampus leading to an antidepressant-like effect.312
Clinically available antidepressants belonging to the TCA and SSRI class of
antidepressants, such as desipramine (31) (TCA) (Figure 8), amitriptyline (61) (TCA)
(Figure 25), imipramine (23) (TCA) (Figure 5), sertraline (62) (SSRI) (Figure 25),
paroxetine (63) (SSRI) (Figure 25), and FLX (3) (SSRI) (Figure 1), have also been shown
to inhibit hOCT3 using 4-(4-diethylaminostyryl)-1-methylpyridinium (4-Di-1-ASP) (64;
Figure 25) as the substrate.29 The IC50 value (2.3 µM) for sertraline (62) indicated that the
concentration which would be required to inhibit hOCT3 is much higher than what could be
achieved clinically.29 On the other hand, desipramine (31) was shown to have an IC50 value
(0.7 µM) within the range of concentrations attained following clinically used doses.29
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Figure 25. Structures of antidepressants amitriptyline (61), sertraline (62) and paroxetine
(63) and hOCT3 substrate 4-(4-diethylaminostyryl)-1-methylpyridium (4-Di-1-Asp) (64).
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III. Specific aims and rationale
2-Amino-6-chloro-3,4-dihydroquinazoline

(A6CDQ)

(65;

Figure

26)

was

synthesized and developed by the Dukat laboratory as part of SAR studies for ligands acting
at 5-HT3 receptors. A6CDQ (65) was identified to be a potent high-affinity 5-HT3 receptor
antagonist (Ki = 80 nM, IC50 = 0.26 µM).35 5-HT3 receptor antagonists such as ondansetron
(27) and bemesetron (29) had been shown to possess antidepressant-like activity in the
mouse TST.36,37 Thus, A6CDQ (65) was examined in the mouse TST and was shown to
possess antidepressant-like activity (ED50 = 0.23 mg/kg,35 Figure 27). When examined at 40
proteins (including GPCRs, LGICs and transporters) A6CDQ (65) was shown to lack
affinity (Ki > 10,000 nM). Therefore, we hypothesized that the antidepressant-like activity
of A6CDQ (65) might be mediated via 5-HT3 receptor antagonism.
A positional isomer of A6CDQ (65), 2-amino-7-chloro-3,4-dihydroquinazoline
(A7CDQ; 66, Figure 26), was determined to possess 25-fold lower affinity at 5-HT3
receptors (Ki = 1,975 nM) as compared to A6CDQ (65).35 In the mouse TST, A7CDQ (66)
was seen to possess equipotent antidepressant-like activity in comparison to A6CDQ (65)
(Figure 27).313 Both A6CDQ (65) and A7CDQ (66) were 20 times more potent than FLX
(3) (20 mg/kg) (Figure 27). One of the present goals was to determine the functional activity
of A7CDQ (66) at 5-HT3 receptors.
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Figure 26. Structures of positional isomers 2-amino-6-chloro-3,4-dihydroquinazoline
(A6CDQ) (65) and 2-amino-7-chloro-3,4-dihydroquinazoline (A7CDQ) (66).

Figure 27. A6CDQ (65) and A7CDQ (66) are ~20-fold more potent than the commercially
available antidepressants, FLX (3), imipramine (23) and desipramine (31) in the mouse
TST.35,313
FLX (3) belongs to one of the most widely prescribed class of antidepressants - the
SSRIs.38 FLX (3) binds with high affinity (Ki = 1 nM)38 to, and potently inhibits, SERT (IC50
= 0.076 µM)38 to prevent the reuptake of 5-HT (1) from the synapse. This leads to an
enhanced concentration of 5-HT (1) in the synapse resulting in antidepressant effects.
Besides its action at SERT, FLX (3) is also functionally active at 5-HT3 receptors i.e., it is a
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functional 5-HT3 receptor antagonist.39 This implies that FLX (3) has no affinity for the
orthosteric site at 5-HT3 receptors but mediates its antagonism via an allosteric site. We
explored the possibility that the 2-aminodihydroquinazolines, A6CDQ (65) and A7CDQ
(66), might be functionally active at hSERT by conducting radioligand binding,
electrophysiological, molecular modeling and Hydropathic INTeractions (HINT) studies at
hSERT.
The guanidine moiety of 2-aminodihydroquinazolines can exist as protonated species
at physiological pH. Thus, we explored the possibility that our compounds, the 2aminodihydroquinazolines, might possess activity at the OCTs.

The specific aims of the current project are:
1. To determine the functional activity of A7CDQ (66) at 5-HT3 receptors.
Approach:
-

Conduct electrophysiological studies of A7CDQ (66) at m5-HT3A receptors
expressed in Xenopus laevis oocytes.

2. To elucidate the non 5-HT3 serotonergic mechanism of antidepressant-like
activity exerted by A6CDQ (65) and A7CDQ (66) in the mouse TST.
Approach:
-

Obtain binding affinities of A6CDQ (65) and A7CDQ (66) at hSERT.
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-

Determine functional activities of A6CDQ (65) and A7CDQ (66) at hSERT by
performing electrophysiological studies.

-

Conduct molecular modeling studies
•

Generate hSERT models.

•

Dock A6CDQ (65) and A7CDQ (66) at hSERT and study their interactions
to determine their modes of binding.

•

Quantify the observed interactions using Hydropathic INTeraction (HINT)
analysis at chosen hSERT-ligand complexes.

3. To elucidate the non-serotonergic mechanism of antidepressant-like activity of
the 2-aminodihydroquinazoline A6CDQ (65) at uptake-2 (OCT3)
Approach:
-

Determine functional activity of the 2-aminodihydroquinazoline A6CDQ (65) at
OCTs (human and mouse) by measuring uptake of [3H]MPP+ (53).

4. To develop structure-activity relationships (SARs) at uptake-2 (OCT3) that are
currently lacking.
Approach:
-

Synthesize 2-aminodihydroquinazoline and their ring-opened (phenylguanidine)
analogs and to test the activity and selectivity of resulting analogs at OCTs (human
and mouse) by measuring uptake of [3H]MPP+ (53).
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5. To

identify

binding

sites

and

modes

of

interactions

of

2-

aminodihydroquinazoline and phenylguanidine analogs at hOCT3 and mOCT3
using molecular modeling.
Approach:
-

Build 3-dimensional homology models of the human and mouse orthologs of OCT3
(hOCT3 and mOCT3) based on the inorganic phosphate transporter (PiPT) as the
template.

-

Study

interactions

of

2-aminodihydroquinazoline

and

their

ring-opened

phenylguanidine analogs at hOCT3 and mOCT3 by performing docking studies.
-

Quantify interactions observed using HINT analysis for selected hOCT3-ligand
complexes.

6. To determine if 2-aminodihydroquinazoline and phenylguanidine analogs
retain antidepressant-like effect.
Approach:
-

Examine selected examples of 2-aminodihydroquinazoline analogs in the mouse tail
suspension test (TST) at different doses (generate dose-response curves).

-

Examine active doses identified in TST in the locomotor activity assay to assess
potential locomotor stimulant effect.
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An overarching goal of this work is to synthesize compounds necessary to evaluate the
hypotheses that have been developed. The syntheses of all target compounds will be
discussed at the beginning of each section.
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IV. Results and discussion
GOAL 1: To determine the functional activity of A7CDQ (66) at 5-HT3 receptors.

A7CDQ (66) was available from previous studies.313

We examined the activity of A7CDQ (66), the positional isomer of A6CDQ (65), at
m5-HT3A receptors expressed in Xenopus laevis oocytes. Similar to A6CDQ (65),35 A7CDQ
(66) was also found to inhibit 5-HT (1)-induced responses at m5-HT3A receptors (IC50 =
5.77 ± 1.13 µM) albeit with a 22-fold lower potency compared to A6CDQ (65). This,
coupled with the 25-fold lower affinity of A7CDQ (66) (Ki = 1,975 nM)35 at 5-HT3 receptors,
suggested that antagonism at 5-HT3 receptors alone is an insufficient explanation for the
equipotent antidepressant-like effect observed for A6CDQ (65) and A7CDQ (66) in the
animal model of depression.

GOAL 2: To elucidate the non 5-HT3 serotonergic mechanism of antidepressant-like
activity exerted by A6CDQ (65) and A7CDQ (66) in the mouse TST.

The compounds, A6CDQ (65) and A7CDQ (66), were available from previous studies.313
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1. Binding studies at hSERT:
Radioligand binding studies conducted at hSERT using [3H]citalopram indicated that
both A6CDQ (65)313 and A7CDQ (66)313 bind poorly with affinities of 5,852 nM and
>10,000 nM, respectively. FLX (3), besides being a classical SSRI, is also a functional 5HT3 receptor antagonist.39 Functional antagonism implies that FLX (3) does not bind to the
orthosteric binding site but achieves the effect (antagonism) via an alternate site (allosteric
site). Hence, despite their poor binding affinities at the orthosteric binding site of hSERT,
we examined if the 2-aminodihydroquinazolines, A6CDQ (65) and A7CDQ (66), would
behave as allosteric modulators at hSERT using electrophysiological studies. In terms of
receptor chemistry, allosteric modulators are defined as binding to a site distinct from the
orthosteric site and could either be negative, positive or silent allosteric modulators.314,315
All three types of allosteric modulators – negative (NAM), positive (PAM) and silent (SAM)
allosteric modulators, lack intrinsic activity.314,315 NAMs and PAMs cause a decrease and an
increase, respectively, in the responses elicited in the presence of an agonist.314,315 Silent
allosteric modulators on the other hand, do not cause any change in the response.314,315 The
phenomenon of allosterism has been reported for transporters such as for DAT by Schmitt
et al.316 in 2013.
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2. Electrophysiological studies at hSERT:
A6CDQ (65) and A7CDQ (66) were found to possess distinct and unique
electrophysiological signatures at hSERT. A6CDQ (65) (10 µM) produced inward hSERTmediated currents similar to the endogenous ligand 5-HT (1) (5 µM) at comparable potencies
(Km = 2.80 µM and Km = 0.94 µM, respectively) (Figures 28 A and 28 D, respectively).
A7CDQ (66) (100 µM), on the other hand, behaved similar to FLX (3) (1 µM) and produced
an outward hSERT-mediated current albeit with a 600-fold lower potency (Km = 43.6 µM
and 0.076 µM, respectively) (Figures 28 B, 28 C and 28 D).
NH 2
NH 2
N

N

NH

NH

Cl

NH 2
N

Cl

NH

Cl

NH 2
N

NH

Cl

Figure 28. A. A6CDQ (65) (10 µM) induced an inward hSERT-mediated current similar to
5-HT (1) (5 µM). B. A7CDQ (66) (100 µM) induced an outward hSERT-mediated current
similar to C. FLX (3) (1 µM). D. A6CDQ (65) similar to 5-HT (1) behaves as a releaser and
A7CDQ (66) similar to FLX (3) behaves as a reuptake inhibitor.

In order to confirm that A7CDQ (66) is a reuptake inhibitor, we tested A7CDQ (66)
in combination with the transport releasers 5-HT (1) and A6CDQ (65). A7CDQ (66) (50
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µM) successfully blocked (i.e., decreased the amplitude of the inward hSERT-mediated
currents by 5-HT (1) (2 µM) (Figure 29 A) and abolished the inward hSERT-mediated
currents by A6CDQ (65) (10 µM) (Figure 29 B)). FLX (3), on the other hand, besides
abolishing the inward hSERT-mediated current by A6CDQ (65), produced a hyperpolarizing
outward hSERT-mediated current (Figure 29 C). Therefore, A7CDQ (66) successfully
antagonized A6CDQ (65) and appeared to behave as a reuptake inhibitor at hSERT, whereas
A6CDQ (65) behaved as a releaser.
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NH 2
NH 2
N

N
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Figure 29. A. A7CDQ (66) (50 µM) blocked the inward hSERT-mediated currents by 5-HT
(1) (2 µM) at hSERT and B. completely abolished inward hSERT-mediated currents by
A6CDQ (65) (10 µM). C. FLX (3) (2 µM) abolished hSERT-mediated currents by A6CDQ
(65) (10 µM) and lead to an outward hSERT-mediated current.
To determine the mechanism of inhibition exerted by A7CDQ (66) at hSERT, kinetic
studies were performed in the absence and presence of varying concentrations of A7CDQ
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(66) (20, 50 and 100 µM, representative recording at 50 µM of A7CDQ (66) shown in Figure
30 B). 5-HT (1) induced inward hSERT-mediated currents in the absence of A7CDQ (66)
(Figure 30 A) generated a Km = 1.3 ± 0.2 µM (Figure 30 C). 5-HT (1) induced inward
hSERT-mediated currents in the presence of 20, 50 and 100 µM of A7CDQ (66) gave the
following Km = 2.1 ± 0.3 (Vmax = 112.3 ± 2.8); Km = 2.3 ± 0.3 (Vmax = 106.7 ± 3.3) and Km
= 2.8 ± 0.3 (Vmax = 102.3 ± 2.2), respectively (Figure 30 C). Statistically significant
differences in Km values and no difference in Vmax values were observed leading to the
conclusion that the mode of inhibition by A7CDQ (66) is competitive in nature.
The low binding affinity of A7CDQ (66) (Ki > 10,000 nM) poses a conundrum in
light of its competitive nature. [3H]Citalopram was the radioligand employed to measure the
binding affinities of both A6CDQ (65) and A7CDQ (66). The low binding affinity of
A7CDQ (66) could potentially be explained by its very poor activity at hSERT, i.e., 600fold lower inhibitory potency of A7CDQ (66) as compared to FLX (3) (Ki = 1 nM) at hSERT.
In the radioligand binding assay, the maximum concentration of A7CDQ (66) tested was 10
µM. There exists a possibility that, had A7CDQ (66) been tested at a higher concentration
(i.e., approaching its IC50), we might have obtained a value for the binding affinity. Thus,
A7CDQ (66) appears to be a competitive reuptake inhibitor of extremely low affinity and
potency.
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Figure 30. A. Electrical recordings of 5-HT (1) induced hSERT-mediated inward currents
at different concentrations of 5-HT (1) (0.1-30 µM) in the absence of A7CDQ (66). B.
Representative electrical recording of 5-HT (1) (0.1-100 µM) induced hSERT-mediated
inward currents in the presence of A7CDQ (66) (50 µM). Similar recordings were also
obtained in the presence of two other concentrations of A7CDQ (66) (20, 100 µM) not shown
here. C. Concentration-response curves of 5-HT (1) in the absence and presence of A7CDQ
(66) (20, 50 and 100 µM). Km = 1.3 ± 0.2 µM for 5-HT (1) in the absence of A7CDQ (66).
Km = 2.1 ± 0.3 µM (Vmax = 112.3 ± 2.8); Km = 2.3 ± 0.3 µM (Vmax = 106.7 ± 3.3); Km = 2.8
± 0.3 µM (Vmax = 102.3 ± 2.2) for 5-HT (1) when concentration of A7CDQ (66) is 20, 50
and 100 µM, respectively.

3. hSERT homology modeling studies:
Having determined that A6CDQ (65) and A7CDQ (66) possess activity at hSERT,
we wished to study their interactions at a molecular level. Switching the position of the
chloro group from the 6- to the 7-position changed the activity from a releaser to a reuptake
inhibitor at hSERT. We conducted molecular modeling studies to determine if there exist
differences in the interactions of the chloro group at the two positions. SERT, along with
DAT and NET, belong to the SLC6 family of transporters. At the time, the crystal structure
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of hSERT was unavailable; thus, we utilized the crystal structure of the Drosophila
melanogaster dopamine transporter (dDAT) co-crystallized with nortriptyline (TCA) (PDB
ID: 4M48).317 Subsequently, in April 2016, the crystal structure of hSERT (PDB ID: 5I6X,
3.15- Å resolution) was solved by Coleman et al.318 in complex with the antidepressants
paroxetine (63) and (S)-citalopram. We compared our homology models with the crystal
structure of hSERT using Sybyl X-2.1 and determined that they differed by a root mean
square deviation (RMSD) of 2.8 Å (Figure 31 A). For large molecules, such as proteins, a
RMSD of <4.0 Å indicates a high degree of similarity.319 The amino acid residues are
numbered differently in the crystal structure and our homology models (discussed in
‘construction and validation of models’). A majority of the residues contributing to the
binding site seem to be oriented in an overlapping manner (Figure 31 B) except for Phe341
(Phe333 in our model) and Ser439 (Ser430 in our model) indicating that our model was
strikingly similar to the crystal structure. The phenyl side chain of Phe341 was seen to be
interacting with the cyanophthalane and fluorophenyl moieties of (S)-citalopram and
paroxetine (63), respectively.318 This interaction might be responsible for the conformation
of the phenyl side chain observed in the crystal structure of hSERT. Ser439 in the crystal
structure, along with other hydrophobic residues create a pocket or cavity which is primarily
hydrophobic in nature.318 This pocket or cavity accommodates the fluoro and dioxol ring
groups of (S)-citalopram and paroxetine (63), respectively.318 In contrast, Ser430 (equivalent
to Ser439 in the crystal structure) in our modeling studies is involved in polar interactions
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with the nitrogen atoms of both A6CDQ (65) and A7CDQ (66). This difference in the nature
of interaction of the Ser residue might pose a problem.

Phe335
(Phe327)

Phe341
(Phe333)
Ala169

Ser336
(Ser328)
Tyr95 Ser439
(Ser430)

Ile172

Ala173
Asp98

Tyr176

Figure 31. A. Crystal structure of hSERT (PDB ID: 5I6X, 3.15-Å resolution) overlapped
with homology models of hSERT displayed as wheat and pale cyan colored ribbons,
respectively. B. The binding site residues of the crystal structure (wheat colored capped
sticks) overlap well with the residues of the homology models (pale cyan-capped sticks)
except for Phe341 and Ser430. The numbering for amino acid residues of our homology
model are shown in parenthesis for those residues whose numbering differs from the crystal
structure.

a. Construction and validation of models:
One hundred 3-dimensional homology models of hSERT were constructed on the
basis of alignment by Sakloth et al.320 The amino acid residues from both the C- and Ntermini (13 and 76 residues, respectively) were truncated as well as those from extracellular
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loop 2 (7 residues). Since SERT is dependent on Na+ and Cl- ions for transport of 5-HT (1),
we extracted two Na+ and one Cl- ions from the crystal structure of dDAT and merged it
with each of the 100 homology models prior to docking of ligands.
To validate the models, we docked the substrate 5-HT (1) and the known competitive
inhibitor FLX (3) at the central substrate (S1) site. We used the residues – Asp98 and Ile172
– to define a binding site since mutagenesis data implicated their importance for binding of
5-HT (1).321 The binding mode for 5-HT (1) identified by our modeling studies was in
agreement to previously conducted studies.322 The protonated amine of 5-HT (1) is involved
in an ionic salt-bridge interaction with the carbonyl oxygen of Asp98 (Figure 32 and 34).
The phenyl ring of 5-HT (1) is involved in a number of interactions, such as hydrophobic
interactions with Ile172, Ala173, Gly434 and an edge-to-face cation-π interaction with
Tyr176 (Figure 32 and 34). Additionally, the 5-OH group of 5-HT (1) is involved in an Hbonding interaction with the backbone carbonyl of Thr431 (Figure 32 and 34). For FLX (3),
the binding mode identified by us was similar to that reported for LeuBAT.323 The protonated
amine of FLX (3), in addition to being involved in an ionic salt-bridge interaction with
carbonyl oxygens of Asp98, is also involved in H-bond interactions with the backbone
carbonyls of Tyr95 and Ala96 (Figure 33). The aromatic rings of FLX (3) – an unsubstituted
phenyl ring and a CF3-substituted phenyl ring – are involved in hydrophobic interactions
with Ile172 and Thr489 and with Ile172, Thr431 and Gly434, respectively (Figure 33).
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Figure 32. Structure of 5-HT (1) docked at hSERT. The ligand and amino acid
residues are shown as green and pale-cyan capped sticks, respectively. Chloride
(lime green) and sodium (marine blue) ions are represented as spheres. The
dashed red line indicates an ionic salt-bridge interaction between the protonated
N-atom of the ligand and the O-atom of the carboxylate group of Asp98.
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Figure 33. Structure of FLX (3) docked at hSERT. The ligand and amino acid residues
are shown as cyan and pale cyan-capped sticks, respectively. Chloride (lime green) and
sodium (marine blue) ions are represented as spheres. The dashed red lines indicate a
bidentate ionic salt-bridge interaction between the protonated N-atom of the ligand and
the O-atoms of the carboxylate group of Asp98.
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b. Docking studies and Hydropathic INTeraction (HINT) analysis:
The electrophysiological and mechanistic studies indicated that A7CDQ (66) acts
similar to the known reuptake inhibitor FLX (3) and inhibits 5-HT (1) in a competitive
manner at hSERT. A6CDQ (65), by virtue of being a releaser similar to 5-HT (1), and being
inhibited by both A7CDQ (66) and FLX (3), might interact at the same site as 5-HT (1).
Thus, both A7CDQ (66), an inhibitor, and A6CDQ (65), a releaser, interact at the same site.
These findings are supported by literature evidence for DAT where both releasers320,324 and
reuptake inhibitors325 interact at the same site and utilize similar amino acid residues.
Therefore, we performed modeling studies by docking the 2-aminodihydroquinazolines,
A6CDQ (65) and A7CDQ (66), at the 5-HT (1) central substrate (S1) binding site using the
two amino acid residues - Asp98 and Ile172 - to define the site.
A6CDQ (65) and A7CDQ (66), docked in a highly similar and overlapping manner
with respect to each other (Figure 34 and 35). The N-atoms of the guanidinium moiety of
the 2-aminodihydroquinazolines were involved in a bidentate salt-bridge ionic interaction
with the carboxylate O-atom of Asp98 at hSERT (Figure 34 and 35). The phenyl rings of
A6CDQ (65) and A7CDQ (66) are involved in hydrophobic interactions with Ile172 and an
edge-to-face cation-π interaction with the phenyl ring of Tyr176 (Figure 34 and 35). The
chloro group of both A6CDQ (65) and A7CDQ (66) are surrounded by a subset of common
and additional distinct hydrophobic amino acid residues. The common hydrophobic amino
acid residues include – Ile172, Ala173, Gly434 and Leu435 (Figure 35). A6CDQ (65), in
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addition is also involved in hydrophobic interactions with Ala169; while A7CDQ (66) is
additionally involved with Tyr176 and Thr431 (Figure 35).

Figure 34. Superimposed structures of 2-aminodihydroquinazolines A6CDQ (65) (orange)
and A7CDQ (66) (magenta) as well as 5-HT (1) (green) and FLX (3) (cyan) docked at
hSERT. The ligands and amino acid residues are shown as capped sticks and pale cyancapped sticks, respectively. Chloride (lime green) and sodium (marine blue) ions are
represented as spheres. The dashed red lines indicate ionic salt-bridge interactions between
the protonated N-atoms of the ligands and the O-atoms of the carboxylate group of Asp98.
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Figure 35. Structures of the 2-aminodihydroquinazolines A6CDQ (65) (orange) and A7CDQ
(66) (magenta) superimposed at the central substrate (S1) binding site of hSERT. The ligands
and amino acid residues are displayed as capped sticks and pale cyan-capped sticks,
respectively. Chloride (lime green) and sodium (marine blue) ions are represented as spheres.
The dashed red lines indicate a bidentate ionic salt-bridge interaction between the N-atoms
of the guanidinium moiety and the O-atom of the carboxylate group of Asp98.
To quantify the interactions observed in our modeling studies we conducted a
Hydropathic INTeraction (HINT) analysis.326 HINT is defined as the sum of electrostatic
and hydrophobic interactions between any two molecules,326 in our case, the transporter,
hSERT and our compounds, A6CDQ (65) and A7CDQ (66). HINT takes into account both
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favorable and unfavorable interactions and a higher HINT score implies favorable
interactions between the two molecules.326
Of the four molecules – 5-HT (1), FLX (3), A6CDQ (65) and A7CDQ (66) - the
known releaser, 5-HT (1) and the reuptake inhibitor, FLX (3) were shown to possess a high
positive HINT score (913 and 1931, respectively) (Table 1). FLX (3) possessed a ~2-fold
higher HINT score than 5-HT (1) and had the highest hydrophobic and electrostatic (polar)
interactions at hSERT (Table 1). The 2-aminodihydroquinazolines A6CDQ (65) and
A7CDQ (66) have 1.8- and 3.2-fold lower HINT scores than 5-HT (1) and FLX (3),
respectively (Table 1). Our HINT analysis is in agreement with the electrophysiological data
obtained and might account for the lower potency and affinity observed for A6CDQ (65)
and A7CDQ (66) at hSERT. The much larger molecule, FLX (3), seems to be capable of
making both greater electrostatic (polar) and hydrophobic interactions at hSERT as
compared to 5-HT (1), A6CDQ (65) and A7CDQ (66).

Our compounds, the 2-

aminodihydroquinazolines, by virtue of being smaller, lack these extensive electrostatic
(polar) and hydrophobic interactions.
The HINT score can be broken down into components consisting of contributions
from individual atoms.326 Among the four shared hydrophobic amino acid residues – Ile172,
Ala173, Gly434 and Leu 435 – the chloro group at the 6-position of A6CDQ (65) makes
higher scoring hydrophobic interactions with these than the chloro group at the 7-position of
A7CDQ (66) (Table 2). Moreover, the 6-Cl group of A6CDQ (65) is also involved in
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hydrophobic interactions with Ala169 that is lacking for the 7-Cl group of A7CDQ (66)
(Table 2). In contrast, the 7-Cl group of A7CDQ (66) is involved with two additional
hydrophobic amino acid residues Tyr176 and Thr431 (Table 2).

Table 1. Summary of HINT scores of 5-HT (1), A6CDQ (65), FLX (3) and A7CDQ (66) at
hSERT. The total HINT score and hydrophobic component for FLX (3) are highlighted in
blue since these are the highest of the four compounds.

Ligand

HINT
score

Hydrophobic

Total
Polar

Polar
interactions with
Asp98

Hydrophobic
interactions
with Ile172

5-HT (1)

913

458

1416

1073

20

A6CDQ (65)

509

559

465

345

88

FLX (3)

1931

1018

1794

875

291

A7CDQ (66)

596

576

596

332

84

64

Table 2. Residue-based break down of HINT scores of A6CDQ (65) and A7CDQ (66) with
respect to the chloro group. The amino acids highlighted in blue are distinct for A6CDQ (65)
and A7CDQ (66).

Ligands

Amino acids involved in
hydrophobic interactions
with chloro group of
ligands

Hydrophobic
contributions to HINT
score

A6CDQ (65)

Ala169

47

Ile172

59

Ala173

45

Gly434

44

Leu435

23

Ile172

26

Ala173

40

Tyr176

15

Thr431

58

Gly434

10

Leu435

21

A7CDQ (66)
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GOAL 3: To elucidate the non-serotonergic mechanism of antidepressant-like activity
of the 2-aminodihydroquinazoline A6CDQ (65) at uptake-2 (OCT3).

Since neither 5-HT3 receptor antagonism nor activities at hSERT could explain their
equipotent antidepressant-like effect in the mouse TST, and because guanidines have been
shown

to

interact

with

OCTs,254

we

examined

our

compounds,

the

2-

aminodihydroquinazoines, at OCTs. The functional studies were conducted in HEK293 cells
expressing human and mouse OCT1-3 by measuring the uptake of [3H]MPP+ (53).

In a preliminary screening, A6CDQ (65) was examined and found to inhibit hOCT3
(IC50 = 3.9 µM; Table 3). Further examination showed that A6CDQ (65) inhibited all three
subtypes of hOCT (Table 3). Moreover, A6CDQ (65) was seen to possess ~4-fold selectivity
for hOCT3 over hOCT2 and was not selective for hOCT3 over hOCT1 (Table 3). Thus it
became our lead in the formulation of SAR currently lacking for OCT3.

GOAL 4: To develop structure-activity relationships (SARs) at uptake-2 (OCT3) that
are currently lacking.
We wished to determine the role played by the chloro group by exploring both the
importance of its presence and position.
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1. Role of the chloro group:

Hypothesis 1: If the presence and position of the chloro substituent contribute to OCT3
inhibition, its positional isomers should be less active or inactive compared to A6CDQ (65).

We tested this hypothesis by synthesizing and examining the other positional isomers, the
5-chloro (A5CDQ; 67), 7-chloro (A7CDQ; 66), and the 8-chloro (A8CDQ; 68) as well as
the des-Cl (ADQ; 69) 2-aminodihydroquinazoline analogs at OCT1-3. ADQ (69)327 was
resynthesized for the current studies. The synthesis of A8CDQ (68) and ADQ (69) are
outlined in Scheme 1 and 2, respectively.

The synthesis of 2-amino-8-chloro-3,4-dihydroquinazoline (A8CDQ; 68) involved
cyclization of 2-amino-3-chlorobenzylamine (71) with cyanogen bromide as shown in
Scheme 1 using a procedure known for other benzylamines.328 2-Amino-3chlorobenzylamine (71) was obtained by reduction of the nitrile group of 2-amino-3chlorobenzonitrile (70) using a procedure reported in the literature for other benzonitrile
scaffolds involving BH3·THF complex.329
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Scheme 1.a Synthesis of A8CDQ (68).
NH 2

Cl
3
4

NH 2
2
1 CN
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3
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a
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72
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a

NH 2 NH 2
2
1
5

N

NH

8

Cl

b,c

6

7

73
71

6

5

68 (68)
A8CDQ

Reagents and conditions: a. BH3·THF, reflux; b. CNBr, toluene, reflux; c. HCl/EtOH

ADQ (69) was synthesized in two steps according to a reported procedure327 starting from
isatoic anhydride (72) to give 2-aminoquinazolin-4(3H)-one (73) and the carbonyl group of
the amide was reduced using a BH3·THF complex based on a literature procedure for the
same compound.327

Scheme 2.a Synthesis of ADQ (69).
NH 2

O
N

O
O

70
72

a

NH 2

NH

a

O

71
73

N

NH

b,c

ADQ
ADQ(69)
(69)

Reagents and conditions: a. S-methylpseudothiourea sulfate, Na2CO3, 80% aq. MeCN,

reflux; b. BH3·THF, reflux; c. HCl/EtOH
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The structures of 2-amino-8-chloro-3,4-dihydroquinazoline hydrochloride (A8CDQ; 68)
and 2-amino-3,4-dihydroquinazoline hydrochloride (ADQ; 69) were confirmed by IR, 1H
NMR and elemental analysis for C, H, N.

At all three OCTs, the presence of the chloro group was important for inhibitory
activities. At hOCT3 specifically, removing the chloro substituent, resulting in ADQ (69)
(IC50 = 12.2 µM), led to a ~3-fold decrease in potency as compared to the lead, A6CDQ (65).
Shifting the chloro group to the 5-position in A5CDQ (67) (IC50 = 0.9 µM), led to a ~4.5fold improvement in inhibitory potency as compared to the lead, A6CDQ (65). More
importantly, we observed a ~13-fold increase in potency for A5CDQ (67) as compared to
ADQ (68) (IC50 = 12.2 µM) (see Table 3). The position of the chloro group is not as critical
as its presence, since all the chloro-substituted 2-aminodihydroquinazoline positional
isomers (A5CDQ (67), A6CDQ (65), A7CDQ (66) and A8CDQ (68)) possessed comparable
inhibitory potencies at hOCT1-3 (Table 3).
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Table 3. Inhibitory potencies of chloro-substituted 2-aminodihydroquinazoline analogs at
hOCT1-3 determined by measuring uptake of [3H]MPP+ (53).
Ligand
ADQ
A5CDQ
NH
A6CDQ
A7CDQ
A8CDQ

NH 2
N
8
R
7

5

(69)
(67)
(65)
(66)
(68)

R

hOCT1

IC50 ± SEM (µM)
hOCT2

H
5-Cl
6-Cl
7-Cl
8-Cl

14.5 ± 3.5
2.3 ± 0.8
3.0 ± 0.8
4.8 ± 1.2
6.1 ± 0.4

46.5 ± 1.1
13.3 ± 6.9
16.4 ± 4.7
9.2 ± 2.8
26.1 ± 19.7

hOCT3
12.2 ± 3.4
0.9 ± 0.2
3.9 ± 2.4
5.9 ± 3.9
1.9 ± 0.2

6

To better understand the role of the chloro substituent, we examined the contribution
of the lipophilic and electronic properties of the chloro group to the inhibitory potency at
hOCT1-3. Our preliminary molecular modeling studies suggested that the chloro group on
the 6-position is involved in hydrophobic interactions at hOCT3 (Figure 36).
Figure 36. Structures of A6CDQ (65)
(orange) and A6MDQ (74) (cyan) docked
at the substrate binding region of hOCT3.
The ligands and amino acid residues are
displayed as capped sticks and light bluecapped sticks, respectively. The dashed
red lines indicate bidentate ionic saltbridge interactions between two N-atoms
of the guanidinium moiety and an O-atom
of the carboxylate group of Asp478. The
Cl and CH3 groups of A6CDQ (65) and
A6MDQ (74) and the hydrophobic amino
acid residues – Trp358, Aal362, Tyr365
and Gln366 are displayed as space-filling
spheres.
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We utilized the classical medicinal chemistry approach of Craig’s plot330 to consider
the 6-methyl analog (A6MDQ; 74). The Craig plot divides substituents into four quadrants
on the basis of their lipophilic and electronic properties (Figure 37).330 A methyl group
possesses similar lipophilic (π = 0.71 and 0.56 for chloro and methyl, respectively)331 but
opposite electronic (σ = 0.23 and -0.17 for chloro and methyl, respectively)331 properties in
comparison to a chloro group (Figure 37).330 The preliminary molecular modeling and
docking studies of A6MDQ (74), displayed a high degree of similarity in the poses of
A6CDQ (65) and A6MDQ (74) at the binding region of hOCT3. Our modeling studies
predicted that A6MDQ (74) will possess activity at hOCT3.

Figure 37. The Craig plot consists of substituents divided on the basis of their electronic
(σ) and lipophilic (π) properties. The chloro and methyl group, encircled in red, possess
similar lipophilic (π) and opposite electronic (σ) properties. Adapted from Craig.330
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Hypothesis 2: If the lipophilic (π) property of the chloro substituent of A6CDQ (65)
contributes to OCT3 inhibition, then the 6-methyl analog (A6MDQ; 74) should be equally
active or more active compared to A6CDQ (65).

The 6-methyl analog, A6MDQ (74) was synthesized in collaboration with Malaika D.
Argade, a graduate student in the Dukat laboratory and its synthesis is shown in Scheme 3.

A6MDQ (74) (IC50 = 2.0 µM; Table 4), was observed to possess comparable
inhibitory potency at hOCT3 as A6CDQ (65) (IC50 = 3.9 µM; Table 3), thereby validating
our hypothesis and supporting our modeling studies. Therefore, the lipophilic (π) property
of the substituent at the 6-position appears to be more important than the electronic (σ)
property. To determine if this holds true for the other positions (5, 7 and 8), we synthesized
and tested the 5-methyl (A5MDQ; 75), 7-methyl (A7MDQ; 76) and the 8-methyl (A8MDQ;
77) analogs as outlined in Scheme 4.
A6MDQ (74) was synthesized in a three-step reaction beginning from oxidation of
5-methylisatin (78) to give 6-methylisatoic anhydride (79) using freshly-prepared urea-H2O2
complex332 according to a procedure by Deligeorgiev et al.333 The 6-methylisatoic anhydride
(79) was converted to 2-amino-6-methylquinazolin-4(3H)-one (80) by reacting it with Smethylpseudothiourea sulfate using a reported procedure.327 Reduction of the amide group
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of 80 was carried out using BH3·THF complex as per a literature procedure for compounds
with quinazoline scaffolds but different substituents334 to give A6MDQ (74).

Scheme 3.a Synthesis of A6MDQ (74).
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5
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6
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6
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78
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N

NH

c,d
6
CH 3
A6MDQ (74)

Reagents and conditions: a. urea-H2O2 complex, HCOOH, H2SO4, sonication; b. S-

methylpsuedothiourea sulfate, Na2CO3, 80% aq. MeCN, reflux; c. BH3·THF, reflux; d.
HCl/EtOH

The synthesis of 2-amino-5-methyl-3,4-dihydroquinazoline (A5MDQ; 75), 2-amino-7methyl-3,4-dihydroquinazoline

(A7MDQ;

76)

and

2-amino-8-methyl-3,4-

dihydroquinazoline (A8MDQ; 77) involved cyclization of the appropriately substituted 2aminobenzylamines (84-86) with cyanogen bromide as shown in Scheme 4 using a
procedure known for other benzylamines.328 The 2-aminobenzylamine analogs (84-86) were
obtained by reduction of a nitrile group on appropriately substituted 2-aminobenzonitriles
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(81-83) using a procedure reported in literature for other benzonitrile scaffolds involving
BH3·THF complex.329
Scheme 4.a Synthesis of A5MDQ (75), A7MDQ (76) and A8MDQ (77).
NH 2

NH 2
2
1 CN
3
R
6
4
5

a

N

b,c

8
R
7

6

NH

5

R = 8-CH3 (77)
= 7-CH3 (76)
= 5-CH3 (75)

R = 3-CH3 (84)
= 4-CH3 (85)
= 6-CH3 (86)

R = 3-CH3 (81)
= 4-CH3 (82)
= 6-CH3 (83)

a

NH 2 NH 2
2
3
1
R
6
4
5

Reagents and conditions: a. BH3·THF, reflux; b. CNBr, toluene, reflux; c. HCl/EtOH

The structures of 2-amino-6-methyl-3,4-dihydroquinazoline hydrochloride (A6MDQ; 74),
2-amino-5-methyl-3,4-dihydroquinazoline
dihydroquinazoline

hydrochloride

(A5MDQ;

(A7MDQ;

76)

75),

2-amino-7-methyl-3,4-

and

2-amino-8-methyl-3,4-

dihydroquinazoline hydrochloride (A8MDQ; 77) were confirmed by IR, 1H NMR, and
elemental analysis for C, H, N.

Following the synthesis and characterization of the compounds, we tested A5MDQ
(75), A7MDQ (76) and A8MDQ (77) at hOCT1-3. At the 5- and 7-position too, the lipophilic
(π) property of the substituent seems to be more important than the electronic (σ) property,
since both A5MDQ (75) and A7MDQ (76) possess comparable inhibitory potencies at
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hOCT3 compared to their chloro-substituted counterpart, A5CDQ (67) and A7CDQ (66)
(Table 4 and 5). Furthermore, in both series, potency decreases in the same rank order: 5 >
6 > 7 > H.
Table 4. Inhibitory potencies of methyl-substituted 2-aminodihydroquinazoline analogs at
hOCT1-3 determined by measuring uptake of [3H]MPP+ (53).
Ligand
ADQ
(69)
A5MDQ (75)
N
NH
A6MDQ (74)
8
A7MDQ (76)
R
A8MDQ (77)
5
7
NH 2

IC50 ± SEM (µM)
hOCT2

R

hOCT1

H
5-CH3
6-CH3
7-CH3
8-CH3

14.5 ± 3.5
4.6 ± 0.6
8.2 ± 2.2
6.3 ± 1.3

46.5 ± 1.2
26.4 ± 0.7
12.1 ± 0.3
12.1 ± 3.2
NDa

hOCT3
12.2 ± 3.4
0.5 ± 0.0
2.0 ± 0.4
8.4 ± 4.3

6
a

Note added in proof (see Appendix A)

Table 5. Comparison of inhibitory potencies of chloro- and methyl-substituted 2aminodihydroquinazoline analogs at hOCT1-3 determined by measuring uptake of
[3H]MPP+ (53).
Ligand
NH 2
N
8
R
7

NH

5

ADQ
(69)
A5MDQ (75)
A6MDQ (74)
A7MDQ (76)
A8MDQ (77)

R
H
5-CH3
6-CH3
7-CH3
8-CH3

IC50 ± SEM (µM)
hOCT3
Ligand
12.2 ± 3.4
0.5 ± 0.0
2.0 ± 0.4
8.4 ± 4.3
NDa

6
a

Note added in proof (see Appendix A)
75

ADQ (69)
A5CDQ (67)
A6CDQ (65)
A7CDQ (66)
A8CDQ (68)

R
H
5-Cl
6-Cl
7-Cl
8-Cl

hOCT3
12.2 ± 3.4
0.9 ± 0.2
3.9 ± 2.4
5.9 ± 3.9
1.9 ± 0.2

2. Probing the 6-position of 2-aminodihydroquinazolines:
In order to further probe the 6-position with respect to steric properties and bulk, we
synthesized a series of halo-substituted 2-aminodihydroquinazoline analogs (i.e. 6-F, 6-Br
and 6-I) and tested them against hOCT1-3 for their activity and selectivity. The synthesis of
A6FDQ (87) is shown in Scheme 5 and that for A6BrDQ (88) and A6IDQ (89) are shown
in Scheme 6.
For A6FDQ (87), the corresponding 6-fluoroisatoic anhydride (91) was synthesized
by oxidation of 5-fluoroisatin (90) using a freshly prepared urea-H2O2 complex332 in the
presence of sulphuric acid as a catalyst using a procedure reported in literature for the same
compound.333 The 6-fluoroisatoic anhydride (91) was converted to 2-amino-6fluoroquinazolin-4(3H)-one (92) whose amide group was reduced to give A6FDQ (87).
Scheme 5.a Synthesis of A6FDQ (87).

HN

N

O

O

O

a

a

NH 2

O

O

5
F

F

90

91

NH
O

b

6

NH 2
N

NH

c,d

6
F

6
F

92

A6FDQ (87)

Reagents and conditions: a. urea-H2O2 complex, HCOOH, H2SO4, sonication; b. S-

methylpseudothiourea sulfate, Na2CO3, 80% aq. MeCN, reflux; c. BH3·THF, reflux; d.
HCl/EtOH
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Similar to the methyl substituted series the synthesis of 2-amino-6-bromo-3,4dihydroquinazoline (A6BrDQ; 88) and 2-amino-6-iodo-3,4-dihydroquinazoline (A6IDQ;
89) was carried out by cyclization of 2-amino-5-bromobenzylamine (95) and 2-amino-5iodobenzylamine (96), respectively, with cyanogen bromide as shown in Scheme 6 using a
procedure known for other benzylamines.328 The reduction of the nitrile group on 2-amino5-bromobenzonitrile (93) and 2-amino-5-iodobenzonitrile (94) was conducted following a
procedure reported in the literature for other benzonitrile scaffolds involving BH3·THF
complex.329

Scheme 6.a Synthesis of A6BrDQ (88) and A6IDQ (89)
NH 2

4

5
X

6

X = Br (93)
X = I (94)

a

N

NH 2 NH 2
2
3
1

NH 2
2
1 CN
3

a

4

5
X

8

b,c

6

NH

7

6
X

5

X = Br (A6BrDQ; 88)
X = I (A6IDQ; 89)

X = Br (95)
X = I (96)

Reagents and conditions: a. BH3·THF, reflux; b. CNBr, toluene, reflux; c. HCl/EtOH

The structures of 2-amino-6-fluoro-3,4-dihydroquinazoline hydrochloride (A6FDQ;
87) and 2-amino-6-bromo-3,4-dihydroquinazoline hydrobromide (A6BrDQ; 88) were
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confirmed by IR, 1H NMR and elemental analysis for C, H, N while that of 2-amino-6-iodo3,4-dihydroquinazoline (A6IDQ; 89) was confirmed by IR, 1H NMR and MS.

With respect to both volume and lipophilicity (π), the values increase from fluoro to
iodo, while for the electronic (σ) property the values are comparable between the halogens
(Table 6). When tested at hOCT1-3, the 6-fluoro analog (A6FDQ (87); IC50 = 0.5 µM) was
at least 3-folds more potent than the lead, A6CDQ (65) (Table 7). This contradicts our earlier
finding, that the lipophilicity (π) of the substituent at the 6-position is more important than
the electronic (σ) properties as the fluoro group is less lipophilic compared to the chloro
group (Table 6). However, at this point we do not know if our compounds act as substrates
for hOCTs. Hence, there might exists differences in SAR for substrates and inhibitors which
might explain the comparable inhibitor potency of A6FDQ (87) and A6CDQ (65) (Table 7).
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Table 6. Values for volume,a electronic (σ) and lipophilic (π) properties331 of halogen
substituents at the 6-position of 2-aminodihydroquinazoline analogs.

H
ADQ (69)

F

I

Br

Cl

A6FDQ (87) A6CDQ (65) A6BrDQ (88) A6IDQ (89)

Volume (Å)

480.3

495.9

530.3

529.0

544.0

σ

0.00

0.06

0.23

0.23

0.18

π

0.00

0.14

0.71

0.86

1.12

a

Calculated for the entire molecule using SYBYL X-2.1 (Tripos International)

Table

7.

Inhibitory

potencies

of

unsubstituted

and

6-halo-substituted

2-

aminodihydroquinazoline analogs at hOCT1-3 determined by measuring uptake of
[3H]MPP+ (53).

NH 2

Ligand

R

ADQ
(69)
H
A6CDQ (65) 6-Cl
A6FDQ (87) 6-F
8
R
A6BrDQ (88) 6-Br
5
7
A6IDQ (89) 6-I
6
a
Note added in proof (see Appendix A)
N

NH

IC50 ± SEM (µM)
hOCT1
hOCT2
hOCT3
14.5 ± 3.5
3.0 ± 0.8
1.3 ± 0.1
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46.5 ± 1.1
16.4 ± 4.7
11.9 ± 0.2
NDa
NDa

12.2 ± 3.4
3.9 ± 2.4
0.5 ± 0.0

3. Role of the methylene bridge:
Our next goal was to determine if the entire quinazoline ring contributes to OCT3 inhibitory
action.

Hypothesis 3: If the intact quinazoline ring contributes to OCT3 inhibition, ring-opened
analogs should be less active or inactive compared to their quinazoline counterparts.

The ring-opened analogs lack the methylene bridge linker between the nitrogen atom and
the phenyl ring. Opening the ring for both A5CDQ (67) and A7CDQ (66) results in the same
compound, 3-CPG (97) which exists as multiple rotamers due to the rotatable bond between
the anilinic nitrogen atom and the phenyl ring (Figure 38). The ring-opened analogs of the
6-chloro (A6CDQ; 65), des-Cl (ADQ; 69) and 6-methyl analogs (A6MDQ; 74) are the
corresponding phenylguanidines analogs 4-CPG (98), PG (99) and 4-MePG (100),
respectively (Figure 38). To further explore the 4-position of the phenylguanidines in terms
of steric properties and bulk, we synthesized and tested the 4-tert-butyl (4-t-BuPG; 101), the
4-benzyl (4-BnPG; 102), and the 4-halo-substituted phenylguanidine analogs, i.e., 4-FPG
(103), 4-BrPG (104), 4-IPG (105). The guanidines 97,34 98,34 99,34 100336 and 102336 were
previously synthesized in our laboratory and were available for the current studies. The
guanidine 101336 was resynthesized and 103-105 were synthesized for the current studies as
outlined in Scheme 7.
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NH 2

NH 2
N

N

NH

NH

N

Cl 7

5 Cl

NH 2

NH 2
N

NH

NH 2

NH

N

NH

6
CH 3

6
Cl

A5CDQ (67)

A7CDQ (66)

A6CDQ (65)

ADQ (69)

A6MDQ (74)

0.9

5.9

3.9

12.2

2.0

NH 2
N

4

NH 2

3 Cl

NH 2
N

NH 2

NH 2
N

3

4
Cl

NH 2

3
4

NH 2
N

NH 2

3
4
CH 3

3-CPG (97)

4-CPG (98)

PG (99)

4-MePG (100)

7.6

2.8

99.8

4.6

Figure 38. 2-Aminodihydroquinazoline analogs (67, 66, 65, 69 and 74) and their ring opened
phenylguanidine counterparts (97, 98, 99 and 100) with their inhibitory potencies (IC50) in
micromolar (µM).
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Scheme 7.a Synthesis of phenylguanidines 101-105.
NH . HNO
3

Cl

NH 2

NH 2

b,c

a
4
R

4
R

R = C(CH 3) (106)
=F
(107)
= Br
(108)
=I
(109)

R = C(CH 3) (110)
=F
(111)
= Br
(112)
=I
(113)

a

HN

NH 3

4
R
R = C(CH 3) (101)
=F
(103)
= Br
=I

(104)
(105)

Reagents and conditions: a. HCl/Et2O, Et2O; b. NH2CN, EtOH; c. NH4NO3, H2O, EtOH

4-tert-Butylphenylguanidine (4-t-BuPG; 101), 4-fluorophenylguanidine (4-FPG;
103), 4-bromophenylguanidine (4-BrPG; 104) and 4-iodophenylguanidine (4-IPG; 105)
were synthesized by reacting cyanogen bromide with the hydrochloride salt of the
corresponding anilines (110-113) according to a reported procedure336 as shown in Scheme
7 and then converted to the nitrate salts using ammonium nitrate in excess. The structures of
4-fluorophenylguanidine nitrate (4-FPG; 103), 4-bromophenylguanidine nitrate (4-BrPG;
104) and 4-iodophenylguanidine nitrate (4-IPG; 105) were confirmed using IR, 1H NMR
and elemental analysis for C, H, N. Because 4-tert-butylphenylguanidine nitrate (4-t-BuPG;
101) is a known compound and was resynthesized, the structure was confirmed using IR, 1H
NMR and melting point (mp 181-183 °C; lit.34 mp 183-185 °C).
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Similar to 2-aminodihydroquinazoline analogs, the ring-opened phenylguanidine
analogs also inhibited the three subtypes of hOCTs (Table 8). The unsubstituted
phenylguanidine (PG; 99) (IC50 = 99.8 µM) was a very weak inhibitor at hOCT1-3 with a
~35-fold lower potency at hOCT3 compared to 4-CPG (98) (IC50 = 2.8 µM; Table 8). Also,
4-BnPG (102) (IC50 = 452.5 µM; Table 8) displayed a ~162-fold decrease in potency at
hOCT3 when compared to 4-CPG (98) (Table 8). The 4-tert-butyl substituted
phenylguanidine (4-t-BuPG; 101), in contrast, was one of the most potent inhibitors of the
phenylguanidine series (IC50 = 2.2 µM; Table 8). Hence, there appears to be a limitation in
the amount of bulk tolerance at the binding region of hOCT1-3. At the 4-position of the
phenylguanidines too, the lipophilic (π) properties of the substituents seem to be more
important than their electronic (σ) properties since the 4-CPG (98) (IC50 = 2.8 µM), 4-MePG
(100) (IC50 = 4.6 µM) and the 4-t-BuPG (101) (IC50 = 2.2 µM) all possess comparable
potencies at hOCT3 (Table 8).
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Table 8. Inhibitory potencies of ring-opened phenylguanidine analogs at hOCT1-3
determined by measuring uptake of [3H]MPP+ (53).
Ligand

R

PG
(99)
3-CPG (97)
NH 2
4-CPG (98)
N
NH 2 4-MePG (100)
4-t-BuPG (101)
4-BnPG (102)
3
4-FPG (103)
4
4-BrPG (104)
4-IPG
(105)
a

R
H
3-Cl
4-Cl
4-CH3
4-C(CH3)3
4-CH2C6H5
4-F
4-Br
4-I

hOCT1
41.1 ± 14.4
13.7 ± 0.8
10.0 ± 0.6
10.0 ± 0.2
0.9 ± 0.2
761.4 ± 254.7

IC50 ± SEM (µM)
hOCT2
89.0 ± 12.2
60.5 ± 4.1
18.9 ± 0.1
9.3 ± 4.8
6.3 ± 3.4
96.2 ± 8.0

hOCT3
99.8 ± 2.8
7.6 ± 0.7
2.8 ± 0.7
4.6 ± 1.1
2.2 ± 0.2
452.5 ± 87.9

NDa

Note added in proof (see Appendix A)

4. Species differences:

Since our rodent model of depression utilized mice, and because OCT data were
obtained using hOCTs, we determined the activity of the 2-aminodihydroquinazoline and
ring-opened phenylguanidine analogs at mOCT1-3. The 2-aminodihydroquinazoline
analogs possessed inhibitory potencies 17.5- to 1.5-fold lower at mOCT1-3 as compared to
their human counterparts (Table 9). A similar trend of differences in potency at mOCT3 vs.
hOCT3 for ligands such as diazepam, ketamine (33) and FLX (3) has been reported in the
literature.337 The range of inhibitory potencies of the 2-aminodihydroquinazoline analogs at
mOCT3 was smaller compared to at hOCT3. For instance, the des-Cl analog, ADQ (69)
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possessed an inhibitory potency that was 1.4-fold lower compared to that of the 5-chloro
analog, A5CDQ (67) (Table 9). In contrast, the difference in inhibitory potencies at hOCT3
between ADQ (69) and A5CDQ (67) was ~13-fold.

Table 9. Inhibitory potencies of all the substituted 2-aminodihydroquinazoline analogs at
mOCT1-3 determined by measuring uptake of [3H]MPP+ (53).

Ligand
ADQ
(69)
A5CDQ (67)
A6CDQ (65)
NH 2
A7CDQ (66)
N
NH A8CDQ (68)
8
A5MDQ (75)
R
A6MDQ (74)
5
7
A7MDQ (76)
6
A8MDQ (77)
A6FDQ (87)
A6BrDQ(88)

R
H
5-Cl
6-Cl
7-Cl
8-Cl
5-CH3
6-CH3
7-CH3
8-CH3
6-F
6-Br

mOCT1
>100
45.2 ± 9.4
38.2 ± 9.3
40.7 ± 13.7
22.0 ± 12.1
ND
>100
27.3 ± 14.7

IC50 ± SEM (µM)
mOCT2
31.8 ± 1.3
16.1 ± 5.5
6.2 ± 0.5
13.0 ± 0.8
18.1 ± 8.5
>100
15.0 ± 0.5
7.7 ± 3.3
ND
ND
ND

mOCT3
18.8 ± 2.3
13.9 ± 1.4
30.3 ± 13.0
15.9 ± 3.1
23.5 ± 2.1
>100
12.7 ± 2.4
27.3 ± 14.7
19.3 ± 4.3

In the phenylguandinde series, all analogs except 4-t-BuPG (101) were weak
inhibitors of mOCT3 with inhibitory potencies above 100 µM (Table 10). Interestingly, the
unsubstituted (PG; 99), chloro-substituted (3-CPG (97) and 4-CPG (98)) as well as the
methyl-substituted (4-MePG; 100) analogs displayed “stimulatory” activity at mOCT1.
Additionally, the unsubtituted analog (PG; 99) also displayed a “stimulatory” activity at
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mOCT2. This stimulatory activity indicates that presence of analogs increases the
accumulation of [3H]MPP+ (53) in the cells. Stabilization of the transporters (mOCT1 and
mOCT2) in an open configuration by the analogs might explain the increased accumulation
of [3H]MPP+ (53) and hence the stimulation observed.
Table 10. Inhibitory potencies of the ring-opened phenylguanidine analogs at mOCT1-3
determined by measuring uptake of [3H]MPP+ (53).
Ligand

R

R

mOCT1

PG
(99)
3-CPG (97)
NH 2
4-CPG (98)
N
NH 2 4-MePG (100)
4-t-BuPG (101)
4-BnPG (102)
3
4-FPG (103)
4
4-BrPG (104)
4-IPG
(105)

H
3-Cl
4-Cl
4-CH3
4-C(CH3)3
4-CH2C6H5
4-F
4-Br
4-I

GOAL

binding

5:

To

identify

IC50 ± SEM (µM)
mOCT2

Stimulation
Stimulation
Stimulation
Stimulation
18.3 ± 1.0
82.0 ± 0.9

Stimulation
>100
14.2 ± 0.4
22.1 ± 2.4
5.0 ± 1.0
92.5 ± 4.3

mOCT3
>100
>100
>100
>100
46.0 ± 2.1
491.8 ± 127.6

ND

sites

and

modes

of

interactions

of

2-

aminodihydroquinazoline and phenylguanidine analogs at hOCT3 and mOCT3 using
molecular modeling.

In order to study the interactions between OCT3 and the 2-aminodihydroquinazoline
and phenyguanidine analogs we conducted molecular modeling studies. The crystal
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structures of OCTs have not yet been solved and so far no 3-dimensional homology models
have been reported for hOCT3. Hence, we generated the first 3-dimensional homology
models of OCT3 based on a suitable template.
Homology models of rOCT1,295 rOCT2,338 rbOCT2,339 and hOCT2340 have,
however, been reported in the literature. In 2005, Popp et al.295 and Zhang et al.339 generated
homology models of rOCT1 and rbOCT2 based on the crystal structures of lactose permease
transporter (LacY, PDB ID: 1PV6)292 and the glycerol-3-phosphate transporter (GlpT, PDB
ID: 1PW4),341 respectively. Popp et al.295 focused on amino acids belonging to TMD4 and
performed mutagenesis studies to determine their role in substrate selectivity, affinity and/or
turnover rates for rOCT1 for TEA+ (54) and MPP+ (53). The chosen amino acid residues
(from position 219-229) of TMD4 are conserved within the three subtypes of OCT1-3 but
are different from those in the closely related family of OATs.295 From their findings, the
authors successfully identified three amino acid residues from TMD4 – Trp218, Tyr222 and
Thr226 – that affected the uptake of MPP+ (53) and TEA+ (54) significantly.295 This coupled
with earlier findings implicating three residues from TMD10 – Ala443, Leu447 and
Gln448294 – and one key residue from TMD11 Asp475293 gives rise to a fairly large binding
region consisting of individual, overlapping binding sites.295
The primary focus of the mutagenesis and homology modeling studies of rbOCT2
was to identify amino acid residues that confer selectivity for rbOCT1 over rbOCT2.339 The
amino acids chosen for this mutagenesis study were Gln353, Arg403 and Glu447.339 Their
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studies concluded that the Glu447 residue is a “key contributor to binding properties of
rbOCT2”.339 This is in agreement with an earlier study by Gorboulev et al.294 identifying
Gln448 in rOCT2 as the residue responsible for the difference in the affinity of
corticosterone for rOCT1 vs. rOCT2. Importantly, the study by Zhang et al.339 involving
rbOCT2 confirmed the amino acid residues identified by Popp et al.295 and others line and
face the central cavity of the transporter.
Continuing on their previous work, Schmitt et al.338 modeled rOCT2 in inward open
and outward open conformations based on LacY (PDB ID: 1 PV6)292 to study the function
of rOCT2 using a charge-to-substrate ratio. This ratio gives an indication of the number of
molecules transported in one cycle.338 A ratio of one implies that a single molecule is
transported while a ratio of greater than one indicates co-transportation of more than one
molecule.338 Their modeling studies suggested that the central cavity in rOCT2 was lined
with negatively charged residues in the outward open conformation.338 On the other hand,
in the inward open conformation, the central cavity of the transporter possessed a neutral
charge.338 This, coupled with their extensive charge-to-substrate ratio studies, indicated that
“nonsubstrate inorganic cations are translocated nonspecifically with organic cation
substrates”.338 The homology models of rOCT2 generated as part of the above study very
closely resembled the homology models of rOCT1295 because of the very high homology
between the two and use of the same template.338
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In 2015, Li et al.340 investigated the role of a number of amino acid residues in rOCT3
and hOCT3 and generated a homology model of hOCT2 based on GlpT (PDB ID: 1PW4)341
as the template. They developed rOCT3 and hOCT3 mutants wherein nonconserved residues
in the substrate binding pocket were mutated to resemble the binding pocket in rOCT1 to
study the role of these residues in substrate selectivity.340 The nonconserved residues studied
were Leu161, Phe445 and Glu445 in rOCT3 and Leu166, Phe450 and Glu451 in hOCT3.340
The role of the conserved Asp residue, previously established for rOCT1295 and rOCT2,338
was also confirmed to be essential for hOCT3 since mutation of the Asp478 residue resulted
in abolishing transport of [3H]MPP+ (53).340

1. Template:
In the early incipient stages of our molecular modeling studies, we generated
homology models of hOCT3 based on the crystal structure of the Escherichia coli lactose
permease transporter (LacY, PDB ID: 1PV6, 3.5-Å resolution)292 as our template. At that
point, the LacY was the most suitable template available according to the basic local
alignment search tool (BLAST)342 and had been previously utilized to generate homology
models of rOCT1295 and rOCT2.338 The LacY was co-crystallized with a galactoside, β-Dgalactopyranosyl-1-thio-ß-D-galactopyranoside

(TDG),

in

an

inward-facing

conformation.292 The LacY belongs to the oligosaccharide: H+ symporter family of the MFS
transporters and consists of 12 TMDs with intracellular N- and C-termini.292 The LacY
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utilizes energy generated from downhill H+ translocation to drive the uphill transport of the
substrate (galactoside).292 In early 2013, the crystal structure of an eukaryotic inorganic
phosphate transporter (PiPT, PDB ID: 4J05, 2.9-Å resolution) was reported.343 PiPT belongs
to the phosphate: H+ symporter family of MFS transporters and has been suggested to serve
as a suitable template for transporters belonging to the SLC22 family.343 Hence, we revised
our modeling studies by generating one hundred 3-dimensional homology models of OCT3
based on PiPT. The crystal structure of PiPT was solved in complex with its substrate,
inorganic phosphate, by Pedersen at al.343 at a resolution of 2.9 Å in an inward occluded
conformation. Similar to the template, PiPT, OCT3 also consists of 12 TMDs with
intracellular N- and C-termini.343 The 12 TMDs of PiPT are divided into two bundles of 6
helices each – the N- and C-domain.343 These domains possess different functions making
the structure of PiPT asymmetric.343 The N-domain of PiPT is primarily involved in
translocation of H+, while the C-domain is involved in substrate recognition.343 Since the in
vitro inhibition data was obtained using hOCT3 and the behavioral assays were conducted
in mice, we built homology models of both hOCT3 and mOCT3 and subsequently conducted
docking studies on both, hOCT3 and mOCT3. HINT analysis326 was conducted on chosen
hOCT3-ligand complexes.
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2. Alignment and generation of models:
The sequence of the template, PiPT was obtained as a FASTA file from the Protein
Databank (PDB ID: 4J05),343 while that of hOCT3 and mOCT3 were obtained from the
Universal Protein Resource (UniProt) database (UniProt accession code: O75751 and
Q9WTW5), respectively. The two sequences, template and protein of interest (hOCT3 or
mOCT3), were aligned using Clustal W 2.0344 followed by manual adjustments to the
sequence (Figure 39). The amino acid residues belonging to the extracellular loop between
TMDs 1 and 2 and that between 6 and 7, were truncated for several reasons – lack of
appropriate corresponding residues in the crystal structure of PiPT being the major reason.
Another reason was the long, floppy, flexible nature of the extracellular loop between TMDs
6 and 7. Moreover, the loop is far away and seemingly uninvolved in the binding region of
hOCT3.
The binding site of the substrate, phosphate, in PiPT is composed of residues from
TMDs 4, 5, 7, 10 and 11.343 They are Tyr150 in TMD4, Gln177 and Phe174 in TMD5,
Asp324, Tyr320 and Tyr328 in TMD7, Asn431 in TMD10 and Lys459 in TMD11.343 Of
these residues, the two tyrosine residues in TMD7, Tyr320 and Tyr328, are conserved in
OCT1.343 A positively-charged lysine residue, Lys459, in the PiPT influences the affinity of
the transporter for phosphate.343 OCT3 possesses a negatively charged aspartate residue,
Asp474, instead of the positively charged lysine residue in PiPT343 (Figure 39). Between the
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two orthologs – human and mouse OCT3 – all the residues composed of the binding region
are conserved (Figure 39).

Figure 39. Sequence alignments of the template (PiPT) and the proteins of interest (hOCT3
and mOCT3). The asterisks (*) indicate residues that are fully conserved between the
sequences (template PiPT and hOCT3 or mOCT3). The colon (:) and period (.) indicate
residues that are highly conserved and weakly conserved between the sequences,
respectively. Lack of any of these symbols indicate differences in amino acid residues. The
amino acid residues highlighted in the red boxes constitute the substrate binding region of
OCTs.
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3. Validation:
To support our modeling studies, we docked the substrate, MPP+ (53), to one hundred
homology models for each hOCT3 and mOCT3 and studied the observed interactions. We
utilized the aspartate residue (Asp478 in hOCT3 and Asp473 in mOCT3) to define a 12 Å
spherical binding pocket in the docking software GOLD suite 5.2.345
In both hOCT3 and mOCT3, the protonated amine of MPP+ (53) was observed to be
involved in an ionic salt-bridge interaction with the carboxylate oxygen atom of the key Asp
residue (Asp478 in hOCT3 and Asp473 in mOCT3) (Figure 40). The pyrdinium ring of
MPP+ (53) was seen to be involved in a π-π stacking interaction with a Trp residue (Trp223
in hOCT3 and Trp218 in mOCT3) (Figure 40). Moreover, the phenyl ring of MPP+ (53) was
involved in a cation-π interaction with the protonated guanidinium moiety of Arg20 (hOCT3
and mOCT3) (Figure 40).
Figure 40. Structure of MPP+ (53)
(cyan in hOCT3 and yellow in
mOCT3) docked in the substrate
binding region of hOCT3 and
mOCT3. The ligands and amino
acid residues are displayed as
capped sticks. The dashed red lines
indicate
ionic
salt-bridge
interactions between the protonated
N-atom of MPP+ (53) and the Oatom of the carboxylate group of
Asp478 and Asp473 in hOCT3 and
mOCT3, respectively. The labels in
the parenthesis correspond to
mOCT3.
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PROCHECK analysis of the selected hOCT3 and mOCT3 models generated
Ramachandran plots. In the Ramachandran plots,346 amino acids are distributed in four
regions - most favored (red), additional allowed region (yellow), generously allowed region
(light yellow) and disallowed region (white). For hOCT3, 87.9% of amino acids were in the
most favored region, 9.1% in the additional allowed region and 3.0% in the disallowed
region (Figure 41). Val36 is the only amino acid residue in the disallowed region and is
located far away from the binding region of hOCT3 (Figure 41). Similar to hOCT3, for
mOCT3, 87.9% of amino acid residues were located in the most favored region and 12.1%
in the additional allowed region (Figure 42). However, in the case of mOCT3, no residues
were found in the disallowed region (Figure 42).

Figure 41. Ramachandran plot of
hOCT3. Phi and psi indicate
backbone conformation angles of
amino acid residues. Val36 is the
only amino acid in the disallowed
region and is located far from the
binding region of hOCT3.

94

Figure 42. Ramachandran plot of
mOCT3. Phi and psi indicate
backbone conformation angles of
amino acid residues. No amino
acid residues were found in the
disallowed region of mOCT3.

4. Docking studies and HINT analysis:
To study the interactions of the 2-aminodihydroquinazoline and phenylguanidine
analogs at the human and mouse orthologs of OCT3, we performed docking studies. The
interactions observed were quantified using HINT analysis326 on chosen transporter-ligand
complexes.

a. Docking at the substrate binding region of hOCT3:
Kinetic studies performed on the lead compound, A6CDQ (65), to determine the
mechanism of inhibition, revealed a competitive mechanism. This indicates that A6CDQ
(65) is exerting its inhibitory effect by interacting at the substrate binding region. The role
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of the key Asp residue (Asp478339 in hOCT3 and Asp475293 in rOCT1) has been established
by mutagenesis studies. Hence, we docked the 2-aminodihydroquinazoline analogs and the
ring-opened phenylguanidine analogs, at the substrate binding region using the Asp residue
to define a spherical region with a radius of 12 Å.
All of the 2-aminodihydroquinazoline analogs docked at hOCT3 in a highly
overlapping manner (Figure 43). Two of the N-atoms of the guanidinium moiety of the 2aminodihydroquinazoline analogs were found to be involved in a bidentate ionic salt-bridge
interaction with one of the O-atoms of the carboxylate group of Asp478 (Figure 43). Besides
this key interaction, all of the 2-aminodihydroquinazoline analogs were also involved in
cation-π interactions with the pyrrole ring of Trp223 and the phenyl ring of Phe165 (Figure
43). The phenyl ring of the 2-aminodihydroquinazoline analogs were additionally involved
in a T-shaped π-π stacking interaction with the phenyl ring of Trp358 (Figure 43).

96

Figure 43. Structures of all the 2-aminodihydroquinazoline analogs – ADQ (yellow) (69),
A5CDQ (red) (67), A6CDQ (orange) (65), A7CDQ (magenta) (66), A8CDQ (green) (68),
A5MDQ (salmon pink) (75), A6MDQ (cyan) (74), A7MDQ (purple) (76), A8MDQ (teal)
(77), A6FDQ (wheat) (87), A6BrDQ (brown) (88) and A6IDQ (fluorescent green) (89) docked at the substrate binding region of hOCT3. The ligands and amino acid residues are
displayed as capped sticks and light blue-capped sticks, respectively. The dashed red lines
indicate a bidentate ionic salt-bridge interaction between the two N-atoms of the guanidinium
moiety of the ligands and an O-atom of the carboxylate group of Asp478.

Role of the chloro group:
In order to identify the interactions involving the chloro group at hOCT3, we docked
and studied in greater detail the chloro substituted 2-aminodihydroquinazoline analogs
(A5CDQ (67), A6CDQ (65), A7CDQ (66), A8CDQ (68)) and the des-Cl analog (ADQ) (69).
The chloro group of the lead compound, A6CDQ (65), was observed to be involved in
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hydrophobic interactions with Trp358, Ala362, Tyr365 and Gln366 at the substrate binding
region of hOCT3 (Figure 44). Similarly, if the 6-methyl analog (A6MDQ; 74), as discussed
in Goal 4 (Figure 36), interacts in a similar manner as A6CDQ (65), it might utilize similar
hydrophobic interactions as the chloro substitutent, i.e., Trp358, Ala362, Tyr 365 and
Gln366. The in vitro biological studies showed that A6MDQ (74) (IC50 = 2.0 µM; Table 3)
possessed a comparable inhibitory potency to A6CDQ (65) (IC50 = 3.9 µM; Table 3) and are
in agreement with our prediction from the preliminary molecular modeling studies. These
findings support our model.

Figure 44. Structures of ADQ
(yellow) (69) and A6CDQ
(orange) (65) docked at the
substrate binding region of
hOCT3. The chloro group (green)
of A6CDQ (65) and the
hydrophobic amino acid residues
(Trp358, Ala362, Tyr365 and
Gln366) are displayed as space
filling spheres. The ligands and
amino acid residues are displayed
as capped sticks and light bluecapped sticks, respectively. The
dashed red lines indicate a
bidentate
ionic
salt-bridge
interaction between the two Natoms of the guanidinium moiety
of the ligands and an O-atom of
the carboxylate group of Asp478.

98

Probing the 6-position of 2-aminodihydroquinazolines:
The 6-halo-substituted 2-aminodihydroquinazoline analogs (A6FDQ (87), A6CDQ
(65), A6BrDQ (88) and A6IDQ (89)) possess substituents with increasing steric and
lipophilic (π) properties (Table 6). Their electronic (σ) properties, however, are comparable
(Table 6). Our modeling studies suggested that the substrate binding region of hOCT3 was
capable of accommodating all four 6-halo-substituted 2-aminodihydroquinazoline analogs
including A6IDQ (89), the analog with the largest substituent (Figure 45 and 46). Similar to
other 2-aminodihydroquinazoline analogs, the guanidinium moiety of the 6-halo-substituted
analogs were also involved in a bidentate ionic salt-bridge interaction with Asp478 (Figure
45).

Figure 45. Structures of
A6FDQ
(87)
(wheat),
A6CDQ
(65)
(orange),
A6BrDQ (88) (brown) and
A6IDQ (89) (fluorescent
green) docked at the substrate
binding region of hOCT3.
The ligands and amino acid
residues are displayed as
capped sticks and light bluecapped sticks, respectively.
The dashed red lines indicate
a bidentate ionic salt-bridge
interaction between the two
N-atoms of the guanidnium
moiety of the ligands and an
O-atom of the carboxylate
group of Asp478.
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Figure 46. Structures of A6FDQ (87) (wheat), A6CDQ (65) (orange), A6BrDQ (88)
(brown) and A6IDQ (89) (fluorescent green) docked at the substrate binding region of
hOCT3. The halogen substituents (6-F, 6-Cl, 6-Br and 6-I) and the hydrophobic amino acid
residues (Trp358, Ala362, Tyr365 and Gln366) are displayed as space filling spheres. The
ligands and amino acid residues are displayed as capped sticks and light blue-capped sticks,
respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction between
the two N-atoms of the guanidnium moiety of the ligands and an O-atom of the carboxylate
group of Asp478.

Role of the methylene bridge:
Docking studies of the ring-opened phenylguanidine analogs revealed two possible
modes of interaction – I and II. The primary difference between the two modes was the
orientation of 4-BnPG (102). In mode I, 4-BnPG (102) is oriented in a manner similar to all
the other phenylguanidine analogs and is involved in an ionic salt-bridge interaction with
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Asp478 (Figure 47). In contrast, in mode II, 4-BnPG (102) was flipped over so that the
guanidinium moiety was now pointed towards Glu451 instead of Asp478 (Figure 48). In
both modes I and II, the rest of the ring-opened phenylguanidine analogs docked in a similar
and overlapping manner and were engaged in a bidentate ionic salt-bridge interaction with
Asp478 (Figure 47 and 48).

Figure 47. Interaction mode I of the ring-opened phenylguanidine analogs at hOCT3.
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100)
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of hOCT3.
The ligands and amino acid residues are displayed as capped sticks and tan capped sticks,
respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction between
the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the carboxylate
group of Asp478. The guanidinium moiety of 4-BnPG (102), similar to other
phenylguanidine analogs, was pointing towards Asp478.
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Figure 48. Interaction mode II of the ring-opened phenylguanidine analogs at hOCT3.
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100)
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of hOCT3.
The ligands and amino acid residues are displayed as capped sticks and pale cyan-capped
sticks, respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction
between the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the
carboxylate group of Asp478. The 4-BnPG (102) is flipped over with its guanidinium
moiety pointing towards Glu451 located on the other end of the binding region.

To determine the probability of the two interaction modes – I or II – we performed
HINT analysis326 and studied in detail the atom-based interactions between the ligands and
the transporter for both modes (see Table 11).
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Table 11. HINT scores for both the interaction modes (I and II) of the phenylguanidine
analogs.
Ligand
PG
(99)
3-CPG (97)

H
3-Cl

Hint
scor
e
96
426

NH 2 4-CPG (98)

4-Cl

250

4-MePG (100)
4-t-BuPG (101)

4-Me
4-tBu

144
143

4-BnPG (102)

4-Bn

-7

NH 2
N
R
3

R

4

Mode I
Amino acids
interacting with
substituent
Arg19, Arg20,
Trp223
Arg20, Trp223
Trp223, Phe250
Phe250, Tyr365,
Val453, Trp358
Val453

Hint
score
549
338
547
356
-467
-484

Mode II
Amino acids
interacting with
substituent
Arg20, Gln247,
Trp358
Trp358, Ser361,
Ala362, Tyr365
Ala362, Tyr365
Val453, Ser361,
Ala362, Tyr365
Ala362, Tyr365

For interaction mode I, the HINT score was positive for all the phenylguanidine
analogs except for the 4-BnPG (102) analog (Table 11). When we looked closely at the atombased contributions to the total HINT score, we discovered that the benzyl group at the 4position of 4-BnPG (102) was clashing with the Glu451 residue in the substrate binding
region of hOCT3 (Figure 49). This clash is potentially responsible for the overall negative
HINT score observed and might explain the low potency of 4-BnPG (102) at hOCT3 (IC50
= 452.5 µM; Table 8). On the other hand, in interaction mode II, both 4-BnPG (102) and 4t-BuPG (101) possessed negative HINT scores (Table 11). This seems counterintuitive since
4-t-BuPG (101) is one of the most potent compound (IC50 = 2.2 µM; Table 8) of the ring-
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opened phenylguanidine series. Thus, HINT analysis indicated that the interaction mode I is
more probable of the two modes.

Figure 49. Interaction mode I of the ring-opened phenylguanidine analogs at hOCT3.
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100)
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of hOCT3.
The ligands and amino acid residues are displayed as capped sticks and tan capped sticks,
respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction between
the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the carboxylate
group of Asp478. The benzyl group of 4-BnPG (102) (red-colored meshed surface) was
clashing with the side chain of Glu451 (tan-colored meshed surface) and might explain the
very weak inhibitory activity of 4-BnPG (102) at hOCT3.
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b. Docking at the substrate binding region of mOCT3:
Docking studies at mOCT3 resulted in poses different to those observed in hOCT3.
Since the binding region of OCT3 is fairly large, the molecules can potentially orient
themselves in various different ways. Upon docking the 2-aminodihydroquinazoline analogs
at mOCT3, we observed the guanidinium moiety interacting in a bidentate ionic salt-bridge
interaction with the carboxylate oxygen atom of Asp473 (analogous to Asp478 in hOCT3)
(Figure 50). This interaction was also observed in hOCT3 and might potentially be important
for the inhibitory activities of our molecules. However, the 2-aminodihydroquinazoline
analogs are oriented at a 90º angle in mOCT3 (Figure 50) as compared to the poses observed
in hOCT3 (Figure 43).
For the phenylguanidine series, similar to hOCT3, we also observed two interaction
modes – I and II – in mOCT3. In mode I (Figure 51), all the analogs are oriented in an
overlapping manner with the nitrogen atoms of the guanidinium moiety involved in a
bidentate ionic-salt bridge interaction with the carboxylate oxygen atom of Asp473. In
contrast, in mode II (Figure 52), all the phenylguanidine analogs, except for 4-BnPG (102)
are oriented in a similar and overlapping manner with the guanidinium moieties pointing
towards Asp473. The 4-BnPG (102) is flipped over and its guanidinium moiety was pointing
towards Glu446 (analogus to Glu451 in hOCT3) which is located at the opposite end of the
binding region (Figure 51). The two modes (I and II) mimic those we observed in hOCT3.
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Unfortunately, our modeling studies are currently unable to explain the species differences
in the activities that are observed for the phenylguanidine series.

Figure 50. Structures of 2-aminodihydroquinazoline analogs - ADQ (yellow) (69), A5CDQ
(red) (67), A6CDQ (orange) (65), A7CDQ (magenta) (66), A8CDQ (green) (68), A5MDQ
(salmon pink) (75), A6MDQ (cyan) (74), A7MDQ (purple) (76), A8MDQ (teal) (77),
A6FDQ (wheat) (87), A6BrDQ (brown) (88) and A6IDQ (fluorescent green) (89) - docked
at the binding region of mOCT3. The ligands and amino acid residues are displayed as
capped sticks and pale cyan-capped sticks, respectively. The dashed red lines indicate a
bidentate ionic salt-bridge interaction between the two N-atoms of the guanidinium moiety
of the ligands and an O-atom of the carboxylate group of Asp478.
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Figure 51. Interaction mode I of the ring-opened phenylguanidine analogs at mOCT3.
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100)
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of mOCT3.
The ligands and amino acid residues are displayed as capped sticks and light blue-capped
sticks, respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction
between the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the
carboxylate group of Asp473.
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Figure 52. Interaction mode II of the ring-opened phenylguanidine analogs at mOCT3.
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100)
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of mOCT3.
The ligands and amino acid residues are displayed as capped sticks and tan capped sticks,
respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction between
the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the carboxylate
group of Asp473. The 4-BnPG (102) is flipped over with its guanidinium moiety pointing
towards Glu446 located on the other end of the binding region.
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GOAL 6: To determine if 2-aminodihydroquinazoline and phenylguanidine analogs
retain antidepressant-like effect.

1. Mouse tail suspension test (TST):
In the course of elucidating the initial SAR, we synthesized and tested a number of
2-aminodihydroquinazoline analogs. We wished to determine if selected analogs retained
their antidepressant-like activity in the mouse TST. To determine if the chloro group or its
position is important for antidepressant-like activity, we tested the 5- and 8-chloro
substituted 2-aminodihydroquinazolines (A5CDQ (67) and A8CDQ (68)) as well as the desCl analog ADQ (69). The Dukat laboratory had already established that both A6CDQ (65)35
and A7CDQ (66)313 possess antidepressant-like effects. A6MDQ (74), the 6-methyl
substituted analog, had comparable inhibitory potency at hOCT3 as A6CDQ (65) and we
tested it to determine if it retained the antidepressant-like activity shown by A6CDQ (65).
Additionally, we tested A6FDQ (87), that was synthesized as part of determining the role of
steric properties and bulk at the 6-position of 2-aminodihydroquinazolines. Finally, to check
the importance of the methylene bridge for antidepressant-like action, we tested the 4-chloro
and 4-tert-butyl substituted ring-opened phenylguanidine analogs, 4-CPG (98) and 4-tBuPG (99), respectively. We also tested the commercially available SSRI, FLX (3) as a
standard against which to compare the activity of our molecules. FLX (3) is commonly used
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in the TST at a dose of 20 mg/kg.347 We examined five doses of FLX (3) and showed that it
was inactive at a dose of <20 mg/kg (Figure 53).
Figure 53. Effect (± SEM) of FLX (3) on
duration of immobility in the mouse TST.
FLX (3) significantly reduced the duration
of immobility at a dose of 20 mg/kg
compared to saline according to one-way
analysis of variance (ANOVA). For FLX
(3) (F5,50 = 3.714, p = 0.0062), Dunnett’s
post-hoc test (** p < 0.01).
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Similar to A6CDQ (65)35 and A7CDQ (66),313 A5CDQ (67) was shown to produce
an antidepressant-like effect at 1.0 mg/kg (Figure 54). The efficacy of A5CDQ (67) (effect
(± SEM) = 22.6 ± 8.9 s) was comparable to FLX (3) (effect (± SEM) = 22.4 ± 8.0 s) at a
dose that was 20-times lower and the effective dose (ED50) was determined to be 0.57 mg/kg
(Figure 55). A8CDQ (68) and ADQ (69), on the other hand, showed a lack of antidepressantlike activity in the mouse TST (Figures 56 and 57, respectively). This coupled with the
comparable inhibitory potencies of the chloro-substituted 2-aminodihydroquinazoline
analogs (A5CDQ (67), A6CDQ (65), A7CDQ (66) and A8CDQ (68)) at mOCT3 suggests
that the SAR for OCT3 inhibitory activity and mouse TST might be different. Our molecular
modeling studies at mOCT3 indicates no potential clashes that A8CDQ (68) might be
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involved in at the binding region. So far, we can conclude that not only the presence, but
also the position, of the chloro group of 2-aminodihydroquinazolines is important for TST
activity in mouse, whereas only the presence of the chloro group is sufficient for inhibitory
activity at OCT3.

Figure 54. Effect (± SEM) of A5CDQ
(67) on duration of immobility in the
mouse TST. A5CDQ (67) significantly
reduced the duration of immobility at a
dose of 1.0 mg/kg as compared to saline
according to one-way analysis of
variance (ANOVA). For A5CDQ (67)
(F7,63 = 5.529, p = 0.0001), Dunnett’s
post-hoc test (**** p < 0.0001) and for
FLX (3) (F5,50 = 3.714, p = 0.0062),
Dunnett’s post-hoc test (** p < 0.01).
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Figure 55. The effective dose for the 5-Cl
analog, A5CDQ (67) was determined to be
0.57 mg/kg, ~2.5-fold lower than that for
the lead compound, A6CDQ (65), (ED50 =
0.23 mg/kg).35
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Figure 56. Effect (± SEM) of A8CDQ
(68) on duration of immobility in the
mouse TST. A8CDQ (68) did not
significantly reduce the duration of
immobility at any of the doses tested (0.130 mg/kg) compared to saline according to
one-way analysis of variance (ANOVA).
For FLX (3) (F5,50 = 3.714, p = 0.0062),
Dunnett’s post-hoc test (** p < 0.01).
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Figure 57. Effect (± SEM) of ADQ (69)
on duration of immobility in the mouse
TST. ADQ (69) did not significantly
reduce the duration of immobility at any
of the doses tested (0.1-30 mg/kg)
compared to saline according to one-way
analysis of variance (ANOVA). For FLX
(3) (F5,50 = 3.714, p = 0.0062), Dunnett’s
post-hoc test (** p < 0.01).
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Another important point for consideration is that we are yet to test A8CDQ (68) at
5-HT3 or hSERT and do not know what, if any, activity it possesses at these targets. A6CDQ
(65) and A7CDQ (66) behave as 5-HT3 antagonists of differing potencies and binding
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affinities. A5CDQ (67) and A7CDQ (66) behave as reuptake inhibitors whereas A6CDQ
(65) and ADQ (69) behave as releasers at hSERT. Therefore, the in vivo activity of the 2aminodihydroquinazoline analogs (A5CDQ (67), A6CDQ (65) and A7CDQ (66)) might be
linked to a combination of mechanisms: 5-HT3 antagonism, SERT activity (releaser or
reuptake inhibitor) and OCT3 inhibition.
Unlike the chloro-substituted 2-aminodihydroquinazoline analogs (A5CDQ (67),
A6CDQ (65),35 and A7CDQ (66)),313 both the 6-methyl and the 6-fluoro analogs, A6MDQ
(74) and A6FDQ (87) showed antidepressant-like effect at a dose of 3.0 mg/kg (Figures 58
and 59, respectively). For A6MDQ (74) (effect (± SEM) = 28.9 ± 8.3 s) and A6FDQ (87)
(effect (± SEM) = 25.0 ± 8.9 s) the effect observed was comparable to that produced by FLX
(3) (effect (± SEM) = 22.4 ± 8.0 s) at a ~6.5-fold lower dose.
The dose-response curves obtained for the selected 2-aminodihydroquinazoline
analogs (A5CDQ (67), A6MDQ (74) and A6FDQ (87)) show the U-shaped curve (see
Figures 54, 58 and 59), which is a feature observed for 5-HT3 agonists348 and is believed to
arise from desensitization of 5-HT3 receptors. A similar U-shaped curve was also observed
for compounds A6CDQ (65) and A7CDQ (66) which are 5-HT3 antagonists.35,313 Our
analogs (A5CDQ (67), A6MDQ (74) and A6FDQ (87)) resulted from structural changes of
compounds A6CDQ (65) and A7CDQ (66), and might potentially possess activity at 5-HT3
receptors. Other possible explanations for the U-shaped curve observed include – differences
in patterns of expressions (presynaptic vs. postsynaptic) as well as densities of 5-HT3
113

receptors and potential sedative effects at higher doses. This was probable since we tested
only the TST-active doses in the locomotor stimulant activity. Limited solubility of the
compounds in saline resulting in suspension at higher doses was unlikely since the
compounds were water-soluble salts and the solutions obtained were clear with no
precipitate observed.
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Figure 59. Effect (± SEM) of A6FDQ
(87) on duration of immobility in the
mouse TST. A6FDQ (87) significantly
reduced the duration of immobility at a
dose of 3.0 mg/kg compared to saline
according to one-way analysis of
variance (ANOVA). For A6FDQ (87)
(F7,66 = 3.197, p = 0.0056), Dunnett’s
post-hoc test (** p < 0.01) and for FLX
(3) (F5,50 = 3.714, p = 0.0062), Dunnett’s
post-hoc test (** p < 0.01).

Figure 58. Effect (± SEM) of A6MDQ
(74) on duration of immobility in the
mouse TST. A6MDQ (74) significantly
reduced the duration of immobility at a
dose of 3.0 mg/kg compared to saline
according to one-way analysis of variance
(ANOVA). For A6MDQ (74) (F6,55 =
3.144, p = 0.0101), Dunnett’s post-hoc test
(* p < 0.05) and for FLX (3) (F5,50 = 3.714,
p = 0.0062), Dunnett’s post-hoc test (** p
< 0.01).
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The ring-opened phenylguanidine analog, 4-CPG (98) was inactive at all doses tested
(0.1-30 mg/kg) in the mouse TST (Figures 60). On the other hand, while 4-t-BuPG (101) did
not decrease the immobility time and thus did not exhibit an antidepressant-like effect, it did
increase immobility at the largest dose tested (30 mg/kg) (Figure 61). This increase in
immobility time could be a result of a sedative-like effect exerted by 4-t-BuPG (101).
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Figure 60. Effect (± SEM) of 4-CPG (98)
on duration of immobility in the mouse
TST. 4-CPG (98) did not significantly
reduce the duration of immobility at any
of the doses tested (0.1-30 mg/kg)
compared to saline according to one-way
analysis of variance (ANOVA). For FLX
(3) (F5,50 = 3.714, p = 0.0062), Dunnett’s
post-hoc test (** p < 0.01).
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The lack of antidepressant-like effects for 4-CPG (98) and 4-t-BuPG (101), coupled
with the previous finding that the 3-chloro substituted phenylguanidine analog, 3-CPG (97),
was inactive (0.1-30 mg/kg) in mouse TST,313 led us to conclude that the methylene bridge
might be an important structural feature for antidepressant-like activity
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Figure 61. Effect (± SEM) of 4-t-BuPG
(101) on duration of immobility in the
mouse TST. 4-t-BuPG (101) did not
significantly reduce the duration of
immobility at any of the doses tested (0.130 mg/kg) compared to saline according to
one-way analysis of variance (ANOVA).
For 4-t-BuPG (101) (F7,71 = 7.247, p <
0.0001), Dunnett’s post-hoc test (**** p <
0.0001) and for FLX (3) (F5,50 = 3.714, p
= 0.0062), Dunnett’s post-hoc test (** p <
0.01).
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2. Locomotor activity assay:
To eliminate the possibility of the antidepressant-like effect observed in the mouse
TST resulting from a locomotor stimulant effect, we tested the active doses of A5CDQ (67),
A6MDQ (74) and A6FDQ (87) identified in mouse TST in the locomotor activity assay. The
mice were injected intraperitoneally with 1.0 mg/kg of A5CDQ (67) or 3.0 mg/kg of
A6MDQ (74) or A6FDQ (87) or saline and their locomotor activity was measured for a
period of 45 min. The test duration for the locomotor activity includes the 30 min pretreatment time of the mouse TST, the duration of the mouse TST (6 min) and the nine
minutes after the mice were no longer suspended by their tails.
The TruScan control and data acquisition software recorded a number of different
parameters, out of which the following eleven parameters were analyzed: movement
episodes, movement time (s), movement distance (cm), ambulatory velocity (cm/s), margin
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distance (cm), margin time (s), center distance (cm), center time (s), center entries, jumps
and vertical plane (V-plane) entries. The first four parameters listed, movement episodes,
movement time (s), movement distance (cm) and ambulatory velocity (cm/s) are altered
upon administration of stimulants.349,350 The movement time (s), distance (cm) and
ambulatory velocity (cm/s) are increased, whereas the movement episodes reduce in
number.349,350 Increases in margin distance (cm) and margin time (s) and a decrease in center
distance (cm), center time (s) and center entries are indicative of anxiety or anxiogenic
effects.349,351,352 V-plane entries correspond to rearing behavior of mice and jumps might
indicate general responsiveness of mice.349,353,354 The unpaired two-tailed t test was used to
compare the mean values of the parameters evaluated for saline and the compounds tested
(A5CDQ (67), A6MDQ (74) and A6FDQ (87)) to determine if differences observed were
statistically significant.
Of the three 2-aminodihydroquinazoline analogs tested, A5CDQ (67; 1.0 mg/kg),
A6MDQ (74; 3.0 mg/kg) and A6FDQ (87; 3.0 mg/kg) at the TST-active doses, no
statistically significant changes were observed for movement time (s), movement distance
(cm) and ambulatory velocity (cm/s) when compared to saline (Figure 62). While no change
in the number of movement episodes were observed for A5CDQ (67; 1.0 mg/kg) and
A6MDQ (74; 3.0 mg/kg), a statistically significant increase for A6FDQ (87; 3.0 mg/kg)
compared to saline was observed according to the unpaired two-tailed t test. A single
movement episode encompasses the period when the movement is initiated by the rodent
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and ends when the rodent stops moving. Locomotor stimulants decrease the rodent’s
tendency to stop and hence decreases the number of movement episodes. But, this is
accompanied by a concomitant increase in the movement distance (cm) and time (s). Since
we observed an increase in movement episodes without an accompanying increase in
movement distance (cm) and movement time (s) for A6FDQ (87; 3.0 mg/kg), we might
conclude that the antidepressant-like effect observed for A5CDQ (67; 1.0 mg/kg), A6MDQ
(74; 3.0 mg/kg) and A6FDQ (87; 3.0 mg/kg) in the mouse TST were free of stimulant effect.
Although the number of center entries and the amount of time spent in the center
was reduced for mice treated with A6MDQ (74; 3.0 mg/kg), the difference was not
statistically significant compared to saline (Figure 63). No differences were observed for
center entries, center distance (cm) and center time (s) for A5CDQ (67; 1.0 mg/kg) and
A6FDQ (87; 3.0 mg/kg) when compared to saline (Figures 63). Additionally, the parameters
- margin distance (cm) and margin time (s) – were similar for the drugs tested and saline
(Figure 64).
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Figure 62. Effect (± SEM) of A5CDQ (67), A6MDQ (74) and A6FDQ (87) at 1.0, 3.0 and 3.0
mg/kg, respectively for movement episodes, movement time (s), movement distance (cm) and
ambulatory velocity (cm/s) in the locomotor activity assay. No significant changes were
observed for the parameters for A5CDQ (67), A6MDQ (74) and A6FDQ (87) compared to
saline except for movement episodes for A6FDQ (87) according to unpaired two-tailed t test.
Unpaired two-tailed t test, for movement episodes, A5CDQ (67) t(15) = 0.1749, p = 0.8635,
A6MDQ (74) t (15) = 0.2331, p = 0.8188, A6FDQ (87) t(13) = 3.416, p = 0.0042 ; for movement
time (s), A5CDQ (67) t(16) = 0.2698, p = 0.7908, A6MDQ (74) t (16) = 0.3734, p = 0.7137,
A6FDQ (87) t(15) = 1.027, p = 0.3207; movement distance (cm), A5CDQ (67) t(15) = 0.2677,
p = 0.7925, A6MDQ (74) t (15) = 0.6018, p = 0.5563, A6FDQ (87) t(15) = 0.2628, p = 0.7963;
ambulatory velocity (cm/s), A5CDQ (67) t(15) = 0.3027, p = 0.7663, A6MDQ (74) t (15) =
0.6425, p = 0.5302, A6FDQ (87) t(15) = 0.1642, p = 0.8718.
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Figure 63. Effect (± SEM) of A5CDQ (67), A6MDQ (74) and A6FDQ (87) at 1.0, 3.0 and 3.0
mg/kg, respectively for center entries, center distance (cm) and center time (s) in the locomotor
activity assay. No significant changes were observed for the parameters for A5CDQ (67),
A6MDQ (74) and A6FDQ (87) compared to saline according to unpaired two-tailed t test.
Unpaired two-tailed t test, for center entries, A5CDQ (67) t(15) = 0.0272, p = 0.9786, A6MDQ
(74) t (14) = 2.078, p = 0.0566, A6FDQ (87) t(15) = 0.5450, p = 0.5938; for center distance
(cm), A5CDQ (67) t(16) = 0.8572, p = 0.4040, A6MDQ (74) t (16) = 0.9231, p = 0.3697,
A6FDQ (87) t(16) = 0.1882, p = 0.8531; center time (s), A5CDQ (67) t(16) = 0.9709, p = 0.3460,
A6MDQ (74) t (15) = 1.445, p = 0.1690, A6FDQ (87) t(16) = 0.2768, p = 0.7854.
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Figure 64. Effect (± SEM) of A5CDQ (67), A6MDQ (74) and A6FDQ (87) at 1.0, 3.0 and 3.0
mg/kg, respectively for margin distance (cm) and margin time (s). No significant changes were
observed for the parameters for A5CDQ (67), A6MDQ (74) and A6FDQ (87) compared to
saline according to unpaired two-tailed t test. Unpaired two-tailed t test, for margin distance
(cm), A5CDQ (67) t(16) = 0.2085, p = 0.8374, A6MDQ (74) t (16) = 0.7735, p = 0.4505,
A6FDQ (87) t(16) = 0.7240, p = 0.4795; for margin time (s), A5CDQ (67) t(16) = 0.9709, p =
0.3460, A6MDQ (74) t (15) = 1.445, p = 0.1690, A6FDQ (87) t(16) = 0.2768, p = 0.7854.

Increased anxiety could account for reduced immobility times in mouse TST.
However, no changes in the amount of time spent in the center vs. the margin eliminated an
anxiogenic-like effect (Figures 63 and 64). Decreases in both jumps and V-plane entries
were observed for all three analogs A5CDQ (67; 1.0 mg/kg), A6MDQ (74; 3.0 mg/kg) and
A6FDQ (87; 3.0 mg/kg). These decreases however, were not statistically significant
compared to saline (Figure 65).
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Figure 65. Effect (± SEM) of A5CDQ (67), A6MDQ (74) and A6FDQ (87) at 1.0, 3.0 and
3.0 mg/kg, respectively for jumps and vertical plane (V-plane) entries in the locomotor
activity assay. No significant changes were observed for the parameters for A5CDQ (67),
A6MDQ (74) and A6FDQ (87) compared to saline according to unpaired two-tailed t test.
Unpaired two-tailed t test, for jumps, A5CDQ (67) t(15) = 1.546, p = 0.1429, A6MDQ (74)
t (16) = 1.730, p = 0.1029, A6FDQ (87) t(16) = 1.498, p = 0.1536; for V-Plane entries,
A5CDQ (67) t(16) = 0.8320, p = 0.4177, A6MDQ (74) t (16) = 1.607, p = 0.1276, A6FDQ
(87) t(16) = 0.7756, p = 0.4493.

The locomotor activity assay indicated an overall lack of locomotor stimulant effect
for all three 2-aminodihydroquinazoline analogs, A5CDQ (67), A6MDQ (74) and A6FDQ
(87) at the TST-active doses and gave further credence to the antidepressant-like effect
observed in mouse TST.
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V. Conclusions

The overarching goal of the current study was to identify the mechanism of
antidepressant-like character of the 2-aminodihydrquinazoline analogs, A6CDQ (65) and
A7CDQ (66). In the course of achieving this goal, we eliminated a solely 5-HT3 receptor
mediated mechanism of antidepressant-like effect and investigated two other potential
mechanisms mediated via hSERT and/or OCTs.
When examined at hSERT we determined that the position of the chloro group
exerted influence on the activity at hSERT. The positional isomers, A6CDQ (65) and
A7CDQ (66), exhibited distinct electrophysiological signatures of a releaser and reuptake
inhibitor, respectively. In trying to determine the reason for this difference in activity, we
performed molecular modeling studies and identified subtle differences in hydrophobic
interactions that the 6- and 7-chloro groups were engaged in at hSERT. However, activity at
hSERT (releaser and reuptake inhibitor) proved incapable of explaining the in vivo activities
of the two positional isomers.
Having eliminated both a solely 5-HT3 and hSERT mediated mechanism of
antidepressant-like effect, we examined OCTs, specifically hOCT3, that has been previously
implicated as being involved in depression.308,309 We successfully identified 2aminodihydroquinazoline analogs as a new class of OCT inhibitors and established an initial
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SAR at hOCT3 (Figure 66) that was lacking. In delineating the SAR, we concluded the
following:
i.

The presence and not the position of the chloro group was important for OCT
inhibitory activity.

ii.

At the 6-position the lipophilic properties of the substituents were more important
than their electronic properties. Also, there seems to exist a region of bulk
tolerance capable of accommodating substituents of considerable volume (such
as iodo, bromo).

iii.

The methylene bridge was not an important structural feature for OCT inhibitory
activity.

At the present time, we do not know how our compounds, the 2aminodihydroquinazolines behave at hOCT3. Are they simply inhibitors or substrates or
both? There might be considerable differences in SARs for all three categories of
compounds. This is illustrated by the 6-fluoro analog, A6FDQ (87) which despite having a
substituent with a lower lipophilic property, possessed ~8-fold greater inhibitory potency at
hOCT3 as compared to the lead, A6CDQ (65). A lack of selectivity for hOCT3 over hOCT1
and hOCT2 was a feature common to the chloro-substituted 2-aminodihydroquinazoline
analogs. A degree of selectivity was achieved by the 5-methyl analog which bore 10– and
57–fold selectivity for hOCT3 over hOCT1 and hOCT2, respectively.
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Removal of methylene
bridge does not affect
inhibitory activity at OCTs

Presence of substituent
important for inhibitory
activity at OCTs

Lipophilic property of Cl
group is more important
than electronic property
Modeling studies suggest
that the binding region is
capable of accommodating
bulky substituents, but only
to a limit.
Figure 66. Summary of SAR of the 2-aminodihydroquinazolines at hOCT3.

Our efforts to understand how the analogs interacted at a molecular level resulted in
the first 3-dimensional homology models of both the human and mouse orthologs of OCT3
(hOCT3 and mOCT3, respectively). Both hOCT3 and mOCT3 share a high degree of
homology with each other with the amino acid residues comprising the binding regions being
conserved. Consequently, it was no surprise when analysis of our docking studies at hOCT3
and mOCT3 indicated a common and key bidendate ionic salt-bridge interaction between
the guanidinium moiety of our molecules and the oxygen atom of Asp478 and Asp473 in
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hOCT3 and mOCT3, respectively. Notwithstanding the high degree of homology between
hOCT3 and mOCT3 there might exist differences in how the proteins fold. This could
potentially influence the binding region. Hence, despite the fact that all the amino acids of
the binding region are conserved between the two orthologs (human and mouse) of OCT3,
the shape of the binding region itself might be considerably different. This might explain the
very weak inhibitory activity of the ring-opened phenylguanidine analogs at mOCT3 as
compared to hOCT3. Since we have used the same template, PiPT, for modeling both
hOCT3 and mOCT3, the orientation of the back bone amino acid residues were highly
overlapping (RMSD ~2.5 Å between hOCT3 and mOCT3). We have essentially forced
mOCT3 and by extension its binding region to adopt and mimic the binding region observed
in hOCT3. Consequently, at this point, our modeling studies are incapable of explaining the
discrepancies in the inhibitory potencies observed for the ring-opened phenylguandine series
at the two orthologs - hOCT3 and mOCT3. Our biological data indicated an importance for
the lipophilic property of the substituents, a feature mirrored in our modeling studies which
identified hydrophobic interactions of the substituents with the residues of the binding
region. Hence, so far, our biological data supports the modeling studies at OCTs.
Despite sharing the key bidentate ionic salt-bridge interaction with Asp478, the ringopened phenylguanidine analogs are oriented differently, i.e., they possess different docking
modes compared to the 2-aminodihydroquinazolines. We identified two potential docking
modes for the phenylguanidine analogs and eliminated one of the modes on the basis of
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unfavorable interactions as indicated by HINT analysis. The SAR of the phenylguanidine
series parallels that of the 2-aminodihydroquinazoline series with the lipophilic (π) property
of the substituents at the 4-position being more important than its electronic (σ) property. A
major feature of the phenylguanidine series, however, was a limitation in the amount of bulk
that could be tolerated at the 4-poisition (which corresponds to the 6-position of 2aminodihydroquinazolines).
So far, inhibitory potencies at OCT3 have shown promise in providing a potential
explanation

for

the

in

vivo

activity

observed.

Unlike

the

SAR

for

2-

aminodihydroquinazolines at OCTs, both the position and the presence of the chloro group
might be important for the antidepressant-like effect in the mouse TST. Additionally,
removal of the methylene bridge, a structural feature unimportant for OCT inhibitory
activity, resulted in loss of antidepressant-like effect in the mouse TST. A striking feature of
the antidepressant-like effect observed was the U shaped dose response curves. This feature
which has been previously observed for 5-HT3 receptor agonists might be a result of multiple
phenomena such as receptor desensitization, differences in receptor localization (presynaptic
vs. postsynaptic) and/or densities, sedative effects at higher doses or limited solubility of the
compounds at higher doses. Since the 2-aminodihydroquinazolines resulted from structural
modifications of 5-HT3 receptor antagonists and were administered as water-soluble salts,
desensitization and limited solubility as potential explanations seem unlikely. Therefore, at
present, the most probable explanation for the U shaped dose response curve appears to be
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potential sedative effects at higher doses since only the antidepressant-like effects of the
active doses identified in the mouse TST were shown to be free of a potential locomotor
stimulant.
In pursuing our overarching goal, we arrived at the conclusion that it was unlikely
that

the

mechanism

underlying

the

antidepressant-like

character

of

the

2-

aminodihydroquinazolines were mediated by a single target but instead might be a result of
activity at a combination of multiple targets (i.e., 5-HT3 receptors, hSERT and/or OCTs).
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VI. Experimental
A. Synthesis

Compounds were characterized using a combination of melting point (mp), proton
nuclear magnetic resonance (1H NMR), infrared (IR), and mass (MS) spectrometry. Purity
of the compounds was determined based on elemental analysis for C, H and N performed by
Atlantic Microlab Inc. (Norcross, GA) and compounds were considered pure if the values
obtained were within 0.4% of theoretical values. The MEL TEMP melting point apparatus
was utilized to obtain uncorrected melting points (mp) of compounds in glass walled
capillary tubes. 1H NMR were obtained either using a Bruker ARX 400 MHz or Bruker
AVANCE III 400 MHz spectrometer. The spectra obtained were reported by indicating the
position of the peaks in parts per million (ppm) downfield from the tetramethylsilane (TMS),
used as an internal standard, followed by the splitting pattern of the peak (s = singlet, d =
doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet), coupling constant
(J, Hz) and integration. IR spectra were determined using Thermo Nicolet iS10 FT-IR. MS
was obtained using a Waters Acquity TQD (tandem quadrapole) spectrometer utilizing
electrospray ionization in positive ion mode. Reactions were followed using thin-layer
chromatography (TLC) on silica gel GHLF plates (250 µm, 2.5 x 10 cm; Analtech Inc.
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Newark, DE). For the purposes of biological studies water-soluble salts of compounds
(hydrochloride, hydrobromide or nitrate) were prepared except for 2-amino-5-methyl-3,4dihydroquinazoline (71) and 2-amino-6-iodo-3,4-dihydroquinazoline (89), for which a
suitable salt could not be obtained because the salts obtained were hygroscopic.

2-Amino-8-chloro-3,4-dihydroquinazoline Hydrochloride (68). The procedure for a
similar compound328 was used to synthesize 68. Cyanogen bromide (3 M solution in CH2Cl2,
3 mL, 8.6 mmol) was added to a stirred solution of 2-amino-3-chlorobenzylamine (73) (0.90
g, 5.6 mmol) in toluene (6 mL). The stirred reaction mixture was heated at reflux for 4.5 h,
allowed to cool to room temperature and stirred overnight. This was followed by removal of
toluene under reduced pressure to give a yellow solid. The residue was dissolved in H2O (60
mL) followed by addition of a saturated solution of NaHCO3 to pH = 9 to 10. The H2O layer
was further basified by addition of NaOH (3 N, to pH 12). The solid was collected by
filtration and washed with H2O (30 mL) to afford 0.85 g (81%) of the crude free base of 68.
The solid was dissolved in EtOH (20 mL) and a saturated solution of gaseous HCl in EtOH
was added (pH 1-2) and the reaction mixture was allowed to stir at room temperature
overnight. The solid was collected by filtration to afford 0.39 g (65%) which upon
recrystallization from EtOH gave 0.17 g (28%) of 68 as a white solid: mp 202-204 °C. 1H
NMR (DMSO-d6) δ 4.52 (s, 2H. CH2), 7.06-7.11 (t, J = 6 Hz, 1H, ArH), 7.15-7.18 (d, J = 12
Hz, 1H, ArH), 7.38-7.40 (d, J = 8 Hz, 1H, ArH), 8.08 (s, 2H, NH2), 8.82 (s, 1H, NH), 10.07
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(s, 1H, NH). Anal. Calcd for (C9H11N3·1HCl) C, 44.06; H, 4.16; N, 19.27. Found: C, 44.05;
H, 4.01; N, 19.15.

2-Amino-3,4-dihydroquinazoline Hydrochloride (69). The procedure for a similar
compound327 was used to synthesize 69. BH3·THF complex (1 M in THF, 7 mL, 7.2 mmol)
was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 2-aminoquinazolin4(3H)-one (71) (0.30 g, 1.8 mmol) in anhydrous THF (5 mL) under an N2 atmosphere. The
stirred reaction mixture was heated at reflux for 2 h to give a pale yellow-colored solution,
allowed to cool to room temperature, quenched by addition of HCl (6 N, to pH 2). The
reaction mixture was then heated to evaporate THF until THF could no longer be detected
by smell. The residue was cooled to 0 °C (ice-bath) and a solution of NaOH (15%, to pH 12)
was added. Hot CHCl3 (3 x 15 mL) was used to extract the desired compound, which settled
between H2O and CHCl3 layers. The solid obtained was collected by filtration and washed
with cold CHCl3 to afford 0.14 g (44%) of the free base of 69 as a white solid: mp 310-314
°C. NMR (DMSO-d6) δ 4.28 (s, 2H, CH2), 5.41 (s, 2H, NH2 D2O ex), 6.06 (s, 1H, NH D2O
ex), 6.58-6.60 (d, J = 8 Hz, 1H, ArH), 6.53-6.68 (t, J = 4 Hz, 1H, ArH), 6.81-6.83 (d, J = 8
Hz, 1H, ArH), 6.94-6.97 (t, J = 4 Hz, 1H, ArH). A saturated solution of gaseous HCl in EtOH
was added to a solution of the free base of 69 in EtOH (2 mL) and the reaction mixture was
allowed to stir for 30 min. The EtOH was removed under reduces pressure to obtain a crude
solid which upon recrystallization from EtOH/Et2O afforded 0.14 g (%) of 69 as cream131

yellow solid: mp 172-174 °C (EtOH/Et2O) (lit.327,355 mp 158-160 °C); Anal. Calcd for
(C8H9N3·1HCl) C, 52.32; H, 5.49; N, 22.88. Found: C, 52.40; H, 5.42; N, 22.74.

2-Aminoquinazolin-4(3H)-one (71). A reported procedure for a similar compound327 was
used to synthesize 73. S-Methylisothiourea sulfate (0.93 g, 6.7 mmol) and Na2CO3 (0.75 g,
7.1 mmol) were added to a solution of isatoic anhydride (72) (1.00 g, 6.7 mmol) in 80% aq.
MeCN (20 mL) and the reaction mixture was heated at reflux for 3 h. The reaction mixture
was then allowed to cool to room temperature. The solid obtained was collected by filtration
and dried to yield 0.35 g (32%) of 73 as a white solid: mp 320-322 °C (lit.327,356 mp >300
°C).

2-Amino-3-chlorobenzylamine (73). The procedure for a similar compound329 was used to
synthesize 71. BH3·THF complex (1 M in THF, 26 mL, 26.2 mmoles) was added in a
dropwise manner at 0 °C (ice-bath) to 2-amino-3-chlorobenzonitrile (70) (1.00 g, 6.6
mmoles) under an N2 atmosphere. The stirred reaction mixture was heated at reflux
overnight, allowed to cool to room temperature, quenched by addition of HCl (6 N, to pH
2), and refluxed for 30 min. The reaction mixture was allowed to cool to room temperature
and then to 0 °C (ice-bath) and basified with NaOH (3 N, to pH 12) and extracted with
CH2Cl2 (2 x 40 mL). The combined organic portion was washed with H2O (100 mL), dried
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(MgSO4) and evaporated under reduced pressure to afford 0.93 g (90%) of 71 as a sticky
solid. IR spectroscopy indicated the absence of a characteristic cyano band at 2226.58 cm-1.

2-Amino-6-methyl-3,4-dihydroquinazoline Hydrochloride (74). The procedure for a
similar compound313 was used to synthesize 74. BH3·THF complex (1 M in THF, 6 mL, 6.0
mmol) was added in a dropwise manner at 0 °C to 2-amino-6-methylquinazolin-4(3H)-one
(80) (0.28 g, 1.6 mmol) under an N2 atmosphere. The stirred reaction mixture was heated at
reflux for 1 h to give a clear solution, allowed to cool to room temperature, quenched by
addition of HCl (6 N, to pH 3). The reaction mixture was then heated to evaporate THF until
THF could no longer be detected by smell. The residue was cooled to 0° C (ice-bath) and a
solution of NaOH (15%, to pH 12) was added. Hot CHCl3 (3 x 10 mL) was used to extract
the desired compound, which settled between H2O and CHCl3 layers. The solid obtained
was collected by filtration and washed with cold CHCl3 to afford 0.15 g (44%) of the free
base of 74 as a white solid: mp >300 °C. A saturated solution of gaseous HCl in EtOH was
added to a solution of the free base of 74 in EtOH until the solution became acidic (pH = 3).
The EtOH was removed under reduced pressure to obtain a crude, white solid which upon
crystallization from EtOH yielded 0.04 g (23%) of 74 as off-white crystals: mp 172-175 °C.
NMR (DMSO-d6) δ 2.25 (s, 3H, CH3), 4.46 (s, 2H, CH2), 6.86-6.88 (d, J = 8 Hz, 1H, ArH),
6.99 (s, 1H, ArH), 7.05-7.07 (d, J = 8 Hz, 1H, ArH), 7.54 (s, 1H, NH D2O ex), 8.46 (s, 1H,
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NH D2O ex), 10.74 (s, 1H, NH D2O ex). Anal. Calcd for (C9H11N3·1.1HCl) C, 54.70; H,
6.06; N, 20.87. Found: C, 53.95; H, 6.06; N, 20.84.

2-Amino-5-methyl-3,4-dihydroquinazoline (75). The procedure for a similar compound328
was used to synthesize 75. Cyanogen bromide (3 M solution in CH2Cl2, 2 mL, 6.2 mmol)
was added to a stirred solution of 2-amino-6-methylbenzylamine (83) (0.56 g, 4.1 mmol) in
toluene (6 mL). The stirred reaction mixture was heated at reflux overnight to give a dark
brown suspension, then allowed to cool to room temperature followed by removal of toluene
under reduced pressure. The residue was dissolved in H2O (20 mL) followed by addition of
a saturated solution of NaHCO3 resulting in precipitation of a yellow solid. The solid was
collected by filtration to afford 0.07 g (11%) of 75 as a light-brown solid: mp 180-184 °C.
1

H NMR (DMSO-d6) δ 2.07 (s, 3H, CH3), 4.33 (s, 2H, CH2), 6.52-6.50 (d, J = 8 Hz, 1H,

ArH), 6.62-6.60 (d, J = 8 Hz, 1H, ArH), 6.93-6.89 (t, J = 8 Hz, 1H, ArH). HMRS (M++H)
calcd. for C9H12N3 162.1005; found 162.1045.

2-Amino-7-methyl-3,4-dihydroquinazoline Hydrochloride (76). The procedure for a
similar compound328 was used to synthesize 76. Cyanogen bromide (3 M solution in CH2Cl2,
3 mL, 9.4 mmol) was added to a stirred solution of 2-amino-4-methylbenzylamine (82) (0.85
g, 6.2 mmol) in toluene (6 mL). The stirred reaction mixture was heated at reflux overnight,
allowed to cool to room temperature followed by removal of toluene under reduced pressure.
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The residue was dissolved in H2O (80 mL) followed by addition of a saturated solution of
NaHCO3 to pH = 9 to 10. The aqueous layer was further basified by addition of NaOH (3 N,
to pH 12). The solid was collected by filtration to afford 0.63 g of crude free base of 76. The
solid was dissolved in MeOH (10 mL) and a saturated solution of gaseous HCl in EtOH was
added (pH 1-2) and the reaction mixture was allowed to stir at room temperature overnight.
The MeOH was removed under reduced pressure to afford 0.60 g (79%) which upon
recrystallization from EtOH gave 0.20 g (26%) of 76 as a white solid: mp 204-205 °C. 1H
NMR (DMSO-d6) δ 2.24 (s, 3H, CH3), 4.41 (s, 2H. CH2), 6.75 (s, 1H, ArH), 6.86-6.89 (d, J
= 12 Hz, 1H, ArH), 7.03-7.05 (d, J = 8 Hz, 1H, ArH), 7.60 (s, 2H, NH2), 8.46 (s, 1H, NH),
10.77 (s, 1H, NH). Anal. Calcd for (C9H11N3·1.1HCl) C, 53.70; H, 6.06; N, 20.87. Found:
C, 53.72; H, 5.97; N, 21.19.

2-Amino-8-methyl-3,4-dihydroquinazoline Hydrochloride (77). The procedure for a
similar compound328 was used to synthesize 77. Cyanogen bromide (3 M solution in CH2Cl2,
3 mL, 9.9 mmol) was added to a stirred solution of 2-amino-3-methylbenzylamine (81) (0.90
g, 6.6 mmol) in toluene (6 mL). The stirred reaction mixture was heated at reflux overnight
and then allowed to cool to room temperature. This was followed by removal of toluene
under reduced pressure to give a sticky orange-pink solid. The residue was dissolved in H2O
(40 mL) followed by addition of a saturated solution of NaHCO3 to pH = 9 to 10. The
aqueous portion was further basified by addition of NaOH (3 N, to pH 12). The solid was
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collected by filtration and washed with H2O (30 mL) to afford 0.49 g of crude free base of
77. The free base was dissolved in EtOH (20 mL) and a saturated solution of gaseous HCl
in EtOH was added (pH 1-2) and the reaction mixture was allowed to stir at room
temperature overnight. EtOH was removed under reduced pressure to afford 0.40 g of a
white solid which upon recrystallization from EtOH gave 0.21 g (16%) of 77 as a white
solid: mp 168-170 °C. 1H NMR (DMSO-d6) δ 2.28 (s, 3H, CH3), 4.47 (s, 2H. CH2), 6.097.02 (q, J = 6 Hz, 2H, ArH), 7.10-7.12 (q, J = 9 Hz, 1H, ArH), 7.85 (s, 2H, NH2), 8.54 (s,
1H, NH), 10.01 (s, 1H, NH). Anal. Calcd for (C9H11N3·1HCl) C, 54.69; H, 6.12; N, 21.26.
Found: C, 54.51; H, 6.06; N, 21.13.

6-Methylisatoic anhydride (79). A reported procedure for a the same compound333 was
used to synthesize 79. Urea-H2O2 complex (0.78 g, 8.3 mmol) and 3 drops of H2SO4 were
added to a solution of 5-methylisatin (78) (1.00 g, 6.2 mmol) in 8 mL of HCOOH. The
reaction mixture was then sonicated for 35 min with occasional stirring. The urea-hydrogen
peroxide complex was prepared according to a reported procedure332 by adding urea (4.00
g, 66.6 mmol) portion wise to H2O2 (30% aq., 11.32 mL) heated to 55 °C and keeping the
temperature below 60 °C. The reaction mixture was poured on to an evaporating dish and
left overnight. The solid obtained was collected by filtration to afford 4.87 g (78%) of the
urea-H2O2 complex as a white solid. The precipitate formed during sonication of reaction
mixture was collected by filtration and washed with Et2O to yield 0.87 g of a bright yellow136

orange solid which upon recrystallization from HOAc gave 0.62 g (56%) of 79 as bright
orange crystals: mp 227-230 °C (lit333 mp 233 °C).

2-Amino-6-methylquinazolin-4(3H)-one (80). The procedure for a similar compound313
was used to synthesize 80. S-Methylisothiouronium sulfate (0.86 g, 3.1 mmol) and Na2CO3
(0.36 g, 3.4 mmol) were added to a solution of 6-methylisatoic anhydride (79) (0.40 g, 2.2
mmol) in 80% aq. MeCN (12 mL). The reaction mixture was heated at reflux for 2.5 h. The
reaction mixture was then allowed to cool to room temperature and the precipitate formed
was collected by filtration and washed with 80% aq. MeCN to yield 0.18 g (46%) of 80 as a
pale white solid: mp >300 °C (lit356 mp >250 °C).

2-Amino-3-methylbenzylamine (84). The procedure for a similar compound329 was used to
synthesize 84. A complex of BH3·THF (1 M in THF, 30 mL, 26.2 mmol) was added in a
dropwise manner at 0 °C (ice-bath) to 2-amino-3-methylbenzonitrile (81) (1.00 g, 7.6 mmol)
under an N2 atmosphere. The stirred reaction mixture was heated at reflux overnight, allowed
to cool to room temperature, quenched by addition of HCl (6 N, to pH 2), and heated at
reflux for 30 min. The reaction mixture was allowed to cool to room temperature and then
to 0 °C (ice bath) and basified with NaOH (3 N, to pH 12) and extracted with CH2Cl2 (2 x
25 mL). The combined organic portion was washed with H2O (50 mL), dried (MgSO4) and
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evaporated under reduced pressure to afford 0.92 g (89%) of 84 as a sticky solid. IR
spectroscopy indicated the absence of a characteristic cyano band at 2219.67 cm-1.

2-Amino-4-methylbenzylamine (85). The procedure for a similar compound329 was used to
synthesize 85. A complex of BH3·THF (1 M in THF, 30 mL, 30.3 mmol) was added in a
dropwise manner at 0 °C (ice-bath) to a stirred solution of 2-amino-4-methylbenzonitrile
(82) (1.00 g, 7.6 mmol) in anhydrous THF (15 mL) under an N2 atmosphere. The stirred
reaction mixture was heated at reflux overnight, allowed to cool to room temperature,
quenched by addition of HCl (6 N, to pH 2), and refluxed for 35 min. The reaction mixture
was allowed to cool to room temperature and then at 0 °C (ice-bath), was basified with NaOH
(3 N, to pH 12) and extracted with CH2Cl2 (2 x 50 mL). The combined organic portion was
washed with H2O (50 mL), dried (MgSO4) and evaporated under reduced pressure to afford
0.89 g (85%) of 85 as a sticky solid: mp 82-86 °C. IR spectroscopy indicated the absence of
a characteristic cyano band at 2208.91 cm-1.

2-Amino-6-methylbenzylamine (86). The procedure for a similar compound329 was used to
synthesize 86. A complex of BH3·THF (1 M in THF, 30 mL, 30.3 mmol) was added in a
dropwise manner at 0 °C (ice-bath) to a stirred solution of 2-amino-6-methylbenzonitrile
(83) (1.00 g, 7.6 mmol) in anhydrous THF (15 mL) under an N2 atmosphere. The stirred
reaction mixture was heated at reflux overnight, allowed to cool to room temperature,
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quenched by addition of HCl (6 N, to pH 2), and heated at reflux for 30 min. The reaction
mixture was allowed to cool to room temperature and then to 0 °C (ice-bath) and basified
with NaOH (15% as well as NaOH pellets, to pH 12) and extracted with CH2Cl2 (4 x 20
mL). The combined organic portion was washed with brine (50 mL), dried (MgSO4) and
evaporated under reduced pressure to afford 0.69 g (67%) of 86 as a sticky, brown solid. IR
spectroscopy indicated the absence of a characteristic cyano band at 2222 cm-1.

2-Amino-6-fluoro-3,4-dihydroquinazoline Hydrochloride (87). The procedure for a
similar compound327,334 was used to synthesize 87. 2-Amino-6-fluoroquinazolin-4(3H)-one
(91) (0.50 g, 2.8 mmol) was added in a portionwise manner to a stirred solution of BH3•THF
complex (1 M in THF, 11 mL, 11.0 mmol) at 0 °C (ice-bath) under an N2 atmosphere. To
this, anhydrous THF (16 mL) was added. The stirred reaction mixture was heated at reflux
for 1.2 h, allowed to cool to room temperature, quenched by addition of HCl (6 N, to pH 2),
and then heated at reflux for 35 min. The reaction mixture was allowed to cool to room
temperature and basified with NaOH (15% as well as NaOH pellets, to pH 12). THF was
evaporated under reduced pressure to give a white precipitate which was collected by
filtration and upon recrystallization from EtOH/Et2O afforded 0.09 g (%) of 87 as a creamcolored solid: mp 228-230 °C 1H NMR (DMSO-d6) δ 4.49 (s, 2H, ArCH2), 6.99-7.02 (m,
1H, ArH), 7.09-7.13 (m, 2H, ArH), 7.68 (s, 2H, NH2), 8.55 (s, 1H, NH), 10.96 (s, 1H, NH).
HRMS (ESI-TOF) calcd for C8H9N3F [M + H] 166.0775, found 166.0761.
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2-Amino-6-bromo-3,4-dihydroquinazoline Hydrobromide (88). The procedure for a
similar compound328 was used to synthesize 88. Cyanogen bromide (3 M solution in CH2Cl2,
2 mL, 6.0 mmol) was added to a stirred solution of 2-amino-5-bromobenzylamine (95) (0.80
g, 4.0 mmol) in toluene (6 mL). The stirred reaction mixture was heated at reflux overnight
and allowed to cool to room temperature. This was followed by removal of toluene under
reduced pressure to give a sticky, yellow solid. The residue was washed with H2O (50 mL)
and the solid was collected by filtration and washed with H2O (30 mL) to afford 0.40 g (32%)
of 85 as a beige solid: mp 196-198 °C. 1H NMR 400 MHz (DMSO-d6) δ 4.49 (s, 2H. CH2),
6.95-6.97 (d, J = 8 Hz, 1H, ArH), 7.44-7.46 (t, J = 4 Hz, 2H, ArH), 7.57 (s, 2H, NH2), 8.30
(s, 1H, NH), 10.52 (s, 1H, NH). Anal. Calcd for (C8H8N3Br·0.75HBr) C, 33.51; H, 3.08; N,
14.65. Found: C, 33.23; H, 3.00; N, 14.35.

2-Amino-6-iodo-3,4-dihydroquinazoline (89). The procedure for a similar compound328
was used to synthesize 89. Cyanogen bromide (3 M solution in CH2Cl2, 0.4 mL, 1.2 mmol)
was added to a stirred solution of 2-amino-5-iodobenzylamine (96) (0.20 g, 0.8 mmol) in
EtOH (6 mL). The stirred reaction mixture was heated at reflux for 3.5 h and allowed to cool
to room temperature. This was followed by removal of EtOH under reduced pressure to give
a sticky, yellow solid. The residue was washed with H2O (10 mL) and the aqueous portion
was basified with NaOH (1 N, to pH ~10-11) and extracted with CH2Cl2 (4 x 25 mL). The
combined organic portion was washed with H2O (30 mL), dried (MgSO4) and evaporated
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under reduced pressure to afford 0.04 g (18%) of 89 as a yellow-colored oil. A saturated
solution of gaseous HCl in anhydrous EtOH was added in a dropwise manner at 0 °C (icebath) to a stirred solution of the oil (0.04 g, 4.9 mmol) in EtOH (5 mL). Both the
hydrochloride and nitrate salt were hygroscopic and the compound was converted back to
the free base to afford 0.01 g (5%) of 89 as a yellow solid: mp 196-198 °C. 1H NMR 400
MHz (DMSO-d6) δ 4.45 (s, 2H. CH2), 6.79-6.81 (d, J = 8 Hz, 1H, ArH), 7.56-7.60 (m, 3H,
ArH), 8.29 (s, 1H, NH), 10.49 (s, 1H, NH). HRMS (ESI-TOF) calcd for C8H8N3I [M + H]
272.9763, found 272.9902.

6-Fluoroisatoic anhydride (91). A reported procedure for the same compound333 was used
to synthesize 91. Urea-hydrogen peroxide complex (0.74 g, 7.9 mmol) and 3 drops of H2SO4
were added to a solution of 5-fluorolisatin (90) (1.00 g, 6.1 mmol) in 8 mL of HCOOH. The
reaction mixture was then sonicated for 45 min with occasional stirring. The urea-H2O2
complex was prepared according to a reported procedure332 by adding urea (4.00 g, 66.6
mmol) portion wise to H2O2 (30% aq., 11 mL) heated to 55 °C taking care to not let the
temperature increase beyond 60 °C. The reaction mixture was poured on to an evaporating
dish and left overnight. The solid obtained was collected by filtration to afford 4.87 g (78%)
of the urea-H2O2 complex as a white solid. The solid precipitated as a result of sonication
was collected by filtration to afford 1.03 g (94%) of 91 as an orange solid: mp 256-258 °C
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(lit.333 mp: 238-240 °C (HOAc)). IR (solid, cm-1) 671, 687, 734, 785, 846, 893, 932, 1002,
1038, 1121, 1145, 1224, 1257, 1268, 1336, 1424, 1515, 1633, 1693, 1749, 3185.

2-Amino-6-fluoroquinazolin-4(3H)-one (92). The procedure for a similar compound327,334
was used to synthesize 92. S-methylisothiourea sulfate (0.92 g, 3.3 mmol) and Na2CO3 (0.37
g, 3.5 mmol) were added to a stirred solution of 6-fluoroisatoic anhydride (91) (0.60 g, 3.3
mmol) in MeCN (80% aq., 10 mL). The stirred reaction mixture was heated at reflux for 1.5
h to give a green solution, then allowed to cool to room temperature. The solid obtained was
collected by filtration and washed with 80% aq. MeCN (30 mL) to afford 0.53 g (89%) of
92 as a cream-colored solid: mp 370 °C. 1H NMR (DMSO-d6) δ 6.39 (s, 1H, NH), 7.22-7.26
(q, J = 4 Hz, 1H, ArH), 7.42-7.47 (m, 1H, ArH) 7.53-7.56 (dd, 1H, ArH). IR (solid, cm-1)
668, 693, 734, 791, 823, 886, 937, 1074, 1127, 1152, 1214, 1251, 1347, 1387, 1479, 1515,
1569, 1659, 2769, 3039, 3334.

2-Amino-5-bromobenzylamine (95). The procedure for a similar compound329 was used to
synthesize 95. A complex of BH3·THF (1 M in THF, 20 mL, 20.3 mmol) was added in a
dropwise manner at 0 °C (ice-bath) to 2-amino-5-bromobenzonitrile (93) (1.00 g, 5.1 mmol)
under an N2 atmosphere. The stirred reaction mixture was heated at reflux for 2.5 h, allowed
to cool to room temperature, quenched by addition of HCl (6 N, to pH 2), and heated at
reflux for 30 min. The reaction mixture was allowed to cool to room temperature and then
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to 0 °C (ice bath) and basified with NaOH (3 N, to pH 12) and extracted with CH2Cl2 (3 x
25 mL). The combined organic portion was washed with H2O (2 x 100 mL), dried (MgSO4)
and evaporated under reduced pressure to afford 0.81 g (79%) of 95 as a white waxy solid:
mp 110-112 °C. IR spectroscopy indicated the absence of a characteristic cyano band at
2218.22 cm-1.

2-Amino-5-iodobenzylamine (96). The procedure for a similar compound329 was used to
synthesize 96. A complex of BH3·THF (1 M in THF, 7 mL, 6.6 mmol) was added in a
dropwise manner at 0 °C (ice-bath) to 2-amino-5-bromobenzonitrile (94) (0.40 g, 1.6 mmol)
under an N2 atmosphere. The stirred reaction mixture was heated at reflux overnight, allowed
to cool to room temperature, quenched by addition of HCl (6 N, to pH 2), and heated at
reflux for 40 min. The reaction mixture was allowed to cool to room temperature and then
to 0 °C (ice bath) and basified with NaOH (3 N, to pH ~10-12) and extracted with CH2Cl2
(2 x 25 mL). The combined organic portion was washed with H2O (30 mL), dried (MgSO4)
and evaporated under reduced pressure to afford 0.39 g (95%) of 96 as a yellowish brown
solid: mp 122-126 °C. IR spectroscopy indicated the absence of a characteristic cyano band
at 2227 cm-1.

4-tert-Butylphenylguanidine Nitrate (101). A reported procedure for the same
compound336 was used to synthesize 101. Cyanamide (0.20 g, 4.9 mmol) was added to a
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stirred solution of 4-tert-butylaniline hydrochloride (110) (0.43 g, 2.3 mmol) in EtOH (2
mL). The stirred reaction mixture was heated at reflux overnight, then allowed to cool to
room temperature followed by removal of EtOH under reduced pressure. The residue was
dissolved in H2O (5 mL) followed by addition of an excess of NH4NO3 resulting in
precipitation of a white solid. The solvent was removed under reduced pressure to afford
0.90 g of white solid, which upon two recrystallizations from EtOH, yielded 0.20 g (34%)
of 101 as a white crystalline powder: mp 181-183 °C (lit.34 mp 183-185 °C). 1H NMR
(DMSO-d6) δ 1.36 (s, 9H, C(CH3)3), 7.22-7.25 (d, J = 12 Hz, 4H, NH), 7.52-7.54 (d, J = 8
Hz, 4H, ArH).

4-Fluorophenylguanidine Nitrate (103). The procedure for a similar compound336 was
used to synthesize 103. Cyanamide (0.81 g, 19.2 mmol) was added to a stirred solution of 4fluoroaniline hydrochloride (107) (1.40 g, 9.5 mmol) in EtOH (8 mL). The stirred reaction
mixture was heated at reflux overnight, then allowed to cool to room temperature followed
by removal of EtOH under reduced pressure. The residue was dissolved in EtOH (2 mL)
followed by addition of excess NH4NO3 (2.19 g, 27.4 mmol) resulting in precipitation of a
pale violet solid. The solid was collected by filtration to afford 1.54 g of a pale violet solid
which upon two recrystallizations from i-PrOH/MeOH, yielded 1.00 g (37%) of 103 as a
pale violet crystalline powder: mp 182-185 °C 1H NMR (DMSO-d6) δ 7.28-7.29 (d, J = 4
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Hz, 2H, ArH), 7.30 (s, 4H, NH2), 9.50 (s, 1H, NH). Anal. Calcd for (C7H8N3F·1HNO3) C,
38.89; H, 4.20; N, 25.92. Found: C, 39.14; H, 4.12; N, 25.90.

4-Bromophenylguanidine Nitrate (104). The procedure for a similar compound336 was
used to synthesize 104. Cyanamide (0.63 g, 15.1 mmol) was added to a stirred solution of 4bromoaniline hydrochloride (112) (1.50 g, 7.2 mmol) in EtOH (6 mL). The stirred reaction
mixture was heated at reflux overnight, then allowed to cool to room temperature followed
by removal of EtOH under reduced pressure. The residue was dissolved in EtOH (2 mL)
followed by addition of excess NH4NO3 (1.30 g, 16.2 mmol) resulting in precipitation of a
pale brown solid. The solid was collected by filtration to afford 1.23 g of a pale violet solid,
which upon recrystallization from i-PrOH/MeOH, yielded 0.77 g (37%) of 104 as a creamcolored powder: mp 188-190 °C 1H NMR (DMSO-d6) δ 7.20-7.22 (d, J = 8 Hz, 2H, ArH),
7.43 (s, 4H, NH2), 7.62-7.64 (d, J = 8 Hz, 2H, ArH), 9.62 (s, 1H, NH). Anal. Calcd for
(C7H8N3Br·1HNO3) C, 30.34; H, 3.27; N, 20.22. Found: C, 30.63; H, 3.16; N, 20.17.

4-Iodophenylguanidine Nitrate (105). The procedure for a similar compound336 was used
to synthesize 105. Cyanamide (0.35 g, 8.2 mmol) was added to a stirred solution of 4iodoaniline hydrochloride (113) (1.00 g, 3.9 mmol) in EtOH (6 mL). The stirred reaction
mixture was heated at reflux overnight, then allowed to cool to room temperature followed
by removal of EtOH under reduced pressure. The residue was dissolved in EtOH (2 mL)
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followed by addition of excess of NH4NO3 (0.81 g, 10.2 mmol) resulting in precipitation of
a pale violet solid. The solid was collected by filtration to afford 1.16 g of a pale violet solid,
which upon two recrystallizations from i-PrOH/MeOH, yielded 0.49 g (45%) of 105 as a
pale violet crystalline powder: mp 182-184 °C. 1H NMR (DMSO-d6) δ 7.05-7.07 (d, J = 8
Hz, 2H, ArH), 7.43 (s, 4H, NH2), 7.77-7.80 (d, J = 12 Hz, 2H, ArH), 9.64 (s, 1H, NH). Anal.
Calcd for (C7H8N3I·1HNO3) C, 25.94; H, 2.80; N, 17.29. Found: C, 26.20; H, 2.80; N, 17.31.

4-tert-Butylaniline Hydrochloride (110). A saturated solution of gaseous HCl in anhydrous
Et2O was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 4-tertbutylaniline (106) (0.74 g, 4.9 mmol) in Et2O (2 mL). The precipitate was collected by
filtration to yield 0.89 g (97%) of 110 as a white-colored solid: mp 188-192 °C (lit. mp
358

268-270 °C, 359270-274 °C). The crude 110 was used without purification in the next step.

4-Fluoroaniline Hydrochloride (111). A saturated solution of gaseous HCl in anhydrous
Et2O was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 4fluoroaniline (107) (1.00 g, 9.0 mmol) in Et2O (6 mL). The precipitate was collected by
filtration to yield 1.40 g of 111 as a white-colored solid: mp 198-200 °C (lit. mp 360235-237
°C, 361246-248 °C, 362253 °C). The crude 111 was used without purification in the next step.
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4-Bromoaniline Hydrochloride (112). A saturated solution of gaseous HCl in anhydrous
Et2O was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 4bromoaniline (108) (1.00 g, 5.8 mmol) in Et2O (6 mL). The precipitate was collected by
filtration to yield 1.66 g of a crude white solid 112 that was used in the next step without
further purification: mp 216-218 °C (lit.363 mp 190 °C).

4-Iodoaniline Hydrochloride (113). A saturated solution of gaseous HCl in anhydrous Et2O
was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 4-iodoaniline (109)
(4.10 g, 18.7 mmol) in Et2O (6 mL). The precipitate was collected by filtration to yield 1.46
g (30%) of 113 as a pale violet-colored solid: mp 200-210 °C. The crude 113 was used
without purification in the next step.

B. Molecular modeling studies and HINT analysis:
1. Homology modeling:
i. hSERT:
Sequences of the template drosophila melanogaster dopamine transporter (dDAT,
PDB ID: 4M48)317 were retrieved as FASTA files from the Protein Databank (PDB) at
hhtp://www.rcsb.org. The sequences were prepared prior to alignment by removal of water
molecules, ligands and/or other molecules used to facilitate crystallization (such as
surfactants). The sequence of the human serotonin transporter (hSERT; UniProt accession
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codes: P31645) was retrieved as a FASTA files from the Universal Protein Resource
(UniPort) Database. The alignment published by Sakloth et al.320 was used to generate the
models. Three dimensional homology models of hSERT were built using Modeller v9.14364
(University of California San Francisco, San Francisco, CA) using dDAT as the template
and were supported by docking the known substrate 5-HT (1) and known reuptake inhibitor
FLX (3).

ii. OCT3:
Sequences of the templates, lactose permease (LacY, PDB ID: 1PV6)292 and
inorganic phosphate transporter (PiPT, PDB ID: 4J05)343 were retrieved as FASTA files
from the Protein Databank (PDB) at http://www.rcsb.org. The sequences were prepared by
removal of water molecules, ligands and/or other molecules used to facilitate crystallization
(such as surfactants). The sequences retrieved consisted of a dimer and this was considered
a by-product of crystallization. Hence, only residues from one monomer was retained. The
sequences of the proteins of interest, human and mouse OCT3 (UniProt accession codes:
O75751 and Q9WTW5, respectively), were retrieved as FASTA files from the Universal
Protein Resource (UniPort) Database. The sequences (template and protein of interest) were
aligned using Clustal W 2.0.344 Three dimensional homology models of human and mouse
OCT3 were built using Modeller v9.14364 (University of California San Francisco, San
Francisco, CA) using PiPT as the template. The homology models built were supported by
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docking the known model substrate MPP+ (53). Ramachandran plots346 were generated to
examine the models and indicated the percentage of amino acid residues in each of the
following region - most favored (red), additional allowed region (yellow), generously
allowed region (light yellow) and disallowed region (white). No amino acids from the
substrate binding region of hOCT3 or mOCT3 were found in the disallowed region.

2. Docking studies:
i.

hSERT:
The ligands (A6CDQ (65), A7CDQ (66), 5-HT (1) and FLX (3)) were sketched in

and energy minimized using Gasteiger-Hückel charges (dielectric constant = 4.0) in SYBYL
X-2.1 (Tripos International). Docking studies at hSERT were conducted using GOLD suite
5.2345 (Cambridge Crystallographic Data Centre, Cambridge, UK), an automated genetic
algorithm docking program with GOLD score as the chosen scoring function. The binding
site was defined as a spherical region of radius 5 Å using Asp98 and Ile172 in the central
substrate (S1) site of hSERT. The docking poses were clustered using a script on the basis
of similarity of poses within a RMSD of 2 Å. The clusters were visually inspected and on
the basis of orientation of the ligands in the binding region, the solution with the best fit was
merged into the transporter. The ligand-transporter complexes were energy minimized using
the Tripos Force Field (Gasteiger-Hückel charges, distance-dependent dielectric constant =
4.0) in SYBYL X-2.1 (Tripos International).
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ii.

OCT3:
The ligands (all 2-aminodihydroquinazoline and ring-opened phenylguanidine

analogs) were sketched in and energy minimized using Gasteiger-Hückel charges (dielectric
constant = 4.0) in SYBYL X-2.1 (Tripos International). Docking studies at both human and
mouse OCT3 were conducted using GOLD suite 5.2345 (Cambridge Crystallographic Data
Centre, Cambridge, UK), an automated genetic algorithm docking program with GOLD
score as the chosen scoring function. The binding site was defined as a spherical region of
radius 12 Å with the delta-carbon atom of Asp478 and Asp473 in hOCT3 and mOCT3,
respectively as the center. The docking poses were clustered using a script on the basis of
similarity of poses within a RMSD of 2 Å. The clusters were visually inspected and on the
basis of orientation of the ligands in the binding region, the solution with the best fit was
merged into the transporter. The ligand-transporter complexes were energy minimized using
the Tripos Force Field (Gasteiger-Hückel charges, distance-dependent dielectric constant =
4.0) in SYBYL X-2.1 (Tripos International) and the models analyzed using PROCHECK.

iii.

HINT analysis:
The chosen ligand-transporter complexes were scored using the HINT (Hydropathic

INTeraction) program326 in SYBYL 8.1, to quantify the interactions observed in molecular
modeling studies. The protein was partitioned using the dictionary option while the ligand
was partitioned using the calculate option using the default settings. The atom-based
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breakdown of HINT score was analyzed to determine the contributions of the individual
atoms to the interactions with amino acid residues at the binding region of hSERT and
hOCT3.

C. Radioligand binding studies
The Ki values for A6CDQ (65) and A7CDQ (66) at hSERT were generously provided
by the National Institute of Mental Health's Psychoactive Drug Screening Program, #
HHSN-271-2013-00017-C (NIMH PDSP).

D. Electrophysiological studies
1. 5-HT3 receptors:
Electrophysiological studies at 5-HT3 receptors were conducted in the Schulte laboratory at
University of Sciences (Philadelphia, PA) by Shailesh Khatri (graduate student).

i.

Expression:
Stage IV oocytes were harvested from the ovarian lobes of Xenopus laevis frogs

following established protocols.35 The selected oocytes were injected with cRNA (50 nL per
oocyte) for the m5-HT3A receptors. The cRNA was prepared using the mMACHINETM High
Yield Capped RNA Transcription Kit (Ambion, TX). After injection, the oocytes were
incubated for a period of 2-4 days at 19 °C.
151

ii.

Two-electrode voltage-clamp:
The experiments were conducted following previously established protocols.35 The

oocytes expressing m5-HT3A receptors were voltage-clamped (–60 mV). Electrodes
employed possessed a resistance of 1–2 MΩ and were filled with 3 M KCl. The buffer used in
the experiments was the ND-96 recording buffer. This buffer consists of the following
components: 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.4.
The ND-96 buffer was used to make solutions of the test compound, A7CDQ (66). A7CDQ
(66) displayed an inability to induce currents at m5-HT3A receptors, but had an effect on 5HT-induced responses at m5-HT3A receptors. Prior to perfusion with a mixture of 5-HT and
test compound, A7CDQ (66) at concentrations ranging from 0.1-30 µM, the oocytes were
perfused with 5-HT (2.2 µM).

iii.

Analysis:
The uninhibited 5-HT (2.2 µM) response was used to normalize all other peak current

amplitudes. The data obtained from the electrical recordings were used to generate
concentration-response curves in GraphPad Prism (GraphPad Software Inc. La Jolla, CA).
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2. hSERT:
Electrophysiological studies at hSERT were conducted in the De Felice laboratory at
Virginia Commonwealth University (Richmond, VA) by Dr. Ernesto Solis Jr. (postdoctoral
fellow).

i.

Expression:

Adult Xenopus laevis females were used to harvest oocytes based on established
protocols.365 After isolation, oocytes belonging to Stage V-VI were selected for cRNA
injection within 24 h. The mMessage Machine T7 kit (Ambion Inc., Austin, TX) was used
to transcribe cRNA from the pOTV vector. This was followed by injection of oocytes with
hSERT cRNA (32.2 ng) (Nanoject AutoOocyteInjector, Drummond Scientific Co.,
Broomall, PA) and incubation at 18 °C for 4-12 days. The incubation was carried out in the
presence of Ringers solution that was supplemented with sodium pyruvate (550 µg/mL),
streptomycin (100 µg/mL), tetracycline (50 µg/mL) and 5% dialyzed horse serum.

ii.

Two-electrode voltage-clamp:
The methodology for the two-electrode voltage-clamp (TEVC) experiments were

followed from previously established procedures.366 Electrodes employed in electrical
recordings possessed resistances from 1-5 MΩ and were filled with 3 M KCl. Oocytes
expressing hSERT were voltage-clamped (–60 mV) with a GeneClamp 500 (Axon
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Instruments). The experiment was conducted at room temperature (23-25 °C). Test
compounds, A6CDQ (65) and A7CDQ (66), were perfused following perfusion of buffer
which was composed of 120 mM NaCl, 7.5 mM HEPES, 5.4 mM KGluconate, 1.2 mM
CaGluconate, pH 7.4.

iii.

Analysis:
5-HT-induced current measured at a concentration of 5 µM was used to normalize

peak current amplitudes of test compounds, A6CDQ (65) and A7CDQ (66). The data
obtained were fitted to the Hill 1 equation, y = Vmax + (Vmin - Vmax) * xn / (kn + xn) and used
to generate concentration-response curves in Origin 8.0 (OriginLab Corporation,
Northampton, MA). The equation gave the Km and Vmax values for the test compounds,
A6CDQ (65) and A7CDQ (66). GraphPad Prism (GraphPad Software Inc. La Jolla, CA) was
utilized to determine the statistical significance of differences in Km observed in the presence
and absence of A7CDQ (66) using one-way analysis of variance (ANOVA).

E. Functional studies at OCTs:
Functional studies were conducted in the Sweet laboratory at Virginia Commonwealth
University (Richmond, VA) by Dr. Xiaolei Pan (graduate student).
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1. Expression:
The human and mouse orthologs of OCT1-3 were stably expressed in human
embryonic kidney 293 (HEK293) cells. Empty vector transferred HEK293 cells were used
as background. Following previously established procedures,256,265 the cells were incubated
at 37 °C in Dulbecco’s modified eagle medium (DMEM), high glucose and additionally
supplemented

with

10%

serum

and

1%

Penicillin/Streptomycin.

2. Drugs:
[3H]MPP+ (53) bought from PerkinElmer Life And Analytical Science (Waltham,
MA) was used as a substrate to test the activities of the compounds. Unlabeled MPP+ (53)
was bought from Sigma-Aldrich (Saint Louis, MO). Compounds A5CDQ (67), A6CDQ
(65), A7CDQ (66), 3-CPG (97), 4-CPG (98), PG (99), 4-MePG (100) and 4-BnPG (102)
were available from previous studies for testing. Compounds A8CDQ (68), ADQ (69),
A5MDQ (75), A6MDQ (74), A7MDQ (76), A8MDQ (77), A6FDQ (87), A6BrDQ (88), 4t-BuPG (101), 4-FPG (103), 4-BrPG (104) and 4-IPG (105) were synthesized for the current
study.

3. Cell accumulation assay:
HEK293 cells seeded into 24-well tissue culture plates for a period of 48 hours were
used to conduct the experiments. The cells were treated with unlabeled MPP+ (53) (1 µM)
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after a 10 min pre-treatment with transport buffer (500 µL). To the unlabeled MPP+ (53)
[3H]MPP+ (0.25 µCi/mL) was added. The compounds were tested at various concentrations
(0.01 to 200 µM) by being applied simultaneously as spiked MPP+ (53). The cells were lysed
and the amount of [3H]MPP+ (53) taken up by the cells were determined by measuring
radioactivity using liquid scintillation counting of the cell lysates. The experiments were
conducted in triplicate.

4. Analysis:
The data obtained were used to generate concentration-response curves in GraphPad
Prism (GraphPad Software Inc. La Jolla, CA) utilizing the log(inhibitor) vs. response model.
Based on the concentration-response curves the inhibitory potency (IC50) was calculated for
each compound and reported as the average of three values (IC50 ± SEM) in µM.

F. Behavioral studies:

1. Animals:
Male ICR mice (20-24 g) from Harlan Laboratories Inc. (Indianapolis, IN) were used
for the mouse TST. The animals were housed and maintained in solid-bottom plastic cages
in a temperature (~22 °C)- and humidity (~50 %)-controlled environment with a standard
12:12 h dark:light cycle. No restrictions were placed on food and water, which were
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available ad lib. After an acclimatization period of 2 days the experiments were conducted
in accordance to IACUC protocol AM10399 with the standards set by the Institutional
Animal Care and Use Committee (IACUC) of Virginia Commonwealth University (VCU)
and the National Institute of Health’s (NIH) Guide for Care and Use of Laboratory Animals.

2. Drugs:
Fluoxetine hydrochloride (Prozac®, Batch 4A/80352; Eli Lily) was purchased from
Tocris. A5CDQ (67), A6MDQ (74), A6FDQ (84) and A8CDQ (68) were used as
hydrochloride salts. 4-t-BuPG (101) was used as a nitrate salt. A5CDQ (67) was available
from previous studies for testing. A6MDQ (74), A6FDQ (84), A8CDQ (68) and 4-t-BuPG
(101) were synthesized for the current study. Solutions of all compounds were prepared by
dissolving in 0.9% saline and were administered via intraperitoneal (ip) injections in a total
volume of 10 mL/kg body weight. The solutions were stored overnight in the refrigerator
and were used over a three-day period.

3. Mouse tail suspension test (TST):
The experiment was conducted by following protocols previously established by the
Dukat laboratory.35 Mice were brought to the room where the experiment was conducted at
least 2 h prior to start of the experiment. Mice were marked and weighed 1 h prior to the
experiment which was conducted between 1200 to 1700 h. Mice were suspended ~1.5 cm
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from the tips of their tails from a bar at a distance of 60 cm from the bench using industrial
grade Duct Tape (2 x ½ inch) after the pretreatment time. The experiments were conducted
in a blind manner as the experimentor was unaware of the identity of the drug as well as
dose being injected. The mice were injected with saline (10 mL/kg; 30 min pre-treatment
time), fluoxetine hydrochloride (1.0, 3.0, 10, 15 or 20 mg/kg; 30 min pre-treatment time),
A5CDQ (67) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pre-treatment time), ADQ (69) (0.1,
0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pre-treatment time), A6MDQ (74) (0.1, 0.3, 1.0, 3.0 or
10 mg/kg; 30 min pre-treatment time), A6FDQ (87) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30
min pre-treatment time), A8CDQ (68) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pretreatment time), 4-CPG (98) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pre-treatment time)
and 4-t-BuPG (101) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pre-treatment time) using a
random number table.367 The mice were administered the compounds via intraperitoneal (ip)
injections and tested only once, and each compound was tested in 8-11 mice (n = 8-11
mice/treatment). The experiment (duration of 6 mins) was video recorded using a Canon
Rebel T3i camera. The immobility times for each compound were determined by viewing
each mouse’s 6 min video recording and using a stopwatch to record the immobility times.
Each mouse was scored in triplicate and a mean of these scores was utilized. Immobility was
defined as lack of movement or passive swaying. Mobility was defined as running motions,
body jerks, movement of only hind or fore legs, or attempts to catch its own tail. The mice
were sacrificed using a CO2 chamber at the end of the experiment.
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4. Locomotor activity assay:
The experiment was conducted by following protocols previously established by the
Dukat laboratory.35 Mice were brought to the room where the experiment was conducted at
least 2 h prior to start of the experiment. Mice were marked and weighed 30 min prior to the
experiment, which was conducted between 1000 to 1500 h. Mice were placed in TruScan
locomotor activity chambers immediately after injections (0 min pre-treatment time). The
mice were injected with saline (10 mL/kg; 0 min pre-injection time), A5CDQ (67) (1.0
mg/kg; 0 min pre-injection time), A6MDQ (74) (3.0 mg/kg; 0 min pre-injection time) or
A6FDQ (87) (3.0 mg/kg; 0 min pre-injection time) using a random number table.367 The
mice were administered the compounds via intraperitoneal (ip) injections and tested only
once, and each compound was tested in 9 mice (n = 9 mice/treatment). The experiment
(duration of 45 mins) was conducted by placing injected mice in TruScan activity system
(Coulbourn Instruments, Allentown, PA) photocell arena chambers (model E63-10; 26 cm
x 26 cm x 39 cm). Since the walls of the chamber were transparent black screens were placed
between the individual chambers to prevent the mice from being influenced by each other.
The movement of the mice were tracked by two infrared photodetectors and the information
was collated using the accompanying software. After each run, the TruScan activity
chambers were wiped down with a detergent solution and the plates washed and dried prior
to the next run. The following parameters were analyzed: movement episodes, movement
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time (s), movement distance (cm), ambulatory velocity (cm/s), margin distance (cm), margin
time (s), center distance (cm), center time (s), center entries, jumps and vertical plane (Vplane) enteries. The mice were sacrificed using a CO2 chamber at the end of the experiment.

5. Analysis:
The data collected were analyzed using one-way analysis of variance (ANOVA)
followed by Dunnett’s post-hoc test for the mouse TST and unpaired two-tailed t test for the
locomotor activity assay in GraphPad Prism6 (GraphPad Software Inc. La Jolla, CA).
Outliers were identified using GraphPad QuickCalcs which utilized Grubb’s test.
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APPENDIX A
Note added in proof: After the dissertation was submitted to the committee, additional
biological data became available. This allowed QSAR studies to be conducted. This
appendix material was presented to the committee and was available for my oral defense.
New biological data are presented in bold red font, and a QSAR discussion is provided.

Table A1. Inhibitory potencies of methyl-substituted 2-aminodihydroquinazoline analogs at
hOCT1-3 determined by measuring uptake of [3H]MPP+ (53).
Ligand
ADQ
(69)
A5MDQ (75)
N
NH
A6MDQ (74)
8
A7MDQ (76)
R
A8MDQ (77)
5
7
NH 2

R

hOCT1

H
5-CH3
6-CH3
7-CH3
8-CH3

14.5 ± 3.5
4.6 ± 0.6
8.2 ± 2.2
6.3 ± 1.3
4.5 ± 1.6

6
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IC50 ± SEM (µM)
hOCT2
46.5 ± 1.1
26.4 ± 0.7
12.1 ± 0.3
12.1 ± 3.2
35.1 ± 11.6

hOCT3
12.2 ± 3.4
0.5 ± 0.0
2.0 ± 0.4
8.4 ± 4.3
3.7 ± 0.3

Table A2. Comparison of inhibitory potencies of chloro- and methyl-substituted 2aminodihydroquinazoline analogs at hOCT1-3 determined by measuring uptake of
[3H]MPP+ (53).
Ligand
ADQ
(69)
A5MDQ (75)
A6MDQ (74)
A7MDQ (76)
A8MDQ (77)

NH 2
N
8
R
7

NH

5

IC50 ± SEM (µM)
hOCT3
Ligand

R
H
5-CH3
6-CH3
7-CH3
8-CH3

12.2 ± 3.4
0.5 ± 0.0
2.0 ± 0.4
8.4 ± 4.3
3.7 ± 0.3

R

ADQ (69)
A5CDQ (67)
A6CDQ (65)
A7CDQ (66)
A8CDQ (68)

H
5-Cl
6-Cl
7-Cl
8-Cl

hOCT3
12.2 ± 3.4
0.9 ± 0.2
3.9 ± 2.4
5.9 ± 3.9
4.9 ± 0.2

6

Table

A3.

Inhibitory

potencies

of

unsubstituted

and

6-halo-substituted

2-

aminodihydroquinazoline analogs at hOCT1-3 determined by measuring uptake of
[3H]MPP+ (53).

NH 2
N
8
R
7

NH

5
6

Ligand
ADQ
(69)
A6CDQ (65)
A6FDQ (87)
A6BrDQ (88)
A6IDQ (89)

R
H
6-Cl
6-F
6-Br
6-I

IC50 ± SEM (µM)
hOCT1
hOCT2
hOCT3
14.5 ± 3.5
3.0 ± 0.8
1.3 ± 0.1
2.7 ± 0.8
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46.5 ± 1.1
16.4 ± 4.7
11.9± 0.2
9.3 ± 1.1
ND

12.2 ± 3.4
3.9 ± 2.4
0.5 ± 0.0
1.9 ± 0.2

Table A4. Inhibitory potencies of ring opened 2-aminodihydroquinazolines, the
phenylguanidine analogs at hOCT1-3 determined by measuring uptake of [3H]MPP+ (53).
Ligand

R

PG
(99)
3-CPG
(97)
NH 2
4-CPG (98)
N
NH 2 4-MePG (100)
4-t-BuPG (101)
4-BnPG (102)
3
4-FPG (103)
4
4-BrPG (104)
4-IPG
(105)

R

hOCT1

H
3-Cl
4-Cl
4-CH3
4-C(CH3)3
4-CH2C6H5
4-F
4-Br
4-I
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41.1 ± 14.4
13.7 ± 0.8
10.0 ± 0.6
10.0 ± 0.2
0.9 ± 0.2
761.4 ± 254.7
22.6 ± 0.8
6.3 ± 1.0
2.4 ± 0.3

IC50 ± SEM (µM)
hOCT2
89.0 ± 12.2
60.5 ± 4.1
18.9 ± 0.1
9.3 ± 4.8
6.3 ± 3.4
96.2 ± 8.0
48.3 ± 18.9
11.3 ± 3.2
4.4 ± 1.5

hOCT3
99.8 ± 2.8
7.6 ± 0.7
2.8 ± 0.7
4.6 ± 1.1
2.2 ± 0.2
452.5 ± 87.9
27.8 ± 11.0
4.8 ± 0.7
1.5 ± 0.3

Quantitative structure-activity relationship (QSAR) studies:

Hansch analysis, a type of QSAR, relates activities of a congeneric series of
compounds to the physicochemical properties of the substituents. A number of
physicochemical properties such as lipophilic (π) and electronic properties, Verloop’s steric
parameters368 as well as volume and polarizability of substituent could be considered for the
analysis. A detailed list of the parameters used in the current study is shown in Table A5 and
their values for the phenylguanidine series (98-105) are shown in Table A6.
To determine the role of the substituent at the 4-position of the phenylguanidine
analogs, a Hansch analysis was performed on the following sets of compounds:
Set I: PG (99), 4-FPG (103), 4-BrPG (104), 4-IPG (105)
Set II: PG (99), 4-FPG (103), 4-BrPG (104), 4-IPG (105), 4-MePG (100)
Set III: PG (99), 4-FPG (103), 4-BrPG (104), 4-IPG (105), 4-MePG (100), 4-t-BuPG (101)
Set IV: PG (99), 4-FPG (103), 4-BrPG (104), 4-IPG (105), 4-MePG (100), 4-t-BuPG (101),
4-BnPG (102)
Set V: 2-aminodihydroquinazolines substituted at the 6-position and their corresponding 4substituted phenylguanidine analogs
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Table A5. Description of parameters used for the QSAR study
Parameter

Description

π

Hydrophobic constant of the substituent331

σ

Hammett electronic constant (for para substituents)331

L

Verloop length of the substituent368

B1

Verloop minimum width of the substituent368

B5

Verloop maximum width of the substituent368

Volume

Solvent accessible volume of the compounda

Polarizability

Polarizability of the compoundb

a

Calculated for the entire molecule using SYBYL X-2.1
Calculated for the entire molecule using ChemSketch 2016.1.1 (Advanced Chemistry
Development Inc.)
b
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(103)

(98)

(104)

(105)

4-FPG

4-CPG

4-BrPG

4-IPG

4-CH3

4-C(CH3)3

4-CH2C6H5

4-MePG (100)

4-t-BuPG (101)

4-BnPG (102)

4-I

4-Br

4-Cl

452.5 ± 87.9

2.2 ± 0.2

4.6 ± 1.1

1.5 ± 0.3

4.8 ± 0.7

2.8 ± 0.7

27.8 ± 11.0

99.8 ± 2.8

IC50 (µM)
hOCT3

3.34

5.66

5.34

5.83

5.32

5.55

4.56

4.00

pIC50
hOCT3

Calculated for the entire molecule using SYBYL X-2.1
Calculated for the entire molecule using ChemSketch 2016.1.1

b

a

H

(99)

PG

4-F

R

Ligand

2.01

1.98

0.56

1.12

0.86

0.71

0.14

0.00

π

-0.09

-0.20

-0.17

0.18

0.23

0.23

0.06

0.00

σ

3.63

4.11

3.00

4.23

3.83

3.52

2.65

2.06

L

1.52

2.59

1.52

2.15

1.95

1.80

1.35

1.00

B1

6.02

2.97

2.04

2.15

1.95

1.80

1.35

1.00

B5

734.0

682.8

527.0

539.2

523.1

513.8

490.3

474.8

Volumea

27.29

22.81

17.26

20.53

18.51

17.33

15.46

15.51

Polariz
-abilityb

Table A6. Values for the different parameters used for the Hansch analysis type of QSAR

studied conducted on the phenylfuanidine analogs (98-105).

Set I: PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105)

Table A7. Summary of the linear regression analysis conducted for the 4-halo-substituted
phenylguanidine analogs (PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105))
(n = 5).
Figure Equation
QSAR Equation
No.
No.
A1
1
0.6093 (± 0.1021) x π – 2.511 (± 0.5203)
A2
2
0.1260 (± 0.03355) x σ – 0.4963 (± 0.1709)
A3
3
32.88 (± 5.282) x Volume + 342.2 (± 26.92)
A4
4
1.142 (± 0.1617) x L – 2.509 (± 0.8241)
A5
5
0.6042 (± 0.08055) x B1 – 1.402 (± 0.4105)
A6
6
0.6042 (± 0.08055) x B5 – 1.402 (± 0.4105)
A7
7
2.479 (± 0.7999) x Polarizability + 4.949 (± 4.076)

r

F

P

0.960
0.908
0.963
0.971
0.974
0.974
0.873

35.61
14.10
38.74
49.85
56.26
56.26
9.60

0.0094
0.0330
0.0084
0.0058
0.0049
0.0049
0.0533

Figure A1. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus
the hydrophobic constant (π) of the substituents (r = 0.960, n = 5, p = 0.0094).
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Figure A2. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus
Hammett constant (σ) of the substituents (r = 0.908, n = 5, p = 0.0330).

Figure A3. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus
volume of the compounds (r = 0.963, n = 5, p = 0.0084).
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Figure A4. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus
Verloop length (L) of the substituents (r = 0.971, n = 5, p = 0.0058).

Figure A5. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus
Verloop minimum width (B1) of the substituents (r = 0.974, n = 5, p = 0.0049).
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Figure A6. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus
Verloop maximum width (B5) of the substituents (r = 0.974, n = 5, p = 0.0049).

Figure A7. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus
polarizability of the compounds (r = 0.873, n = 5, p = 0.0533).
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Set II: PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105), 4-MePG (100)

Table A8. Summary of the linear regression analysis conducted for the 4-substituted
phenylguanidine analogs (PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105),
4-MePG (100)) (n = 6).
Figure Equation
QSAR Equation
No.
No.
A8
8
0.5909 (± 0.1020) x π – 2.448 (± 0.5238)
A9
9
0.09076 (± 0.1056) x σ – 0.3744 (± 0.5425)
A10
10
33.83 (± 5.278) x Volume + 338.9 (± 27.11)
A11
11
1.082 (± 0.2204) x L – 2.303 (± 1.132)
A12
12
0.5734 (± 0.1125) x B1 – 1.295 (± 0.5776)
A13
13
0.6263 (± 0.09375) x B5 – 1.478 (± 0.4816)
A14
14
2.385 (± 0.7338) x Polarizability + 5.272 (± 3.770)

r

F

P

0.945
0.393
0.955
0.926
0.931
0.958
0.852

33.58
0.739
41.08
24.12
26.00
44.62
10.56

0.0044
0.4386
0.0030
0.0080
0.0070
0.0026
0.0314

Figure A8. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
hydrophobicity constant (π) of the substituents (r = 0.945, n = 6, p = 0.0044).
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Figure A9. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus Hammett
constant (σ) of the substituents (r = 0.393, n = 6, p = 0.4386).

Figure A10. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus volume
of the compounds (r = 0.955, n = 6, p = 0.0030).
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Figure A11. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
Verloop length (L) of the substituents (r = 0.926, n = 6, p = 0.0080).

Figure A12. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
Verloop minimum width (B1) of the substituents (r = 0.931, n = 6, p = 0.0070).
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Figure A13. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
Verloop maximum width (B5) of the substituents (r = 0.958, n = 6, p = 0.0026).

Figure A14. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
polarizability of the compounds (r = 0.852, n = 6, p = 0.0314).
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Set III: PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105), 4-MePG (100), 4t-BuPG (101)

Table A9. Summary of the linear regression analysis conducted for the 4-substituted
phenylguanidine analogs (PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105),
4-MePG (100), 4-t-BuPG (101)) (n = 7).
Figure Equation
QSAR Equation
No.
No.
A15
15
0.7899 (± 0.2771) x π – 3.323 (± 1.445)
A16
16
0.02857 (± 0.1216) x σ – 0.1008 (± 0.6340)
A17
17
61.81 (± 37.29) x Volume + 215.8 (± 194.4)
A18
18
1.136 (± 0.1996) x L – 2.538 (± 1.041)
A19
19
0.6910 (± 0.1825) x B1 – 1.813 (± 0.9516)
A20
20
0.7923 (± 0.2336) x B5 – 2.209 (± 1.218)
A21
21
3.127 (± 1.162) x Polarizability + 2.009 (± 6.058)

r

F

P

0.787
0.104
0.595
0.931
0.861
0.835
0.769

8.126
0.052
2.747
32.38
14.34
11.51
7.243

0.0358
0.8235
0.1583
0.0023
0.0128
0.0194
0.0432

Figure A15. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the
hydrophobicity constant (π) of the substituents (r = 0.787, n = 7, p = 0.0358).
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Figure A16. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the
Hammett constant (σ) of the substituents (r = 0.104, n = 7, p = 0.8235).

Figure A17. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus volume
of the compounds (r = 0.595, n = 7, p = 0.1583).
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Figure A18. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
Verloop length (L) of the substituents (r = 0.931, n = 7, p = 0.0023)

Figure A19. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
Verloop minimum width (B1) of the substituents (r = 0.861, n = 7, p = 0.0128).
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Figure A20. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
Verloop maximum width (B5) of the substituents (r = 0.835, n = 7, p = 0.0194).

Figure A21. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
polarizability of the compounds (r = 0.769, n = 7, p = 0.0432).
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Set IV: PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105), 4-MePG (100), 4t-BuPG (101), 4-BnPG (102)

Table A10. Summary of the linear regression analysis conducted for the 4-substituted
phenylguanidine analogs (PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105),
4-MePG (100), 4-t-BuPG (101), 4-BnPG (102)) (n = 8).

Figure Equation
QSAR Equation
No.
No.
A22
22
0.01229 (± 0.3457) x π + 0.8617 (± 1.735)
A23
23
0.05305 (± 0.07668) x σ – 0.2326 (± 0.3848)
A24
24
-28.19 (± 41.74) x Volume + 700.1 (± 209.5)
A25
25
0.4509 (± 0.2914) x L + 1.147 (± 1.463)
A26
26
0.3958 (± 0.1610) x B1 – 0.2241 (± 0.8082)
A27
27
-0.8194 (± 0.6368) x B5 + 6.466 (± 3.196)
A28
28
-1.156 (± 1.800) x Polarizability + 25.06 (± 9.035)

r

F

P

0.014
0.272
0.266
0.534
0.708
0.465
0.254

0.001
0.479
0.456
2.394
6.043
1.656
0.412

0.9728
0.5149
0.5247
0.1728
0.0492
0.2456
0.5446

Figure A22. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the
hydrophobicity constant (π) of the substituents (r = 0.014, n = 8, p = 0.9278).
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Figure A23. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the
Hammett constant (σ) of the substituents (r = 0.272, n = 8, p = 0.5149).

Figure A24. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the
volume of the compounds (r = 0.266, n = 8, p = 0.5247).
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Figure A25. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
Verloop length (L) of the substituents (r = 0.534, n = 8, p = 0.1728).

Figure A26. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
Verloop minimum width (B1) of the substituents (r = 0.708, n = 8, p = 0.0492).
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Figure A27. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus
Verloop maximum width (B5) of the substituents (r = 0.465, n = 8, p = 0.2456).

Figure A28. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the
polarizability of the compounds (r = 0.254, n = 8, p = 0.5446).
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Table A11. Internal correlations between the various parameters (highlighted in bold blue
font) for the phenylguandine series (98-105) as indicated by Pearson’s r.
π
π

σ

Volume

L

B1

B5

Polarizability

-0.351

0.946

0.776

0.678

0.831

0.949

-0.537

0.154

0.001

-0.382

-0.349

0.539

0.439

0.919

0.958

0.901

0.432

0.634

0.179

0.438

σ

-0.351

Volume

0.946

-0.537

L

0.776

0.154

0.539

B1

0.678

0.001

0.439

0.901

B5

0.831

-0.382

0.919

0.432

0.179

Polarizability

0.949

-0.349

0.958

0.634

0.438
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0.946
0.946

Set V: 2-Aminodihydroquinazolines substituted at the 6-position and their corresponding 4substituted phenylguanidine analogs

Table A12. Comparison of inhibitory potencies of 4-substitued phenylguanidines (98-100,
103, and 104) and their corresponding 6-substituted 2-aminodihydroquinazolines (65, 69,
and 87-89) at hOCT3.

NH 2
N

NH 2

NH 2

N

4
R

6
R

Ligand

IC50 (µM)

IC50 (µM)

hOCT3

hOCT3

H

99.8 ± 2.8

12.2 ± 3.4

4-FPG (103)

4-F

27.8 ± 11.0

4-CPG (98)

4-Cl

4-BrPG (104)
4-MePG (100)

PG

NH

(99)

R

R

Ligand

H

ADQ

0.5 ± 0.0

6-F

A6FDQ (87)

2.8 ± 0.7

3.9 ± 2.4

6-Cl

A6CDQ (65)

4-Br

4.8 ± 0.7

1.9 ± 0.2

6-Br

A6BrDQ (88)

4-CH3

4.6 ± 1.1

2.0 ± 0.4

6-CH3

A6MDQ (89)

222

(69)

223
2.00 ± 0.40

1.88 ± 0.16

3.91 ± 2.35

0.47 ± 0.01

12.16 ± 3.35

IC50 (µM)
hOCT3

5.69

5.73

5.41

6.33

4.92

pIC50
hOCT3

b

π

0.56

0.86

0.71

0.14

0.00

Calculated for the entire molecule using SYBYL X-2.1
Calculated for the entire molecule using ChemSketch 2016.1.1

6-CH3

A6MDQ (74)

a

6-Br

A6BrDQ (88)

6-F

A6FDQ (87)

6-Cl

H

(69)

ADQ

A6CDQ (65)

R

Ligand

-0.17

0.23

0.23

0.06

0.00

σ

3.00

3.83

3.52

2.65

2.06

L

1.52

1.95

1.80

1.35

1.00

B1

2.04

1.95

1.80

1.35

1.00

B5

526.6

529.0

530.3

495.9

480.3

Volumea

18.53

19.77

18.60

16.73

16.78

Polariz
-abilityb

Table A13. Values for the different parameters use in the Hansch analysis type of QSAR

studied conducted on the 6-substituted 2-aminodihydroquinazolines (65, 69, 74, 87 and 88).

Table A14. Summary of the linear regression analysis conducted for the 6-substituted 2aminodihydroquinazoline analogs and their corresponding 4-substituted phenylguanidine
analogs (n = 11).
Figure Equation
QSAR Equation
No.
No.
A29
29
0.3203 (± 0.1698) x π – 1.194 (± 0.9115)
A30
30
0.04676 (± 0.07857) x σ – 0.1694 (± 0.4218)
A31
31
21.98 (± 9.058) x Volume + 394.6 (± 48.63)
A32
32
0.6398 (± 0.3106) x L – 0.2898 (± 1.667)
A33
33
0.3460 (± 0.1629) x B1 – 0.2642 (± 0.8746)
A34
34
0.3924 (± 0.1767) x B5 – 0.4176 (± 0.9485)
A35
35
1.590 (± 0.6545) x Polarizability + 9.249 (± 3.514)

r

F

P

0.532
0.195
0.629
0.566
0.578
0.587
0.629

3.560
0.3542
5.887
4.245
4.510
4.943
5.901

0.0918
0.5664
0.0382
0.0695
0.0627
0.0535
0.0380

Figure A29. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus hydrophobicity constant (π) of the
substituents (r = 0.532, n = 11, p = 0.0918).
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Figure A30. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus Hammett constant (σ) of the
substituents (r = 0.195, n = 11, p = 0.5664).

Figure A31. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus volume of the compounds (r = 0.629,
n = 11, p = 0.0382).
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Figure A32. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus Verloop length (L) of the substituents
(r = 0.566, n = 11, p = 0.0695).

Figure A33. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus Verloop minimum width (B1) of the
substituents (r = 0.578, n = 11, p = 0.067).
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Figure A34. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus Verloop maximum width (B5) of the
substituents (r = 0.587, n = 11, p = 0.0535).

Figure A35. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus polarizability of the compounds (r =
0.629, n = 11, p = 0.0380).
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Table A15. Cook’s distances (Cook’s D) for the 6-substituted 2-aminodihydroquinazoline
analogs (65, 69, 74, 87 and 88) and their corresponding 4-substituted phenylguanidine
analogs (99-100, 103-105) for all of the parameters used in the Hansch analysis (n = 11).

Cook’s Da
Ligand
PG

(99)

4.00

0.5847

0.2752

0.7142

0.6477 0.6691 0.7082

Polariz
-ability
0.5832

4-FPG

(103)

4.56

0.0839

0.0737

0.0749

0.0830 0.0836 0.0817

0.0455

4-CPG

(98)

5.55

0.0005

0.0030

0.0068

0.0001 0.0000 0.0024

0.0218

4-BrPG (104)

5.32

0.0396

0.0062

0.0130

0.0623 0.0628 0.0211

0.0119

4-IPG

(105)

5.83

0.0018

0.0345

0.0000

0.0038 0.0030 0.0028

0.0762

4-MePG (100)

5.34

0.0002

0.0406

0.0238

0.0008 0.0007 0.0421

0.0032

ADQ

(69)

4.92

0.0010

0.0214

0.0228

0.0131 0.0227 0.0494

0.0098

A6FDQ (87)

6.33

0.7424

0.1300

0.5668

0.4310 0.4033 0.5801

0.4724

A6CDQ (65)

5.41

0.0022

0.0007

0.0267

0.0039 0.0049 0.0003

0.0057

A6BrDQ (88)

5.73

0.0028

0.0232

0.0026

0.0007 0.0006 0.0062

0.0108

A6MDQ (74)

5.69

0.0180

0.3077

0.0032

0.0334 0.0335 0.0005

0.0073

0.4020

0.2490

0.3960

0.3480 0.3510 0.4080

0.3390

Cut-off
(3 x mean)
a

pIC50

π

σ

Volume

L

B1

B5

The Statistical Package for the Social Sciences (SPSS Science, Chicago, IL).
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Table A16. Summary of the linear regression analysis conducted for the 6-substituted 2aminodihydroquinazoline analogs and their corresponding 4-substituted phenylguanidine
analogs without A6FDQ (87) (n = 10).
Figure Equation
QSAR Equation
No.
No.
A36
36
0.5694 (± 0.1207) x π – 2.428 (± 0.6351)
A37
37
0.07067 (± 0.09569) x σ – 0.2879 (± 0.5036)
A38
38
35.56 (± 6.138) x Volume + 327.3 (± 32.31)
A39
39
1.038 (± 0.2681) x L – 2.265 (± 1.411)
A40
40
0.5526 (± 0.1423) x B1 – 1.288 (± 0.7490)
A41
41
0.6497 (± 0.1275) x B5 – 1.692 (± 0.6711)
A42
42
2.517 (± 0.4961) x Polarizability + 4.655 (± 2.611)

r

F

0.858 22.26 0.0015
0.253 0.5454 0.4813
0.899 33.57 0.0004
0.808 15.00 0.0047
0.808 15.08 0.0047
0.874 25.96 0.0009
0.873 25.73 0.0010

Figure A36. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus hydrophobicity constant (π) of the
substituents (r = 0.858, n = 10, p = 0.0015).
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P

Figure A37. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus Hammett constant (σ) of the
substituents (r = 0.253, n = 10, p = 0.4813).

Figure A38. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus volume of the compounds (r = 0.899,
n = 10, p = 0.0004).
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Figure A39. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus Verloop length (L) of the substituents
(r = 0.808, n = 10, p = 0.0047).

Figure A40. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus Verloop minimum width (B1) of the
substituents (r = 0.808, n = 10, p = 0.0047).
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Figure A41. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus Verloop minimum width (B1) of the
substituents (r = 0.874, n = 10, p = 0.0009).

Figure A42. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their
corresponding 4-substituted phenylguandines versus polarizability of the compounds (r =
0.873, n = 10, p = 0.0010).
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Table A17. Internal correlations between the various parameters (highlighted in bold blue
font) for the combined phenylguanidine and 2-aminodihydroquinazoline series as indicated
by Pearson’s r (n = 10).
π
π

σ

Volume

L

B1

B5

Polarizability

0.481

0.925

0.979

0.976

0.904

0.856

0.187

0.611

0.605

0.088

0.351

0.865

0.867

0.969

0.846

1.000

0.840

0.801

0.844

0.790

σ

0.481

Volume

0.925

0.187

L

0.979

0.611

0.865

B1

0.976

0.605

0.867

1.000

B5

0.904

0.088

0.969

0.840

0.844

Polarizability

0.856

0.351

0.846

0.801

0.790

0.759
0.759

Table A18. Summary of the linear regression analysis conducted for the 6-substituted 2aminodihydroquinazoline analogs and their corresponding 4-substituted phenylguanidine
analogs without PG (99) (n = 10).
Equation
No.
43
44
45
46
47
48
49

QSAR Equation

r

F

P

0.2613 (± 0.2461) x π – 0.8626 (± 1.351)
0.03486 (± 0.1146) x σ – 0.1026 (± 0.6288)
16.76 (± 12.96) x Volume + 423.9 (± 71.09)
0.4985 (± 0.4478) x L + 0.5041 (± 2.457)
0.2653 (± 0.2343) x B1 + 0.1889 (± 1.286)
0.2898 (± 0.2526) x B5 + 0.1587 (± 1.386)
1.523 (± 0.9554) x Polarizability + 9.625 (± 5.242)

0.351
0.107
0.416
0.366
0.372
0.376
0.491

1.127
0.093
1.673
1.239
1.282
1.316
2.541

0.3194
0.7690
0.2320
0.2980
0.2904
0.2845
0.1496
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Discussion of QSAR studies:
We have identified two properties, volume and lipophilicity (π) of the substituents as
potentially playing a role in the inhibitory activity of phenylguanidines at hOCT3. We
considered four different sets of compounds adding one new compound to the set at a time.
In the first set of compounds, we used only the 4-halo-substituted phenylguanidine analogs.
The biological data suggested that progressively increasing the volume of the substituent at
the 4-position of the phenylguanidines from the unsubstituted PG (99) to the 4-iodo
substituted analog (4-IPG; 105) improved the inhibitory potency at hOCT3 (Table A6). This
lends credence to the positive correlation observed between the pIC50 of the 4-halosubstituted phenylguanidines and the solvent accessible volume (r = 0.963, n = 5, p = 0.0084)
(Table A7, Figure A3). Since the substituents under consideration possessed similar
electronic (σ) properties, we observed a positive correlation with the Hammett constant (σ)
(r = 0.908, n = 5, p = 0.0330) (Table A7, Figure A2).
Our modeling studies had indicated the lipophilic (π) properties of the substituent at
the 4-position to be more important than its electronic (σ) properties. Addition of 4-MePG
(100) bearing the methyl group with opposite electronic properties (σ) compared to halogens
led to loss of correlation with the Hammett constant (σ) (r = 0.393, n = 6, p = 0.4386) (Table
A8, Figure A9). This, coupled with retention of positive correlation with the lipophilic (π)
properties (r = 0.945, n = 6, p = 0.0044) (Table A8, Figure A8) of the substituent at the 4position, further supported the results of our molecular modeling. With the addition of 4-tBuPG (101) in the third set of compounds, a loss of positive correlation with volume (r =
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0.595, n = 7, p = 0.1538) (Table A9, Figure A17) was observed while a positive correlation
was retained with lipophilic (π) properties, Verloop length (L), minimum width (B1) and
maximum width (B5) as well as polarizability (Table A9). Finally, addition of 4-BnPG (102)
resulted in poor positive correlation between pIC50, and only the Verloop minimum width
(B1) of the substituents (r = 0.708, n = 8, p = 0.0492) (Table A10, Figure A26) was
significant.
Overall, out of the seven parameters considered for the Hansch analysis, two
parameters, i.e., the volume and the lipophilic (π) properties of the substituents were
identified as potentially important for inhibitory activity at hOCT3. For the Hansch analyses
performed, two potential caveats exist. The first being, out of the eight substituents examined
at the 4-position of phenylguanidines (Table A6), the benzyl group was the only substituent
that was aromatic in nature. This could be a contributing factor to the ~205-fold lower
inhibitory potency at hOCT3 of 4-BnPG (102) compared to 4-t-BuPG (101). The 4cyclohexylmethyl group has comparable volume as the 4-Bn group but lacks the aromatic
nature and could help us answer if there was truly a limitation in bulk tolerance. The second
was there exists significant high internal correlations between a number of parameters
evaluated including π and volume, π and B5, and π and polarizability among others as shown
by the positive Pearson’s r value (Table A11). The Pearson’s r value can range from -1 to
+1. A value of r = 0 indicates a lack of correlation while a value of -1 or +1 is indicative of
a negative or positive correlation, respectively. The following parameters were positively
correlated to each other: π and volume, π and B5, π and polarizability, volume and B5, volume
and polarizability, length and B1, B5 and polarizability, and polarizability and volume (Table
235

A11). For each parameter considered in the Hansch analysis, a minimum of 6 compounds
are required for a statistically valid correlation. As such, we currently lack the requisite
number of compounds to accurately identify the parameters (π, volume, B5 and
polarizability) important for inhibitory activity at hOCT3.
For the final set of compounds, we combined the two series of compounds, 2aminodihydroquinazolines and phenylguanidines. The reasoning behind doing this was
while these two series differed in their orientations (docking poses) in the binding region,
both utilized the key Asp478 residue in a bidentate ionic salt-bridge interaction. Our
modeling studies indicated that the lipophilic (π) properties of the substituent at the 6position of 2-aminodihydroquinazolines might be more important than their electronic (σ)
properties. In accordance with our findings from the molecular modeling studies, no
significant correlation was observed between pIC50 and Hammett constant (σ) of the
substituents (r = 0.195, n = 11, p = 0.5664) (Figure A30) (Table A14). A statistically
significant but modest correlation was observed between pIC50 of the analogs and volume (r
= 0.629, n = 11, p = 0.0382) (Figure A31) as well as with polarizability (r = 0.629, n = 11,
p = 0.0380) (Figure A35) (Table A14). Additionally, no significant correlation was observed
between pIC50 of the analogs and the other parameters evaluated (Table A14). In all of the
correlations obtained, A6FDQ (87) appeared to be a potential outlier and removal of A6FDQ
(87) from the sample set might lead to improved correlations with the parameters under
consideration. Of note, the 4-fluoro group of A6FDQ (87) despite possessing lower
lipophilic (π) property than the 4-chloro group of A6CDQ (65) (π = 0.06 and 0.71 for fluoro
and chloro group, respectively) exhibited ~8-fold higher potency than A6CDQ (65) at
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hOCT3. This was in contrast to our results from the modeling studies. However, at present,
we do not know if the 2-aminodihydroquinazoline analogs are only inhibitors or only
substrates or both. Hence, there might be differences in the SARs of these categories of
compounds, i.e., substrates and inhibitors. To determine if A6FDQ (87) was indeed a
potential outlier we determined the Cook’s distances (Cook’s D) for all the compounds for
the seven parameters under consideration (Table A15). The Cook’s distance identifies data
points as outliers if the distance is greater than the cut off which can be defined in several
ways such as three times the mean Cook’s distance or greater than 4/n (where n is the sample
size) or greater than 1.0. The Cook’s D was greater than the cut offs for A6FDQ for all of
the parameters (Table A15) for two of the three methods of cut offs (i.e. 4/n and 3 times the
mean Cook’s distance). Though removal of A6FDQ (87) led to improved correlations (Table
A16), the parameters themselves had high positive internal correlation (Table A17). This
made identification of parameters important for inhibitory activity extremely difficult. The
unsubstituted phenylguanidine, PG (99), was also identified as an outlier according to the
Cook’s D test (Table A15). However, PG (99) does not appear to be a true outlier since
removal did not result in improved correlations with any of the seven parameters considered
(Table A18). Moreover, PG (99) followed the trend of being less active than the substituted
analogs in both the ring opened phenylguanidine as well as 2-aminodihydroquinazoline
series. Additionally, the 6-methyl analog, A6MDQ (74) was identified as an outlier by the
Cook’s D test for Hammett constant (σ) if the cut off considered was three times the mean
Cook’s distance (Table A15). If on the other hand, the cut off was considered to be 4/n
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(where n is the sample size), which in the current scenario was 4/11 = 0.393, then A6MDQ
(74) was not an outlier (Table A15).
So far, volume and lipophilic properties of the substituents appear to be important
for the inhibitory potencies of the 2-aminodihydroquinazoline and their ring opened
phenylguanidine analogs at hOCT3. A lack of sufficient number of compounds and high
internal correlation between parameters prevented a more accurate identification of
properties important for activity at hOCT3.
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